0001493152-16-012289.txt : 20160812 0001493152-16-012289.hdr.sgml : 20160812 20160812163235 ACCESSION NUMBER: 0001493152-16-012289 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160812 DATE AS OF CHANGE: 20160812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDICA Corp CENTRAL INDEX KEY: 0001269026 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33624 FILM NUMBER: 161828674 BUSINESS ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 801-839-3516 MAIL ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA CORP DATE OF NAME CHANGE: 20031104 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

Amedica Corporation

(Exact name of registrant as specified in its charter)

DELAWARE		84-1375299
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

[ ]

Accelerated filer

[ ]

Non-accelerated filer

[ ] (Do not check if a smaller reporting company)

Smaller reporting company

[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): [ ] Yes [X] No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

23,582,001 shares of common stock, $0.01 par value, were outstanding at August 8, 2016

Amedica Corporation

Table of Contents

Part I. Financial Information

Item 1. Financial Statements		3

Condensed Consolidated Balance Sheet (unaudited)		3

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)		4

Condensed Consolidated Statement of Cash Flows (unaudited)		5

Notes to Condensed Consolidated Financial Statements (unaudited)		6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		14

Item 3. Quantitative and Qualitative Disclosures About Market Risk		21

Item 4. Controls and Procedures		21

Part II. Other Information

Item 1. Legal Proceedings		22

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		22

Item 3. Defaults Upon Senior Securities		22

Item 4. Mine Safety Disclosures		22

Item 5. Other Information		22

Item 6. Exhibits		22

Signatures		23

Part I. Financial Information

Item 1. Financial Statements

Amedica Corporation

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	June 30, 2016			December 31, 2015
Assets
Current assets:
Cash and cash equivalents	$	5,155		$	11,485
Trade accounts receivable, net of allowance of $26 and $49, respectively		1,950			2,660
Prepaid expenses and other current assets		531			229
Inventories, net		8,144			9,131
Total current assets		15,780			23,505

Property and equipment, net		2,090			2,472
Intangible assets, net		3,437			3,687
Goodwill		6,163			6,163
Other long-term assets		35			35
Total assets	$	27,505		$	35,862

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,960		$	643
Accrued liabilities		3,469			3,421
Current portion of lease liability		19			-
Current portion of long-term debt		10,681			16,365
Total current liabilities		16,129			20,429

Deferred rent		376			432
Long-term debt		469			-
Lease liability, net of current portion		38			-
Other long-term liabilities		166			171
Derivative liabilities		574			598

Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 250,000,000 shares authorized; 13,306,001 and 10,886,248 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively		133			109
Additional paid-in capital		214,609			210,660
Accumulated deficit		(204,989	)		(196,537	)
Total stockholders’ equity		9,753			14,232
Total liabilities and stockholders’ equity	$	27,505		$	35,862

See accompanying notes.

Amedica Corporation

Condensed Consolidated Statements of Operations and Comprehensive Loss - Unaudited

(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2016			2015			2016			2015
Product revenue	$	4,023		$	4,780		$	8,196		$	9,523
Costs of revenue		1,017			1,363			1,910			2,885
Gross profit		3,006			3,417			6,286			6,638
Operating expenses:
Research and development		1,553			1,553			3,161			3,396
General and administrative		1,360			1,334			2,922			3,361
Sales and marketing		2,594			3,126			5,188			6,483
Total operating expenses		5,507			6,013			11,271			13,240
Loss from operations		(2,501	)		(2,596	)		(4,985	)		(6,602	)
Other income (expense):
Interest expense		(2,353	)		(1,134	)		(3,253	)		(2,234	)
Loss on extinguishment of debt		(244	)		-			(244	)		(79	)
Change in fair value of derivative liabilities		35			(923	)		24			(1,100	)
Loss on extinguishment of derivative liabilities		-			(1,245	)		-			(1,261	)
Other expense		(1	)		(35	)		6			(38	)
Total other income (expense)		(2,563	)		(3,337	)		(3,467	)		(4,712	)
Net loss before income taxes		(5,064	)		(5,933	)		(8,452	)		(11,314	)
Provision for income taxes		-			-			-			-
Net comprehensive loss		(5,064	)		(5,933	)		(8,452	)		(11,314	)
Other comprehensive loss, net of tax:
Total comprehensive loss	$	(5,064	)	$	(5,933	)	$	(8,452	)	$	(11,314	)
Net loss per share attributable to common stockholders:
Basic and diluted	$	(0.40	)	$	(1.64	)	$	(0.71	)	$	(4.16	)
Weighted average common shares outstanding:
Basic and diluted		12,761,814			3,622,491			11,981,865			2,717,688

See accompanying notes.

Amedica Corporation

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

	Six Months Ended June 30,
	2016			2015
Cash flow from operating activities
Net loss	$	(8,452	)	$	(11,314	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		772			841
Amortization of intangible assets		250			250
Amortization of lease incentive for tenant improvements		10			10
Non cash interest expense		2,365			1,130
Loss on extinguishment of debt		244			79
Stock based compensation		145			704
Change in fair value of derivative liabilities		(24	)		1,100
Loss on extinguishment of derivative liabilities		-			1,261
(Gain) loss on disposal of equipment		(7	)		4
Provision for inventory reserve		696			625
Bad debt recovery		-			(7	)
Changes in operating assets and liabilities:
Trade accounts receivable		711			11
Prepaid expenses and other current assets		(219	)		(289	)
Inventories		296			556
Accounts payable and accrued liabilities		834			(284	)
Net cash used in operating activities	$	(2,379	)	$	(5,323	)
Cash flows from investing activities
Purchase of property and equipment		(350	)		(417	)
Proceeds from sale of property and equipment		23			7
Net cash used in investing activities	$	(327	)	$	(410	)
Cash flows from financing activities
Proceeds from the exercise of warrants		1			-
Payments on long-term debt		(3,424	)		-
Issuance costs paid for debt		(198	)		-
Payments for capital lease		(3	)		-
Purchase of treasury stock		-			(120	)
Net cash used in financing activities	$	(3,624	)	$	(120	)
Net decrease in cash and cash equivalents		(6,330	)		(5,853	)
Cash and cash equivalents at beginning of period		11,485			18,247
Cash and cash equivalents at end of period	$	5,155		$	12,394

Noncash investing and financing activities
Deferred financing costs included in accounts payable and accrued liabilities	$	69		$	-
Debt converted to common stock	$	2,480		$	202
Common stock issued for cashless exercise of warrant derivative liabilities	$	-		$	11,563
Issuance of treasury stock upon conversion of RSUs to common stock	$	-		$	120
Capital lease for property and equipment	$	60		$	-
Supplemental cash flow information
Cash paid for interest	$	938		$	1,110

See accompanying notes.

AMEDICA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

Amedica Corporation (“Amedica” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. Amedica is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, Amedica commercializes silicon nitride in the spine implant market. The Company believes that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. Amedica also believes that it is the first and only company to commercialize silicon nitride medical implants. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are sold primarily in the United States.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.

In accordance with the adoption of Accounting Standards Update (“ASU”) 2015-03, the Company’s debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments			As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592	)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592	)		16,365

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources

For the six months ended June 30, 2016 and 2015, the Company incurred a net loss of $8.5 million and $11.3 million, respectively, and used cash in operations of $2.4 million and $5.3 million, respectively. The Company had an accumulated deficit of $205.0 million and $196.5 million at June 30, 2016 and December 31, 2015, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.

As discussed further in Note 7, in June 2014, the Company entered into a term loan with Hercules Technology Growth Capital, Inc. (“Hercules Technology”), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (“HT III” and, together with Hercules Technology, “Hercules”) as lender (the “Hercules Term Loan”). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $4.5 million at June 30, 2016. At June 30, 2016, the Company’s cash balance was approximately $5.2 million. Prior to completion of a secondary offering in July 2016 described further herein in Note 11, the Company anticipated that it would need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. As a result of completing a secondary offering in July 2016, the Company now believes it is in position to maintain compliance with the liquidity covenant related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance beyond that date, the Company would need to refinance the note or obtain additional funding in or prior to the second quarter of 2017. If the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company may seek to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Company’s ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.

See Note 7 for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (“Riverside”) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.

Significant Accounting Policies

There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

New Accounting Pronouncements

In March 2016 the Financial Accounting Standards Board (“FASB”) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this update will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.

In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entity’s ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Company’s financial statements of adopting the new standard is currently being assessed by management.

In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

2. Basic and Diluted Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants for the purchase of common stock, convertible notes, stock options and unvested restricted stock units. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive due to the Company reporting a net loss. The Company had potentially dilutive securities representing approximately 1.5 million and 1.0 million shares of common stock at June 30, 2016 and 2015, respectively.

3. Inventories

The components of inventory were as follows (in thousands):

	June 30, 2016		December 31, 2015
Raw materials	$	773	$	819
WIP		268		235
Finished Goods		7,103		8,077
Total inventory	$	8,144	$	9,131

Finished goods include consigned inventory in the amounts of approximately $3.6 million and $3.8 million as of June 30, 2016 and December 31, 2015, respectively.

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2016			December 31, 2015
Customer relationships	$	3,990		$	3,990
Developed technology		4,685			4,685
Other patents and patent applications		562			562
Trademarks		350			350
Total intangibles		9,587			9,587
Less accumulated amortization		(6,150	)		(5,900	)
Total intangibles net of amortization	$	3,437		$	3,687

Based on the recorded intangibles at June 30, 2016, the estimated amortization expense is expected to be $250,000 during the remainder of 2016 and approximately $501,000 per year through 2020 and $834,000 thereafter.

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company measures and records certain financial instruments at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

Level 1	-	quoted market prices for identical assets or liabilities in active markets.

Level 2	-	observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3	-	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis at June 30, 2016 and December 31, 2015. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at June 30, 2016 and December 31, 2015:

	Fair Value Measurements at June 30, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	574	$	574

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2016 and 2015. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 and 2015:

	Common Stock Warrants			Convertible Notes			Total Derivative Liability
Balance at December 31, 2014	$	(11,358	)	$	(2,612	)	$	(13,970	)
Decrease in liability due to debt conversions		-			179			179
Decrease in liability due to warrants being exercised		10,302			-			10,302
Change in fair value		208			(1,308	)		(1,100	)
Balance at June 30, 2015	$	(848	)	$	(3,741	)	$	(4,589	)

Balance at December 31, 2015	$	(598	)	$	-		$	(598	)
Decrease in fair value included in earnings, as other income		24			-			24
Balance at June 30, 2016	$	(574	)	$	-		$	(574	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered mark-to-market liabilities and are re-measured to fair value at each reporting period in accordance with accounting guidance.

The assumptions used in estimating the common stock warrant liability at June 30, 2016 and December 31, 2015 were as follows:

	June 30, 2016			December 31, 2015
Weighted-average risk free interest rate		0.84	%		1.71	%
Weighted-average expected life (in years)		3.5			3.7
Expected dividend yield		0	%		0	%
Weighted average expected volatility		119	%		119	%

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2016		December 31, 2015
Commissions	$	592	$	867
Payroll and related expenses		562		683
Royalties		472		515
Interest payable		195		222
Final loan payment fees		1,091		783
Other		557		351
Total accrued liabilities	$	3,469	$	3,421

7. Debt

Hercules Term Loan

On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, and was 12.7% at June 30, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are currently being made in equal installments of approximately $500,000, with the remainder due at maturity. The Company’s obligations to Hercules are secured by a first priority security interest in substantially all of its assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.

On September 8, 2015, the Company entered into a Consent and First Amendment to Loan and Security Agreement (the “Amendment”) with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at June 30, 2016 was $4.5 million. As a result of the secondary offering completed in July 2016, the Company now believes it is in position to maintain compliance with the liquidity covenant related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance beyond that date, the Company would need to refinance the note or obtain additional funding in or prior to the second quarter of 2017, and has therefore classified the entire obligation as a current liability.

See discussion below with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (“Riverside”) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.

Magna Note

In August 2014, the Company entered into a Securities Purchase Agreement with Magna pursuant to which the Company sold to Magna an unsecured promissory note with an aggregate principal amount of $3.5 million (the “Magna Note”). The outstanding principal amount of the Magna Note was $763,000 at June 30, 2016. The Magna Note matures on August 11, 2016, and accrues interest at an annual rate of 6.0%.

Hercules and Riverside Debt Exchange

On April 4, 2016, the Company entered into an Assignment and Second Amendment to Loan and Security Agreement (the “Assignment Agreement”) with Riverside Merchant Partners, LLC (“Riverside”), and Hercules, pursuant to which Hercules sold $1.0 million of the principal amount outstanding under the Hercules Term Loan to Riverside. In addition, pursuant to the terms of the Assignment Agreement, Riverside acquired an option to purchase an additional $2.0 million of the principal amount outstanding under the Hercules Term Loan from Hercules. On April 18, 2016, Riverside exercised and purchased an additional $1.0 million of the principal amount of the Hercules Term Loan and on April 27, 2016, Riverside exercised the remainder of its option and purchased an additional $1.0 million of the principal amount of the Hercules Term Loan from Hercules.

Riverside Debt

On April 4, 2016, the Company entered into an exchange agreement (the “Exchange Agreement”) with Riverside, pursuant to which the Company agreed to exchange $1.0 million of the principal amount outstanding under the Hercules Term Loan held by Riverside for a subordinated convertible promissory note in the principal amount of $1.0 million (the “First Exchange Note”) and a warrant to purchase 100,000 shares of common stock of the Company at a fixed exercise price of $1.63 per share (the “First Exchange Warrant”) (the “Exchange”). All principal accrued under the Exchange Notes is convertible into shares of common stock at the election of the Holder at any time at a fixed conversion price of $1.43 per share (the “Conversion Price”). The closing stock price on April 4, 2016, was $1.63 and a beneficial conversion feature of $246,000 was recorded to equity and as a debt discount. The warrant value of $106,000 was recorded to equity and as a debt discount.

In addition, pursuant to the terms and conditions of the Exchange Agreement, the Company and Riverside had the option to exchange an additional $2.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of up to $2.0 million and an additional warrant to purchase 100,000 shares of common stock (the “Second Exchange Warrant”). The Exchange Agreement also provided that if the volume-weighted average price of the Company’s common stock was less than the Conversion Price, the Company would issue up to an additional 150,000 shares of common stock (the “True-Up Shares”) to Riverside, which was subsequently reduced to 140,000 shares of common stock.

On April 18, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the “Second Exchange Note”). The closing stock price on April 18, 2016, was $2.02 and a beneficial conversion feature of $413,000 was recorded to equity and as a debt discount. Additionally, on April 28, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the “Third Exchange Note”) and an additional warrant to purchase 100,000 shares of the Company’s common stock at a fixed exercise price of $1.66 per share. The warrant value of $107,000 was recorded to equity and as a debt discount. The closing stock price on April 28, 2016, was $1.66 and a beneficial conversion feature of $268,000 was recorded to equity and as a debt discount. Financing costs were $267,000 and were recorded to interest expense. The unamortized deferred financing costs and debt discount of the Hercules Term Loan exchanged were $244,000 at the time of the exchange and were recorded as a loss on extinguishment of debt related to the debt exchange. The First Exchange Note, the Second Exchange Note and the Third Exchange Note are collectively referred to herein as the “Exchange Notes.”

Pursuant to the terms of the Exchange Notes, since the volume-weighted average price of the Company’s common stock was less than the Conversion Price on May 6, 2016, the Company issued an additional 140,000 shares of common stock to Riverside and recorded the value of the True-Up Shares of $199,000 to interest expense and equity.

All principal outstanding under each of the Exchange Notes was to be due on April 3, 2018 (the “Maturity Date”). Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Company’s option, at a conversion price of $1.34 per share. As of June 30, 2016, the entire principal amount of the First and Second Exchange Notes, $300,000 of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes had been converted into 1,742,718 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $700,000. The debt discounts associated with the converted debt was recorded to interest expense. As noted in Note 11 below, in July 2016, the Company redeemed in full the remaining principal balance and interest related to the Riverside Debt.

Outstanding long-term debt consisted of the following (in thousands):

	June 30, 2016									December 31, 2015
	Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount			Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
Hercules Term Loan		10,628			(706	)		9,922			17,051			(1,420	)		15,631
Convertible Note		700			(231	)		469			-			-			-
Magna Note		763			(4	)		759			763			(29	)		734
Total debt		12,091			(941	)		11,150			17,814			(1,449	)		16,365
Less: Current portion		(11,391	)		710			(10,681	)		(17,814	)		1,449			(16,365	)
Long-term debt	$	700		$	(231	)	$	469		$	-		$	-		$	-

The following summarizes by year the future principal payments as of June 30, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Riverside Note		Total
2016	$	3,111	$	763	$	-	$	3,874
2017		6,858		-		-		6,858
2018		659		-		700		1,359
Total future principal payments	$	10,628	$	763	$	700	$	12,091

8. Equity

During the six months ended June 30, 2016, 536,388 shares of common stock were issued upon the cashless exercise of 1,137,365 Series A warrants issued in September 2015 and 647 shares of common stock were issued upon warrants exercised for cash.

1,882,718 shares of common stock were issued related to the Riverside Debt discussed in Note 7.

9. Stock-Based Compensation

Option and Equity Plans

In May 2016, the stockholders of the Company approved a proposal to increase the number of shares of common stock available for issuance under the 2012 Employee, Director and Consultant Equity Incentive Plan (the “2012 Plan”) by 800,000 shares, from 342,425 to 1,142,425.

The total number of shares available for grant under the 2012 Plan at June 30, 2016 was 921,272.

Stock Options

A summary of the Company’s stock option activity for the six months ended June 30, 2016 was as follows:

	Options			Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373		$	41.53
Granted		23,004		$	1.69
Expired		(13,702	)	$	24.17
Outstanding at June 30, 2016		121,675		$	35.95
Exercisable at June 30, 2016		81,111		$	56.73
Vested and expected to vest at June 30, 2016		119,738		$	36.37

The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the six months ended June 30, 2016 and 2015:

	Six Months Ended June 30
	2016			2015
Weighted-average risk-free interest rate		1.86	%		1.63	%
Weighted-average expected life (in years)		6.3			6.3
Expected dividend yield		0	%		0	%
Weighted-average expected volatility		65	%		47	%

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Cost of revenue	$	3	$	5	$	7	$	34
Research and development		24		37		53		159
General and administrative		35		31		75		359
Selling and marketing		2		10		17		152
Capitalized into inventory		1		7		3		46
Total stock-based compensation expense	$	65	$	90	$	155	$	750

Unrecognized stock-based compensation at June 30, 2016 was as follows (in thousands):

		Unrecognized Stock- Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	370				1.5

10. Commitments and Contingencies

On April 1, 2016, Hampshire MedTech Partners II, GP (“Hampshire GP”) filed suit against the Company in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued to Hampshire MedTech Partners II, LP (“Hampshire LP”) on November 6, 2014 (the “Warrant”). Hampshire GP alleges that as a result of a subsequent financing the Company breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. The Company intends to vigorously defend itself in this suit.

From time to time, the Company is subject to other various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

11. Subsequent Events

Secondary Offering

In July, 2016, the Company completed a secondary offering, in which the Company sold 5,258,000 Class A Units, including 1,650,000 units sold pursuant to the exercise by the underwriters of their over-allotment option, priced at $1.00 per unit, and 7,392 Class B Units, priced at $1,000 per unit. Each Class A Unit consisted of one share of common stock and one warrant to purchase one share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 1,000 shares of common stock and warrants to purchase 1,000 shares of common stock. The securities comprising the units were immediately separable and were issued separately. In total, the Company issued 5,258,000 shares of common stock, 7,392 shares of preferred stock convertible into 7,392,000 shares of common stock, and warrants to purchase 12,650,000 shares of common stock at a fixed exercise price of $1.00 per share. The Company received proceeds of approximately $11.3 million, net of underwriting and other offering costs.

Subsequent to the secondary offering, 5,018 shares of convertible preferred stock have been converted into 5,018,000 shares of common stock.

Magna Note

In July 2016, the Company paid Magna $888,000 to redeem in full the remaining principal balance and interest related to the Magna Note.

Riverside Debt

In July 2016, the Company paid Riverside $840,000 to redeem in full the remaining principal balance and interest related to the Riverside Debt.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2015 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2015, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q.

Overview

We are a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, we commercialize silicon nitride in the spine implant market. We believe that our silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non- medical fields. We also believe that we are the first and only company to commercialize silicon nitride medical implants.

We have received 510(k) regulatory clearance in the United States, a CE mark in Europe, and ANVISA approval in Brazil for a number of our devices that are designed for spinal fusion surgery. To date, more than 25,000 of our silicon nitride devices have been implanted into patients, with an 8-year successful track record. We have a pending FDA 510(k) submission for clearance in the United States of a novel composite spinal fusion device that combines porous and solid silicon nitride, and obviates the need for bone grafts. The FDA recently sent us additional questions about our submission and we are currently in the process of submitting a response.

We believe that silicon nitride has a superb combination of properties that make it ideally suited for human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers; all of which have practical limitations. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial infection, resistance to corrosion, superior strength and fracture resistance, and ease of diagnostic imaging, among other advantages.

We market and sell our Valeo brand of silicon nitride implants to surgeons and hospitals in the United States and to selected markets in Europe and South America through more than 50 independent sales distributors who are supported by an in-house sales and marketing management team. These implants are designed for use in cervical (neck) and thoracolumbar (lower back) spine surgery. We recently entered into a 10-year exclusive distribution agreement with Shandong Weigao Orthopaedic Device Company Limited (“Weigao”) to sell Amedica-branded silicon nitride spinal fusion devices within the People’s Republic of China (“China”). Weigao, a large orthopaedic company, has expertise in acquiring Chinese Food and Drug Administration (“CFDA”) approval of medical devices, and will assist us in obtaining regulatory approval. Weigao has committed to minimum purchase requirements totaling 225,000 implants in the first six years following CFDA clearance. We are also working with other partners in Japan to obtain regulatory approval for silicon nitride in that country as well.

In addition to silicon nitride, we also sell metal-based products in the United States that provide surgeons and hospitals with a complete package for spinal surgery. These metal products are designed to address spinal deformity and degenerative conditions. Although these metal products have accounted for approximately 54% and 51% of our product revenues for the quarterly periods ended June 30, 2016 and June 30, 2015, respectively, we remain focused on developing and promoting silicon nitride, and driving its adoption through a scientifically-intense, data-driven strategy.

In addition to direct sales, we have targeted original equipment manufacturer (“OEM”) and private label partnerships in order to accelerate adoption of silicon nitride, both in the spinal space, and also in future markets such as hip and knee replacements, dental, extremities, trauma, and sports medicine. Existing biomaterials, based on plastics, metals, and bone grafts have well-recognized limitations that we believe are addressed by silicon nitride, and we are uniquely positioned to convert existing, successful implant designs made by other companies into silicon nitride. We believe OEM and private label partnerships will allow us to work with a variety of partners, accelerate the adoption of silicon nitride, and realize incremental revenue at improved operating margins, when compared to the cost-intensive direct sales model.

We believe that silicon nitride addresses many of the biomaterial-related limitations in fields such as hip and knee replacements, dental implants, sports medicine, extremities, and trauma surgery. We further believe that the inherent material properties of silicon nitride, and the ability to formulate the material in a variety of compositions, combined with precise control of the surface properties of the material, opens up a number of commercial opportunities across orthopedic surgery, neurological surgery, maxillofacial surgery, and other medical disciplines.

We operate a 30,000 square foot manufacturing facility at our corporate headquarters in Salt Lake City, Utah, and we believe we are the only vertically integrated silicon nitride medical device manufacturer in the world.

Recent Developments

On July 8, 2016, we completed a secondary offering, in which we sold 5,258,000 Class A Units, including 1,650,000 units sold pursuant to the exercise by the underwriters of their over-allotment option, priced at $1.00 per unit, and 7,392 Class B Units, priced at $1,000 per unit. Each Class A Unit consisted of one share of common stock and one warrant to purchase one share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 1,000 shares of common stock and warrants to purchase 1,000 shares of common stock. The securities comprising the units were immediately separable and were issued separately. In total, we issued 5,258,000 shares of common stock, 7,392 shares of preferred stock convertible into 7,392,000 shares of common stock, and warrants to purchase 12,650,000 shares of common stock at a fixed exercise price of $1.00 per share. The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed priced and do not contain any variable pricing features nor any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The Company received proceeds of approximately $11.3 million, net of underwriting and other offering costs.

Subsequent to the secondary offering, 5,018 shares of convertible preferred stock have been converted into 5,018,000 shares of common stock.

Components of our Results of Operations

We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating performance.

Product Revenue

We derive our product revenue primarily from the sale of spinal fusion devices and related products used in the treatment of spine disorders. Our product revenue is generated from sales to three types of customers: (1) surgeons and hospitals; (2) stocking distributors; and (3) private label customers. Most of our products are sold on a consignment basis through a network of independent sales distributors; however, we also sell our products to independent stocking distributors and private label customers. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability is reasonably assured. We generate the majority of our revenue from the sale of inventory that is consigned to independent sales distributors that sell our products to surgeons and hospitals. For these products, we recognize revenue at the time we are notified the product has been used or implanted and all other revenue recognition criteria have been met. For all other transactions, we recognize revenue when title and risk of loss transfer to the stocking distributor or private label customers, and all other revenue recognition criteria have been met. We generally recognize revenue from sales to stocking distributors and private label customers at the time the product is shipped to the distributor. Stocking distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at time of shipment. Our stocking distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. Our policy is to classify shipping and handling costs billed to customers as an offset to total shipping expense in the statement of operations, primarily within sales and marketing. In general, our customers do not have any rights of return or exchange.

We believe our product revenue from the sale of our silicon nitride based products will increase due to our sales and marketing efforts and as we introduce new silicon nitride based products into the market and our product revenue from the sale of our non-silicon nitride products to increase as we introduce new products into the market. We expect that our product revenue will continue to be primarily attributable to sales of our products in the United States.

Cost of Revenue

The expenses that are included in cost of revenue include all direct product costs if we obtained the product from third-party manufacturers and our in-house manufacturing costs for the products we manufacture. We obtain our non-silicon nitride products, including our metal and orthobiologic products, from third-party manufacturers, while we currently manufacture our silicon-nitride products in-house.

Specific provisions for excess or obsolete inventory are also included in cost of revenue. In addition, we pay royalties attributable to the sale of specific products to some of our surgeon advisors that assisted us in the design, regulatory clearance or commercialization of a particular product. These payments are recorded as cost of revenue.

Gross Profit

Our gross profit measures our product revenue relative to our cost of revenue. We expect our gross profit to decrease as we expand the penetration of our silicon nitride technology platform through OEM and private label partnerships.

Research and Development Expenses

Our net research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research activities. To the extent that certain research and development expenses are directly related to our manufactured products, such expenses and related overhead costs are allocated to inventory.

We expect to incur additional research and development costs as we continue to develop new spinal fusion products, our product candidates for total joint replacements, such as our total hip replacement product candidate, and dental applications which may increase our total research and development expenses.

Sales and Marketing Expenses

Sales and marketing expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel employed in sales, marketing, medical education and training. In addition, our sales and marketing expenses include commissions and bonuses, generally based on a percentage of sales, to our sales managers and independent sales distributors. We provide our products in kits or banks that consist of a range of device sizes and separate instruments sets necessary to perform the surgical procedure. We generally consign our instruments to our distributors or our hospital customers that purchase the device used in spinal fusion surgery. Our sales and marketing expenses include depreciation of the surgical instruments.

We expect our sales and marketing expenses will remain flat or slightly decline due to the cost saving measures implemented during the first quarter. Additionally, we expect our commissions to increase in absolute terms over time but remain approximately the same or decrease as a percentage of product revenue.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries, benefits and other related costs, including stock-based compensation for certain members of our executive team and other personnel employed in finance, legal, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses include allocated facility expenses, related travel expenses and professional fees for accounting and legal services.

We expect our general and administrative expenses to remain relatively flat.

RESULTS OF OPERATIONS

The following is a tabular presentation of our condensed consolidated operating results for the three and six months ended June 30, 2016 and 2015 (in thousands)

	Three Months Ended June 30,												Six Months Ended June 30,
	2016			2015			$ Change			% Change			2016			2015			$ Change			% Change
Product revenue	$	4,023		$	4,780		$	(757	)		(16	)%	$	8,196		$	9,523		$	(1,327	)		(14	)%
Costs of revenue		1,017			1,363			(346	)		(25	)%		1,910			2,885			(975	)		(34	)%
Gross profit		3,006			3,417			(411	)		(12	)%		6,286			6,638			(352	)		(5	)%
Operating expenses:
Research and development		1,553			1,553			-			0	%		3,161			3,396			(235	)		(7	)%
General and administrative		1,360			1,334			26			2	%		2,922			3,361			(439	)		(13	)%
Sales and marketing		2,594			3,126			(532	)		(17	)%		5,188			6,483			(1,295	)		(20	)%
Total operating expenses		5,507			6,013			(506	)		(8	)%		11,271			13,240			(1,969	)		(15	)%
Los s from operations		(2,501	)		(2,596	)		95			4	%		(4,985	)		(6,602	)		1,617			24	%
Other income (expense), net		(2,563	)		(3,337	)		774			23	%		(3,467	)		(4,712	)		1,245			26	%
Net loss before income taxes		(5,064	)		(5,933	)		869			15	%		(8,452	)		(11,314	)		2,862			25	%
Provision for income taxes		-			-			-						-			-			-
Net loss	$	(5,064	)	$	(5,933	)	$	869			15	%	$	(8,452	)	$	(11,314	)	$	2,862			25	%

Product Revenue

The following table sets forth our product revenue from sales of the indicated product category for the three and six months ended June 30, 2016 and 2015 (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2016		2015		$ Change			% Change			2016		2015		$ Change			% Change
Silicon Nitride	$	1,845	$	2,353	$	(508	)		(22	)%	$	4,083	$	5,010	$	(927	)		(19	)%
Non-Silicon Nitride		2,178		2,427		(249	)		(10	)%		4,113		4,513		(400	)		(9	)%
Total product revenue	$	4,023	$	4,780	$	(757	)		(16	)%	$	8,196	$	9,523	$	(1,327	)		(14	)%

For the three months ended June 30, 2016, total product revenue was $4.0 million as compared to $4.8 million in the same period 2015, a decrease of $0.8 million, or 16%. This decrease was due to lower private label sales during the quarter and weaker than expected commercial sales in a key geographic area as we continue to implement our commercial sales expansion strategy. The decrease in revenue for the three months ended June 30, 2016 was also attributable, in part, to continued market pricing pressure and hospital vendor consolidation.

For the six months ended June 30, 2016, total product revenue was $8.2 million as compared to $9.5 million in the same period 2015, a decrease of $1.3 million, or 14%. This decrease was due to lower private label sales during the quarter and weaker than expected commercial sales in a key geographic area as we continue to implement our commercial sales expansion strategy. The decrease in revenue for the six months ended June 30, 2016 was also attributable, in part, to continued market pricing pressure and hospital vendor consolidation.

The following table sets forth, for the periods indicated, our product revenue by geographic area (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2016		2015		$ Change			% Change			2016		2015		$ Change			% Change
Domestic	$	3,951	$	4,759	$	(808	)		(17	)%	$	7,960	$	9,491	$	(1,531	)		(16	)%
International		72		21		51			243	%		236		32		204			638	%
Total product revenue	$	4,023	$	4,780	$	(757	)		(16	)%	$	8,196	$	9,523	$	(1,327	)		(14	)%

International revenue increased $0.1 million during the three months ended June 30, 2016 as compared to the same periods in 2015, primarily as a result of increased sales of our silicon nitride products in Brazil and Europe.

International revenue increased $0.2 million during the six months ended June 30, 2016 as compared to the same periods in 2015, primarily as a result of increased sales of our silicon nitride products in Brazil and Europe.

Cost of Revenue and Gross Profit

For the three months ended June 30, 2016, our cost of revenue decreased $0.3 million, or 25%, as compared to the same period in 2015. The decrease was primarily due to the decline in sales and the moratorium on the medical device excise tax. Furthermore, there was minimal private label revenue during the three months ended June 30, 2016 resulting in increased gross profit during the three months ended June 30, 2016 as compared to the same period in 2015.

For the six months ended June 30, 2016, our cost of revenue decreased $1.0 million, or 34%, as compared to the same period in 2015. The decrease was primarily due to the decline in sales and the moratorium on the medical device excise tax in addition to receiving a refund for the medical device excise tax. Furthermore, there was minimal private label revenue during the six months ended June 30, 2016 resulting in increased gross profit during the six months ended June 30, 2016 as compared to the same period in 2015.

Research and Development Expenses

For the three months ended June 30, 2016, research and development expenses were unchanged as compared to the same period in 2015. Personnel related expenses decreased $0.1 million but were offset by an increase of $0.1 million in consulting and clinical study expenses.

For the six months ended June 30, 2016, research and development expenses decreased $0.2 million, or 7%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.6 million decrease in personnel related expenses and a $0.1 million decrease of stock compensation expense. These improvements were offset by an increase of $0.4 million in consulting and clinical study related expenses and a $0.1 million increase in product testing and validation related expenses.

General and Administrative Expenses

For the three months ended June 30, 2016, general and administrative expenses remained substantially unchanged as compared to the same period in 2015. Personnel related expenses decreased $0.1 million but were offset by an increase of $0.1 million in legal fees.

For the six months ended June 30, 2016, general and administrative expenses decreased $0.4 million, or 13%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.3 million decrease in personnel related expenses, a $0.3 million decrease in stock compensation expense, and a $0.2 decrease in tax expense. These improvements were offset, in part, by a $0.2 million increase in patent related, a $0.1 million increase in legal expenses, and a $0.1 million increase in investor relation expenses.

Sales and Marketing Expenses

For the three months ended June 30, 2016, sales and marketing expenses decreased $0.5 million, or17%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.1 million decrease in personnel related expenses and a decrease of $0.4 million in commissions due to lower sales.

For the six months ended June 30, 2016, sales and marketing expenses decreased $1.3 million, or 20%, as compared to the same period in 2015. This decrease was primarily attributable to a $0.5 million decrease in personnel related expenses, a decrease of $0.1 million of stock compensation expense, a $0.1 million decrease in market study related expenses, and a decrease of $0.6 million in commissions due to lower sales.

Other Income (Expense), Net

For the three months ended June 30, 2016, other expense decreased $0.8 million, or 23%, as compared to the same period in 2015. This decrease was primarily due to a net decrease of $2.3 million in the expense related to our derivative liabilities. These improvements were offset by a $1.3 million increase in interest expense primarily related to the debt discount associated with the Riverside Debt and a $0.2 increase in loss on extinguishment of debt associated with the Hercules and Riverside Debt Exchanged.

For the six months ended June 30, 2016, other expense decreased $1.2 million, or 26%, as compared to the same period in 2015. This decrease was primarily due to a net decrease of $2.4 million in the expense related to our derivative liabilities. These improvements were offset by a $1.0 million increase in interest expense primarily related to the debt discount associated with the Riverside Debt and a $0.2 increase in loss on extinguishment of debt associated with the Hercules and Riverside Debt Exchanged.

Liquidity and Capital Resources

For the six months ended June 30, 2016 and 2015, we incurred a net loss of $8.5 million and $11.3 million, respectively, and used cash in operations of $2.4 million and $5.3 million, respectively. We have an accumulated deficit of $205.0 million as of June 30, 2016. To date, our operations have been principally financed from proceeds from the issuance of convertible preferred stock and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. As of June 30, 2016, we had approximately $5.2 million in cash and cash equivalents.

We will need to, from time-to-time, seek additional financing through the issuance of common stock and/or debt, to satisfy our debt obligations and financial covenants, meet our working capital requirements, make continued investment in research and development and make capital expenditures needed for us to maintain and expand our business. We anticipate that our current financial resources will enable us to maintain compliance with the financial and liquidity covenants related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance with the financial and liquidity covenants related to the Hercules Term Loan past that time, we will need to obtain additional funding. If we are unable to access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of Hercules Technology. We may not be able to obtain additional financing on terms favorable to us, if at all. It is also possible that we may allocate significant amounts of capital toward solutions or technologies for which market demand is lower than anticipated and, as a result, abandon such efforts. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may even have to scale back our operations. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock.

Going Concern

Our ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm our business, financial condition and results of operations. These uncertainties create substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm included an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern in their report on our annual financial statements for the fiscal year ended December 31, 2015. The financial information throughout this quarterly report have been prepared on a basis which assumes that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. This financial information and statements do not include any adjustments that may result from the outcome of this uncertainty.

Cash Flows

The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands):

	Six Months Ended June 30,
	2016			2015
Net cash used in operating activities	$	(2,379	)	$	(5,323	)
Net cash used in investing activities		(327	)		(410	)
Net cash used in financing activities		(3,624	)		(120	)
Net cash used	$	(6,330	)	$	(5,853	)

Net Cash Used in Operating Activities

Net cash used in operating activities decreased $2.9 million to $2.4 million during the six months ended June 30, 2016, from $5.3 million for the same period in 2015. The decrease in cash used in operating activities during 2016 was primarily due to an overall decrease of $1.2 million in operational expenditures as we continue to focus our efforts to reduce costs. Additionally, accounts receivable decreased $0.7 million, accounts payable and prepaid expenses increased $1.3 million, which is offset by a decrease in cash provided by inventory of $0.3 million.

Net Cash Used in Investing Activities

Net cash used in investing activities during the six months ended June 30, 2016 was consistent with the level of cash used in the same period 2015. This cash was primarily used for additional instrumentation.

Net Cash Used in Financing Activities

Net cash used in financing activities was $3.6 million during the six months ended June 30, 2016, compared to $0.1 million used during the same period in 2015. This increase in net cash used by financing activities in 2016 was primarily attributable to principal payments made on our notes payable.

Indebtedness

Hercules Term Loan

On June 30, 2014, we entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, which was 12.7% at June 30, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are currently being made in equal installments of approximately $500,000, with the remainder due at maturity. Our obligations to Hercules are secured by a first priority security interest in substantially all of our assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.

On September 8, 2015, we entered into a Consent and First Amendment to Loan and Security Agreement with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at June 30, 2016 was $4.5 million and is currently $4.0 million. We anticipate that our current financial resources will enable us to maintain compliance with the financial and liquidity covenants related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance with the financial and liquidity covenants related to the Hercules Term Loan past that date we will need to restructure the note or obtain additional funding.

Hercules sold $3.0 million in principal of its term loan to Riverside during April 2016 and is discussed further below. The Hercules principal balance as of June 30, 2016 was $10.6 million and is currently $9.5 million.

Hercules and Riverside Debt Assignment

In April 2016, we entered into an Assignment Agreement with Riverside, and Hercules, pursuant to which Hercules sold $3.0 million of the principal amount outstanding under the Hercules Term Loan to Riverside. For a more detailed description of the Assignment Agreement refer to Note 7 in the consolidated financial statements of this Report.

Riverside Debt

All principal outstanding under each of the Exchange Notes was to be due on April 3, 2018 (the “Maturity Date”). Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Company’s option, at a conversion price of $1.34 per share. As of June 30, 2016, the entire principal amount of the First and Second Exchange Notes, $300,000 of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes had been converted into 1,742,718 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $700,000. The debt discounts associated with the converted debt was recorded to interest expense. As noted in Note 11, in July 2016, the Company redeemed in full the remaining principal balance and interest related to the Riverside Debt.

Magna Note

The outstanding principal amount of the Magna Note was $763,000 at June 30, 2016. In July 2016, we redeemed in full the remaining principal balance and interest related to the Magna Note.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no material changes to those policies during the six months ended June 30, 2016. The preparation of the financial statements in accordance with U.S. generally accepted accounting principles requires us to make judgments, estimates and assumptions regarding uncertainties that affect the reported amounts of assets and liabilities. Significant areas of uncertainty that require judgments, estimates and assumptions include the accounting for income taxes and other contingencies as well as valuation of derivative liabilities, asset impairment and collectability of accounts receivable. We use historical and other information that we consider to be relevant to make these judgments and estimates. However, actual results may differ from those estimates and assumptions that are used to prepare our financial statements.

New Accounting Pronouncements

See discussion under Note 1, Organization and Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q, for information on new accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Principal Accounting Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in rules and forms adopted by the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Principal Accounting Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In connection with the preparation of this report, our management, under the supervision and with the participation of our Chief Executive Officer and our Principal Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2016.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the first quarter of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

On April 1, 2016, Hampshire MedTech Partners II, GP (“Hampshire GP”) filed suit against us in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued by us to Hampshire MedTech Partners II, LP (“Hampshire LP”) on November 6, 2014 (the “Warrant”). Hampshire GP alleges that as a result of a subsequent financing we breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. We answered Hampshire GP’s complaint on July 6, 2016 and denied the material allegations. We intend to vigorously defend ourselves in this suit.

We are not aware of any other pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various additional legal proceedings from time to time.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

From, April 6, 2016 to June 30, 2016 the Company issued Riverside Merchant Partners, LLC (“Riverside”) a total of 1,882,718 shares of common stock in connection with the conversion of $2.5 million in convertible debt principal and interest held by Riverside. The recipient is an accredited investor and the issuance was exempt from registration under the Securities Act of 1933 in reliance on exemptions provided by Section 4(2) of the Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number

3.1	Form of Certificate of Designation of Series A Preferred Stock		Amendment No. 3 to Form S-1 (Exbit 3.3)	06/30/2016	333-211520

4.1	Common Stock Purchase Warrant		Form 8-K	04/05/2016	001-33624

4.2	Form of Series E Warrant		Amendment No. 3 to Form S-1 (Exhibit 4.25)	06/30/2016	333-211520

4.3	Form of Underwriters Warrant to be Issued in Offering		Amendment No. 3 to Form S-1 (Exhibit 4.26)	6/30/2016	333-211520

4.4	Form of Series A Preferred Stock Certificate		Amendment No. 3 to Form S-1 (Exhibit 4.27)	06/30/2016	333-211520

10.1	Assignment and Second Amendment to Loan and Security Agreement, dated April 4, 2016, by and among the Company Riverside Merchant Partners, LLC, Hercules Technology III, L.P. and Hercules Capital, Inc., the financial institutions signatory thereto, Amedica Corporation, and the guarantors signatory thereto		Form 8-K	04/05/2016	001-33624

10.2	Exchange Agreement dated April 4, 2016, by and among Amedica Corporation and Riverside Merchant Partners, LLC		Form 8-K	04/05/2016	001-33624

10.3	Subordinated Convertible Promissory Note, dated April 4, 2016, by and among Amedica Corporation and Riverside Merchant Partners, LLC		Form 8-K	04/05/2016	001-33624

31.1	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certificate of the Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

32	Certifications of the Chief Executive Officer and Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AMEDICA CORPORATION

Date: August 12, 2016	/s/ B. Sonny Bal
	B. Sonny Bal
	Chief Executive Officer (Principal Executive Officer)

Date: August 12, 2016	/s/ Ty A. Lombardi
	Ty A. Lombardi
	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amedica Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2016	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Ty A. Lombardi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Amedica Corporation;

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2016	By:	/s/ Ty A. Lombardi
		Ty A. Lombardi
		Chief Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Amedica Corporation, a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report for the quarter ended June 30, 2016 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2016	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

Date: August 12, 2016	By:	/s/ Ty A. Lombardi
		Ty A. Lombardi
		Chief Financial Officer

EX-101.INS 5 amda-20160630.xml XBRL INSTANCE FILE 0001269026 2016-01-01 2016-06-30 0001269026 2015-06-30 0001269026 2016-08-08 0001269026 2016-06-30 0001269026 2014-12-31 0001269026 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001269026 us-gaap:CustomerRelationshipsMember 2015-12-31 0001269026 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0001269026 AMDA:OtherPatentsAndPatentApplicationsMember 2015-12-31 0001269026 us-gaap:TrademarksMember 2015-12-31 0001269026 us-gaap:CustomerRelationshipsMember 2016-06-30 0001269026 us-gaap:DevelopedTechnologyRightsMember 2016-06-30 0001269026 AMDA:OtherPatentsAndPatentApplicationsMember 2016-06-30 0001269026 us-gaap:TrademarksMember 2016-06-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-06-30 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-06-30 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-06-30 0001269026 us-gaap:FairValueMeasurementsRecurringMember AMDA:CommonStockWarrantsMember 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2016-01-01 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2016-01-01 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-01-01 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-01-01 2015-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2015-01-01 2015-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-01-01 2015-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-12-31 0001269026 AMDA:HerculesTermLoanMember us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001269026 us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001269026 AMDA:HerculesTermLoanMember 2016-06-30 0001269026 AMDA:HerculesTermLoanMember 2015-12-31 0001269026 AMDA:MagnaNoteMember 2015-12-31 0001269026 AMDA:HerculesTechnologyCapitalIncMember AMDA:LoanAndSecurityAgreementMember 2014-06-30 0001269026 AMDA:LoanAndSecurityAgreementMember AMDA:HerculesTechnologyCapitalIncMember 2014-06-29 2014-06-30 0001269026 AMDA:HerculesTermLoanMember us-gaap:PrimeRateMember 2016-06-30 0001269026 AMDA:HerculesTermLoanMember us-gaap:PrimeRateMember 2014-06-30 0001269026 AMDA:HerculesTermLoanMember 2016-01-01 2016-06-30 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2015-09-07 2015-09-08 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember us-gaap:MinimumMember 2015-09-08 0001269026 AMDA:MagnaNoteMember 2016-06-30 0001269026 AMDA:TwoThouandTwelvePlanMember 2016-06-30 0001269026 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001269026 AMDA:CostOfRevenueMember 2016-01-01 2016-06-30 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001269026 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001269026 AMDA:CapitalizedIntoInventoryMember 2016-01-01 2016-06-30 0001269026 AMDA:CostOfRevenueMember 2015-01-01 2015-06-30 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-06-30 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001269026 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0001269026 AMDA:CapitalizedIntoInventoryMember 2015-01-01 2015-06-30 0001269026 us-gaap:EmployeeStockOptionMember 2016-06-30 0001269026 AMDA:MagnaNoteMember us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001269026 AMDA:TwoThouandTwelvePlanMember 2016-05-01 2016-05-31 0001269026 2015-01-01 2015-12-31 0001269026 2015-01-01 2015-06-30 0001269026 2015-12-31 0001269026 AMDA:HerculesTermLoanMember us-gaap:MinimumMember 2016-06-30 0001269026 AMDA:RiversideMerchantPartnersLLCMember 2016-06-30 0001269026 us-gaap:ScenarioPreviouslyReportedMember 2015-12-31 0001269026 us-gaap:RestatementAdjustmentMember 2015-12-31 0001269026 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0001269026 us-gaap:CommonStockMember 2016-01-01 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember AMDA:CommonStockWarrantsMember 2015-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2015-06-30 0001269026 AMDA:HerculesTermLoanMember 2014-06-30 0001269026 AMDA:SeriesAWarrantsMember 2016-01-01 2016-06-30 0001269026 AMDA:SeriesAWarrantsMember 2016-06-30 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2015-09-08 0001269026 AMDA:HerculesTermLoanMember AMDA:FirstAmendmentToLoanAndSecurityAgreementMember 2016-06-30 0001269026 AMDA:RiversideMerchantPartnersLLCMember AMDA:HerculesTermLoanMember 2016-06-30 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2016-06-30 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2014-08-31 0001269026 AMDA:SecuritiesPurchaseAgreementMember AMDA:MagnaNoteMember 2016-01-01 2016-06-30 0001269026 AMDA:HampshireMedTechPartnersIIGPMember 2016-03-29 2016-04-02 0001269026 2016-04-01 2016-06-30 0001269026 2015-04-01 2015-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2015-06-30 0001269026 us-gaap:ConvertibleDebtMember 2016-06-30 0001269026 us-gaap:ConvertibleDebtMember 2015-12-31 0001269026 AMDA:RiversideNoteMember us-gaap:ConvertibleNotesPayableMember 2016-06-30 0001269026 us-gaap:CommonStockMember 2016-06-30 0001269026 AMDA:RiversideMember 2016-06-30 0001269026 AMDA:TwoThouandTwelvePlanMember us-gaap:MinimumMember 2016-05-31 0001269026 AMDA:TwoThouandTwelvePlanMember us-gaap:MaximumMember 2016-05-31 0001269026 AMDA:CostOfRevenueMember 2016-04-01 2016-06-30 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001269026 AMDA:CostOfRevenueMember 2015-04-01 2015-06-30 0001269026 us-gaap:ResearchAndDevelopmentExpenseMember 2015-04-01 2015-06-30 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001269026 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001269026 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0001269026 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001269026 AMDA:CapitalizedIntoInventoryMember 2015-04-01 2015-06-30 0001269026 AMDA:CapitalizedIntoInventoryMember 2016-04-01 2016-06-30 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassAUnitsMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassAUnitsMember AMDA:UnderwritersMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassBUnitsMember AMDA:UnderwritersMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember 2016-07-01 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassAUnitsMember us-gaap:CommonStockMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassAUnitsMember AMDA:WarrantsMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassBUnitsMember us-gaap:CommonStockMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:ClassBUnitsMember AMDA:WarrantsMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember us-gaap:CommonStockMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember us-gaap:PreferredStockMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember us-gaap:CommonStockMember 2016-07-01 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:WarrantsMember 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:WarrantsMember 2016-07-01 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:MagnaNoteMember 2016-07-01 2016-07-31 0001269026 us-gaap:SubsequentEventMember AMDA:RiversideDebtMember 2016-07-01 2016-07-31 0001269026 AMDA:HerculesAndRiversideDebtAssignmentMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-04 0001269026 AMDA:HerculesAndRiversideDebtAssignmentMember AMDA:RiversideMerchantPartnersLLCMember 2016-04-18 0001269026 AMDA:ExchangeAgreementMember AMDA:RiversideDebtMember 2016-04-02 0001269026 AMDA:ExchangeAgreementMember AMDA:RiversideDebtMember 2016-04-04 0001269026 AMDA:ExchangeAgreementMember AMDA:RiversideDebtMember us-gaap:WarrantMember 2016-04-04 0001269026 AMDA:ExchangeAgreementMember AMDA:RiversideDebtMember 2016-04-03 2016-04-04 0001269026 AMDA:ExchangeAgreementMember AMDA:HerculesAndRiversideDebtAssignmentMember 2016-04-04 0001269026 AMDA:ExchangeAgreementMember AMDA:HerculesTermLoanMember AMDA:RiversideDebtMember 2016-04-18 0001269026 AMDA:ExchangeAgreementMember AMDA:HerculesTermLoanMember 2016-04-27 2016-04-28 0001269026 AMDA:ExchangeAgreementMember AMDA:HerculesTermLoanMember AMDA:RiversideDebtMember 2016-04-28 0001269026 AMDA:RiversideDebtMember 2016-05-06 0001269026 AMDA:ExchangeAgreementMember 2016-06-30 0001269026 AMDA:ExchangeAgreementMember AMDA:FirstSecondAndThirdExchangeAgreementMember 2016-01-01 2016-06-30 0001269026 AMDA:ExchangeAgreementMember AMDA:FirstSecondAndThirdExchangeAgreementMember 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2014-12-31 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2016-06-30 0001269026 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:ConvertibleDebtMember 2015-12-31 0001269026 AMDA:ExchangeAgreementMember AMDA:HerculesTermLoanMember AMDA:RiversideDebtMember 2016-04-17 2016-04-18 0001269026 us-gaap:SubsequentEventMember AMDA:SecondaryOfferingMember AMDA:CommonStockOneMember 2016-07-01 2016-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure AMEDICA Corp 10-Q 2016-06-30 false --12-31 Smaller Reporting Company

15780000

23505000

531000

229000

821000

-592000

1950000

2660000

12394000

5155000

18247000

11485000

4500000

27505000

35862000

35000

6163000

3437000

3687000

2090000

2472000

16129000

20429000

10681000

16365000

16957000

-592000

3469000

3421000

1960000

643000

574000

598000

574000

598000

166000

171000

376000

432000

27505000

35862000

-204989000

-196537000

133000

109000

26000

49000

0.01

250000000

8196000

9523000

4023000

4780000

1910000

2885000

1017000

1363000

6286000

6638000

3006000

3417000

3161000

3396000

1553000

2922000

3361000

1360000

1334000

5188000

6483000

2594000

3126000

11271000

13240000

5507000

6013000

-4985000

-6602000

-2501000

-2596000

-244000

-79000

-244000

24000

-208000

1308000

1100000

-1100000

35000

-923000

-1261000 -1245000

-3467000

-4712000

-2563000

-3337000

-8452000

-11314000

-5064000

-5933000

-0.71

-4.16

-0.4

-1.64

11981865

2717688

12761814

3622491

9753000

14232000

536388

2480000

202000

-8452000

-11314000

-5064000

-5933000

-7000

696000 625000

7000

-4000

145000

704000

2365000

1130000

10000

250000

772000

841000

-2379000

-5323000

834000

-284000

-296000

-556000

219000

289000

-711000

-11000

-327000

-410000

23000

7000

350000

417000

3424000

120000

-3624000

-120000

-6330000

-5853000

11563000

938000

1110000

3600000

3800000

250000

501000

834000

9587000

3990000

4685000

562000

350000

3990000

4685000

562000

350000

9587000

6150000

5900000

100000

179000

10302000

-11358000

-13970000

-598000

-574000

-848000

-4589000

-3741000

-2612000

0.0084

0.0171

P3Y6M

P3Y8M12D

0.00

1.19

3111000

3874000

763000

6858000

659000

1359000

700000

11150000

10628000

12091000

9922000

15631000

734000

759000

763000

16365000

469000

700000

12091000

10628000

17051000

763000

20000000

500000

763000

17814000

3000000

1000000

4500000

3000000

763000

3500000

700000

1000000

2000000

1000000

11391000 17814000 700000

941000

706000

1420000

29000

4000

1449000

231000

-710000

-1449000

231000

2018-01-01

2016-08-11

200000

1700000

0.127

0.125

0.092

0.060

0.06

500000

23004

155000

7000

53000

75000

17000

3000

34000

159000

359000

152000

46000

750000

65000

90000

3000

24000

5000

37000

35000

31000

10000

2000

7000

1000

121675

112373

81111

119738

35.95

41.53

1.69

56.73

36.37

0.0186

0.0163

P6Y3M18D

0.00

0.65

0.47

370000

P1Y6M

3253000

2234000

2353000

1134000

The assumptions used in estimating the common stock warrant liability at June 30, 2016 and December 31, 2015 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Weighted-average risk free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">0.84</td> <td style="width: 1%; line-height: 115%">%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">1.71</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.5</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119</td> <td style="line-height: 115%">%</td></tr> </table>

Outstanding long-term debt consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 16%; line-height: 115%">Hercules Term Loan</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">10,628</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">(706</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">9,922</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">17,051</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">(1,420</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">15,631</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Convertible Note</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(231</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(4</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">759</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">734</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Total debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,091</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(941</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,150</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17,814</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,449</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less: Current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(11,391</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">710</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10,681</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(17,814</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,449</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,365</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Long-term debt</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(231</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>

The following summarizes by year the future principal payments as of June 30, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Years Ending December 31,</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Hercules Term Loan </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Magna Note</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Riverside Note</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,111</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">763</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,874</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,858</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,858</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">659</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,359</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total future principal payments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">10,628</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,091</td> <td style="line-height: 115%"> </td></tr> </table>

A summary of the Companys stock option activity for the six months ended June 30, 2016 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">112,373</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">41.53</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,004</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(13,702</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">24.17</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">121,675</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">35.95</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">81,111</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">56.73</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Vested and expected to vest at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119,738</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">36.37</td> <td style="line-height: 115%"> </td></tr> </table>

The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the six months ended June 30, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Six Months Ended June 30</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 115%">Weighted-average risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">1.86</td> <td style="width: 1%; line-height: 115%">%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">1.63</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">65</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">47</td> <td style="line-height: 115%">%</td></tr> </table>

Unrecognized stock-based compensation at June 30, 2016 was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrecognized Stock- Based Compensation</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Period of Recognition (in years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 115%">Stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 24%; text-align: right; line-height: 115%">370</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 24%; text-align: right; line-height: 115%">1.5</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

921272

342425

1142425

8144000

9131000

13306001

10886248

5258000

13306001

10886248

150000

140000

-6000

38000

1000

35000

As discussed further in Note 7, the Company entered into a term loan with Hercules Technology Growth Capital, Inc. (“Hercules Technology”), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (“HT III” and, together with Hercules Technology, “Hercules”) as lender (the “Hercules Term Loan”). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $4.5 million at June 30, 2016.

3000000

1000000

1500000

773000

819000

268000

235000

7103000

8077000

24000

800000

2500000

300000

700000

The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at June 30, 2016 was $4.5 million.

13702

24.17

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at June 30, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Description</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">574</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">574</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Description</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Common Stock Warrants </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Convertible Notes</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total Derivative Liability</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Balance at December 31, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(11,358</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(2,612</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(13,970</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to debt conversions</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to warrants being exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10,302</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10,302</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Change in fair value</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">208</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(1,308</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(1,100</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at June 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(848</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(3,741</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,589</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598</td> <td style="line-height: 115%">) </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598</td> <td style="line-height: 115%">) </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in fair value included in earnings, as other income</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">24</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">24</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(574</td> <td style="line-height: 115%">) </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(574</td> <td style="line-height: 115%">) </td></tr> </table>

AMDA Q2 1137365 647 1882718

1000000

469000

38000

-8452000

-11314000

-5064000

-5933000

1000

198000

3000

69000 120000 60000

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended June 30,</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Six Months Ended June 30,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Cost of revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">5</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">7</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">34</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">24</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">37</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">53</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">159</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">35</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">31</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">75</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">359</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">152</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Capitalized into inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">46</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">65</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">155</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">750</td> <td style="line-height: 115%"> </td></tr> </table>

5258000

1650000

7392

1.00

1000

1.00

1.63

1.66

Each Class A Unit consisted of one share of common stock and one warrant to purchase one share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 1,000 shares of common stock and warrants to purchase 1,000 shares of common stock.

1 1 1000 1000

7392000

12650000

5018000

11300000

2000000

1000000

2000000

1000000

1.43

1.34

246000

268000

106000

107000

1.63 2.02 1.66

199000

140000

1742718

2016 19000

214609000

210660000

3000000

592000

867000

562000

683000

472000

515000

195000

222000

1091000 783000

557000

351000

1. Organization and Summary of Significant Accounting Policies   Organization   Amedica Corporation (Amedica or the Company) was incorporated in the state of Delaware on December 10, 1996. Amedica is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, Amedica commercializes silicon nitride in the spine implant market. The Company believes that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. Amedica also believes that it is the first and only company to commercialize silicon nitride medical implants. The Company acquired US Spine, Inc. (US Spine), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Companys products are sold primarily in the United States.   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Companys significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.   In accordance with the adoption of Accounting Standards Update (ASU) 2015-03, the Companys debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.   The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 49%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(592</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.   Liquidity and Capital Resources   For the six months ended June 30, 2016 and 2015, the Company incurred a net loss of $8.5 million and $11.3 million, respectively, and used cash in operations of $2.4 million and $5.3 million, respectively. The Company had an accumulated deficit of $205.0 million and $196.5 million at June 30, 2016 and December 31, 2015, respectively. To date, the Companys operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.   As discussed further in Note 7, in June 2014, the Company entered into a term loan with Hercules Technology Growth Capital, Inc. (Hercules Technology), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (HT III and, together with Hercules Technology, Hercules) as lender (the Hercules Term Loan). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $4.5 million at June 30, 2016. At June 30, 2016, the Companys cash balance was approximately $5.2 million. Prior to completion of a secondary offering in July 2016 described further herein in Note 11, the Company anticipated that it would need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. As a result of completing a secondary offering in July 2016, the Company now believes it is in position to maintain compliance with the liquidity covenant related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance beyond that date, the Company would need to refinance the note or obtain additional funding in or prior to the second quarter of 2017. If the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company may seek to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Companys ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Companys ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.   See Note 7 for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.   Significant Accounting Policies   There have been no significant changes to the Companys significant accounting policies as described in the Companys Annual Report on Form 10-K for the year ended December 31, 2015.   New Accounting Pronouncements   In March 2016 the Financial Accounting Standards Board (FASB) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (IASB) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this update will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.   In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entitys ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entitys ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Companys financial statements of adopting the new standard is currently being assessed by management.   In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

2. Basic and Diluted Net Loss per Common Share   Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants for the purchase of common stock, convertible notes, stock options and unvested restricted stock units. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive due to the Company reporting a net loss. The Company had potentially dilutive securities representing approximately 1.5 million and 1.0 million shares of common stock at June 30, 2016 and 2015, respectively.

3. Inventories   The components of inventory were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Raw materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">819</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">WIP</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">268</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">235</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Finished Goods</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,077</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">8,144</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,131</td> <td style="line-height: 115%"> </td></tr> </table>   Finished goods include consigned inventory in the amounts of approximately $3.6 million and $3.8 million as of June 30, 2016 and December 31, 2015, respectively.

4. Intangible Assets   Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Developed technology</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other patents and patent applications</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Trademarks</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,150</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(5,900</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles net of amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,437</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,687</td> <td style="line-height: 115%"> </td></tr> </table>   Based on the recorded intangibles at June 30, 2016, the estimated amortization expense is expected to be $250,000 during the remainder of 2016 and approximately $501,000 per year through 2020 and $834,000 thereafter.

5. Fair Value Measurements   Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis   The Company measures and records certain financial instruments at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; line-height: 115%"> </td> <td style="width: 48px; line-height: 115%">Level 1</td> <td style="width: 14px; text-align: center; line-height: 115%"> -</td> <td style="text-align: justify; line-height: 115%">quoted market prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> - </td> <td style="text-align: justify; line-height: 115%">observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: justify; line-height: 115%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 115%"> </td> <td style="line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> - </td> <td style="text-align: justify; line-height: 115%">unobservable inputs reflecting managements assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table>   The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis at June 30, 2016 and December 31, 2015. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at June 30, 2016 and December 31, 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Description</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">574</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">574</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Fair Value Measurements at December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Description</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Derivative liability</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-left: 10pt; line-height: 115%">Common stock warrants</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 10%; text-align: right; line-height: 115%">598</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>   The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the six months ended June 30, 2016 and 2015. The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Common Stock Warrants </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Convertible Notes</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total Derivative Liability</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Balance at December 31, 2014</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(11,358</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(2,612</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(13,970</td> <td style="width: 1%; line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to debt conversions</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">179</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Decrease in liability due to warrants being exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10,302</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10,302</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Change in fair value</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">208</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(1,308</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(1,100</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at June 30, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(848</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(3,741</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(4,589</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598</td> <td style="line-height: 115%">) </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">(598</td> <td style="line-height: 115%">) </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Decrease in fair value included in earnings, as other income</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">24</td> <td style="padding-bottom: 1.5pt"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">24</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Balance at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(574</td> <td style="line-height: 115%">) </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(574</td> <td style="line-height: 115%">) </td></tr> </table>   Common Stock Warrants   The Company has issued certain warrants to purchase shares of common stock, which are considered mark-to-market liabilities and are re-measured to fair value at each reporting period in accordance with accounting guidance.   The assumptions used in estimating the common stock warrant liability at June 30, 2016 and December 31, 2015 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Weighted-average risk free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">0.84</td> <td style="width: 1%; line-height: 115%">%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">1.71</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.5</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119</td> <td style="line-height: 115%">%</td></tr> </table>   Other Financial Instruments   The Companys recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Commissions</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">592</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">867</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Payroll and related expenses</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">683</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Royalties</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">472</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">515</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Interest payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">195</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">222</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Final loan payment fees</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,091</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">783</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">557</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">351</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,421</td> <td style="line-height: 115%"> </td></tr> </table>

7. Debt   Hercules Term Loan   On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20 million term loan. The Hercules Term Loan matures on January 1, 2018. The Hercules Term Loan included a $200,000 closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and is being amortized to interest expense over the life of the loan. The Hercules Term Loan also includes a non-refundable final payment fee of $1.7 million. The final payment fee is being accrued and recorded to interest expense over the life of the loan. The Hercules Term Loan bears interest at the rate of the greater of either (i) the prime rate plus 9.2%, and (ii) 12.5%, and was 12.7% at June 30, 2016. Interest accrues from the closing date of the loan and interest payments are due monthly. Principal payments commenced August 1, 2015 and are currently being made in equal installments of approximately $500,000, with the remainder due at maturity. The Companys obligations to Hercules are secured by a first priority security interest in substantially all of its assets, including intellectual property. The Hercules Term Loan contains certain covenants related to restrictions on payments to certain Company affiliates and financial reporting requirements.   On September 8, 2015, the Company entered into a Consent and First Amendment to Loan and Security Agreement (the Amendment) with Hercules. The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at June 30, 2016 was $4.5 million. As a result of the secondary offering completed in July 2016, the Company now believes it is in position to maintain compliance with the liquidity covenant related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance beyond that date, the Company would need to refinance the note or obtain additional funding in or prior to the second quarter of 2017, and has therefore classified the entire obligation as a current liability.   See discussion below with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.   Magna Note   In August 2014, the Company entered into a Securities Purchase Agreement with Magna pursuant to which the Company sold to Magna an unsecured promissory note with an aggregate principal amount of $3.5 million (the Magna Note). The outstanding principal amount of the Magna Note was $763,000 at June 30, 2016. The Magna Note matures on August 11, 2016, and accrues interest at an annual rate of 6.0%.   Hercules and Riverside Debt Exchange   On April 4, 2016, the Company entered into an Assignment and Second Amendment to Loan and Security Agreement (the Assignment Agreement) with Riverside Merchant Partners, LLC (Riverside), and Hercules, pursuant to which Hercules sold $1.0 million of the principal amount outstanding under the Hercules Term Loan to Riverside. In addition, pursuant to the terms of the Assignment Agreement, Riverside acquired an option to purchase an additional $2.0 million of the principal amount outstanding under the Hercules Term Loan from Hercules. On April 18, 2016, Riverside exercised and purchased an additional $1.0 million of the principal amount of the Hercules Term Loan and on April 27, 2016, Riverside exercised the remainder of its option and purchased an additional $1.0 million of the principal amount of the Hercules Term Loan from Hercules.   Riverside Debt   On April 4, 2016, the Company entered into an exchange agreement (the Exchange Agreement) with Riverside, pursuant to which the Company agreed to exchange $1.0 million of the principal amount outstanding under the Hercules Term Loan held by Riverside for a subordinated convertible promissory note in the principal amount of $1.0 million (the First Exchange Note) and a warrant to purchase 100,000 shares of common stock of the Company at a fixed exercise price of $1.63 per share (the First Exchange Warrant) (the Exchange). All principal accrued under the Exchange Notes is convertible into shares of common stock at the election of the Holder at any time at a fixed conversion price of $1.43 per share (the Conversion Price). The closing stock price on April 4, 2016, was $1.63 and a beneficial conversion feature of $246,000 was recorded to equity and as a debt discount. The warrant value of $106,000 was recorded to equity and as a debt discount.   In addition, pursuant to the terms and conditions of the Exchange Agreement, the Company and Riverside had the option to exchange an additional $2.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of up to $2.0 million and an additional warrant to purchase 100,000 shares of common stock (the Second Exchange Warrant). The Exchange Agreement also provided that if the volume-weighted average price of the Companys common stock was less than the Conversion Price, the Company would issue up to an additional 150,000 shares of common stock (the True-Up Shares) to Riverside, which was subsequently reduced to 140,000 shares of common stock.   On April 18, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Hercules Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the Second Exchange Note). The closing stock price on April 18, 2016, was $2.02 and a beneficial conversion feature of $413,000 was recorded to equity and as a debt discount. Additionally, on April 28, 2016, the Company and Riverside exercised their option to exchange an additional $1.0 million of the principal amount of the Term Loan for an additional subordinated convertible promissory note in the principal amount of $1.0 million (the Third Exchange Note) and an additional warrant to purchase 100,000 shares of the Companys common stock at a fixed exercise price of $1.66 per share. The warrant value of $107,000 was recorded to equity and as a debt discount. The closing stock price on April 28, 2016, was $1.66 and a beneficial conversion feature of $268,000 was recorded to equity and as a debt discount. Financing costs were $267,000 and were recorded to interest expense. The unamortized deferred financing costs and debt discount of the Hercules Term Loan exchanged were $244,000 at the time of the exchange and were recorded as a loss on extinguishment of debt related to the debt exchange. The First Exchange Note, the Second Exchange Note and the Third Exchange Note are collectively referred to herein as the Exchange Notes.   Pursuant to the terms of the Exchange Notes, since the volume-weighted average price of the Companys common stock was less than the Conversion Price on May 6, 2016, the Company issued an additional 140,000 shares of common stock to Riverside and recorded the value of the True-Up Shares of $199,000 to interest expense and equity.   All principal outstanding under each of the Exchange Notes was to be due on April 3, 2018 (the Maturity Date). Each of the Exchange Notes bears interest at a rate of 6% per annum, with the interest that would accrue on the initial principal amount of the Exchange Notes during the first 12 months being guaranteed and deemed earned as of the date of issuance. Prior to the Maturity Date, all interest accrued under the Exchange Notes is payable in cash or, if certain conditions are met, payable in shares of common stock at the Companys option, at a conversion price of $1.34 per share. As of June 30, 2016, the entire principal amount of the First and Second Exchange Notes, $300,000 of the Third Exchange Note, and the interest related to the First, Second, and Third Exchange Notes had been converted into 1,742,718 shares of common stock leaving the total principal balance outstanding under the Exchange Notes at $700,000. The debt discounts associated with the converted debt was recorded to interest expense. As noted in Note 11 below, in July 2016, the Company redeemed in full the remaining principal balance and interest related to the Riverside Debt.    Outstanding long-term debt consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Outstanding Principal </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unamortized Discount and Debt Issuance Costs</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Net Carrying Amount</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 16%; line-height: 115%">Hercules Term Loan</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">10,628</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">(706</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">9,922</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 8%; text-align: right; line-height: 115%">17,051</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">(1,420</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 10%; text-align: right; line-height: 115%">15,631</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Convertible Note</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(231</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Magna Note</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(4</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">759</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(29</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">734</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Total debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">12,091</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(941</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">11,150</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17,814</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(1,449</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Less: Current portion</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(11,391</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">710</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(10,681</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(17,814</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,449</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(16,365</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Long-term debt</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">(231</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td></tr> </table>   The following summarizes by year the future principal payments as of June 30, 2016 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Years Ending December 31,</td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Hercules Term Loan </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Magna Note</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Riverside Note</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">2016</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,111</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">763</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">-</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3,874</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">2017</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,858</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6,858</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">2018</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">659</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">-</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1,359</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total future principal payments</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">10,628</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">763</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">700</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,091</td> <td style="line-height: 115%"> </td></tr> </table>

8. Equity   During the six months ended June 30, 2016, 536,388 shares of common stock were issued upon the cashless exercise of 1,137,365 Series A warrants issued in September 2015 and 647 shares of common stock were issued upon warrants exercised for cash.   1,882,718 shares of common stock were issued related to the Riverside Debt discussed in Note 7.

9. Stock-Based Compensation   Option and Equity Plans   In May 2016, the stockholders of the Company approved a proposal to increase the number of shares of common stock available for issuance under the 2012 Employee, Director and Consultant Equity Incentive Plan (the 2012 Plan) by 800,000 shares, from 342,425 to 1,142,425.   The total number of shares available for grant under the 2012 Plan at June 30, 2016 was 921,272.   Stock Options   A summary of the Companys stock option activity for the six months ended June 30, 2016 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Options </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 20%; text-align: right; line-height: 115%">112,373</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">41.53</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">23,004</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(13,702</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">24.17</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">121,675</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">35.95</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercisable at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">81,111</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">56.73</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Vested and expected to vest at June 30, 2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">119,738</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">36.37</td> <td style="line-height: 115%"> </td></tr> </table>   The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the six months ended June 30, 2016 and 2015:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Six Months Ended June 30</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 115%">Weighted-average risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">1.86</td> <td style="width: 1%; line-height: 115%">%</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">1.63</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected life (in years)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">6.3</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Weighted-average expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">65</td> <td style="line-height: 115%">%</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">47</td> <td style="line-height: 115%">%</td></tr> </table>   Summary of Stock-Based Compensation Expense   Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Three Months Ended June 30,</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Six Months Ended June 30,</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Cost of revenue</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">3</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">5</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">7</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 12%; text-align: right; line-height: 115%">34</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Research and development</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">24</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">37</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">53</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">159</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">General and administrative</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">35</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">31</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">75</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">359</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Selling and marketing</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">10</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">17</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">152</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Capitalized into inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">1</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">3</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">46</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total stock-based compensation expense</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">65</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">155</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">750</td> <td style="line-height: 115%"> </td></tr> </table>   Unrecognized stock-based compensation at June 30, 2016 was as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Unrecognized Stock- Based Compensation</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Weighted Average Remaining Period of Recognition (in years)</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 115%">Stock options</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 24%; text-align: right; line-height: 115%">370</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 24%; text-align: right; line-height: 115%">1.5</td> <td style="width: 1%; line-height: 115%"> </td></tr> </table>

10. Commitments and Contingencies   On April 1, 2016, Hampshire MedTech Partners II, GP (Hampshire GP) filed suit against the Company in the Travis County, Texas 200th Judicial District Court relating to a Warrant to Purchase Shares of Common Stock issued to Hampshire MedTech Partners II, LP (Hampshire LP) on November 6, 2014 (the Warrant). Hampshire GP alleges that as a result of a subsequent financing the Company breached the anti-dilution provision of the Warrant by failing to increase the number of shares subject to the Warrant as well as failing to reduce the exercise price of the Warrant. Hampshire GP seeks damages in excess of $1,000,000. The Company intends to vigorously defend itself in this suit.   From time to time, the Company is subject to other various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Companys consolidated financial position, operating results or cash flows.

11. Subsequent Events   Secondary Offering   In July, 2016, the Company completed a secondary offering, in which the Company sold 5,258,000 Class A Units, including 1,650,000 units sold pursuant to the exercise by the underwriters of their over-allotment option, priced at $1.00 per unit, and 7,392 Class B Units, priced at $1,000 per unit. Each Class A Unit consisted of one share of common stock and one warrant to purchase one share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 1,000 shares of common stock and warrants to purchase 1,000 shares of common stock. The securities comprising the units were immediately separable and were issued separately. In total, the Company issued 5,258,000 shares of common stock, 7,392 shares of preferred stock convertible into 7,392,000 shares of common stock, and warrants to purchase 12,650,000 shares of common stock at a fixed exercise price of $1.00 per share. The Company received proceeds of approximately $11.3 million, net of underwriting and other offering costs.   Subsequent to the secondary offering, 5,018 shares of convertible preferred stock have been converted into 5,018,000 shares of common stock.   Magna Note   In July 2016, the Company paid Magna $888,000 to redeem in full the remaining principal balance and interest related to the Magna Note.   Riverside Debt   In July 2016, the Company paid Riverside $840,000 to redeem in full the remaining principal balance and interest related to the Riverside Debt.

Organization   Amedica Corporation (Amedica or the Company) was incorporated in the state of Delaware on December 10, 1996. Amedica is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, Amedica commercializes silicon nitride in the spine implant market. The Company believes that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. Amedica also believes that it is the first and only company to commercialize silicon nitride medical implants. The Company acquired US Spine, Inc. (US Spine), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Companys products are sold primarily in the United States.

Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (SEC). Such rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 23, 2016. The results of operations for the six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December 31, 2016. The Companys significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.   In accordance with the adoption of Accounting Standards Update (ASU) 2015-03, the Companys debt issuance costs have been reclassified to be presented in the Condensed Consolidated Balance Sheets as a direct reduction from the debt liability rather than as an asset.   The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 49%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(592</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, stock-based compensation, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources   For the six months ended June 30, 2016 and 2015, the Company incurred a net loss of $8.5 million and $11.3 million, respectively, and used cash in operations of $2.4 million and $5.3 million, respectively. The Company had an accumulated deficit of $205.0 million and $196.5 million at June 30, 2016 and December 31, 2015, respectively. To date, the Companys operations have been principally financed from proceeds from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations through 2016.   As discussed further in Note 7, in June 2014, the Company entered into a term loan with Hercules Technology Growth Capital, Inc. (Hercules Technology), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (HT III and, together with Hercules Technology, Hercules) as lender (the Hercules Term Loan). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $4.5 million at June 30, 2016. At June 30, 2016, the Companys cash balance was approximately $5.2 million. Prior to completion of a secondary offering in July 2016 described further herein in Note 11, the Company anticipated that it would need to refinance the note or obtain additional funding early in the third quarter of 2016 to maintain compliance through 2016 with the liquidity covenant related to the Hercules Term Loan. As a result of completing a secondary offering in July 2016, the Company now believes it is in position to maintain compliance with the liquidity covenant related to the Hercules Term Loan into the second quarter of 2017. To maintain compliance beyond that date, the Company would need to refinance the note or obtain additional funding in or prior to the second quarter of 2017. If the Company is unable to refinance the note or access additional funds prior to becoming non-compliant with the financial and liquidity covenants related to the Hercules Term Loan, the entire remaining balance of the debt under the Hercules Term Loan could become immediately due and payable at the option of the lender. Although the Company may seek to refinance the note or obtain additional financing, additional funding may not be available to the Company on favorable or acceptable terms, or at all. Any additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders, and debt financing, if available, may involve more restrictive covenants. The Companys ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm its business, financial condition and results of operations. These uncertainties create substantial doubt about the Companys ability to continue as a going concern. No adjustment has been made to our financial statements as a result of this uncertainty.   See Note 7 for further discussion with respect to the assignment of $3.0 million of the principal balance of the Hercules Term Loan to Riverside Merchant Partners, LLC (Riverside) and the subsequent agreement between the Company and Riverside to exchange the $3.0 million of the Hercules Term Loan held by Riverside for subordinated convertible promissory notes in the aggregate principal amount of $3.0 million.

New Accounting Pronouncements   In March 2016 the Financial Accounting Standards Board (FASB) updated the accounting guidance related to stock compensation. This update simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company is still evaluating the impact that this standard will have on its consolidated financial statements.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (IASB) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. Additionally, this update will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the potential impact this new standard may have on its financial statements.   In August 2014, the FASB updated the accounting guidance related to disclosure of uncertainties about an entitys ability to continue as a going concern. The new standard provides guidance on determining when and how to disclose going concern uncertainties in the financial statements. It requires management to perform interim and annual assessments of an entitys ability to continue as a going concern. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The impact on the Companys financial statements of adopting the new standard is currently being assessed by management.   In May 2014, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the potential impact of this adoption on its consolidated financial statements.

The following is a reconciliation of the effect of these reclassifications on the Companys Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Reported</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Adjustments</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">As Revised</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Assets:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 49%; padding-left: 10pt; line-height: 115%">Prepaid expenses and other current assets</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">821</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">(592</td> <td style="width: 1%; line-height: 115%">)</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">229</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Liabilities:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%">Current portion of long-term debt</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,957</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">(592</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">16,365</td> <td style="line-height: 115%"> </td></tr> </table>

The components of inventory were as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016 </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Raw materials</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">819</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">WIP</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">268</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">235</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Finished Goods</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,103</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">8,077</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total inventory</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">8,144</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">9,131</td> <td style="line-height: 115%"> </td></tr> </table>

Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Customer relationships</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">3,990</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Developed technology</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,685</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Other patents and patent applications</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Trademarks</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">350</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">9,587</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Less accumulated amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(6,150</td> <td style="line-height: 115%">)</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">(5,900</td> <td style="line-height: 115%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%">Total intangibles net of amortization</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,437</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,687</td> <td style="line-height: 115%"> </td></tr> </table>

Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">June 30, 2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">December 31, 2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 115%">Commissions</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">592</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 20%; text-align: right; line-height: 115%">867</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Payroll and related expenses</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">562</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">683</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Royalties</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">472</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">515</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Interest payable</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">195</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">222</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Final loan payment fees</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,091</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">783</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Other</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">557</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">351</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Total accrued liabilities</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,469</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">3,421</td> <td style="line-height: 115%"> </td></tr> </table>

244000

267000

Principal payments commenced August 1, 2015 and are currently being made in equal installments of approximately $500,000, with the remainder due at maturity.

413000

888000

840000

5018

23582001 0001269026

EX-101.SCH 6 amda-20160630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basic and Diluted Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Inventories - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Debt - Schedule of Outstanding Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Debt - Schedule of Future Principal Payments on Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 amda-20160630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 amda-20160630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 amda-20160630_lab.xml XBRL LABEL FILE Employee Stock Option [Member] Award Type [Axis] Customer Relationships [Member] Finite Lived Intangible Assets By Major Class [Axis] Developed Technology [Member] Other Patents And Patent Applications [Member] Trademarks [Member] Indefinite Lived Intangible Assets By Major Class [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Recurring [Member] Measurement Frequency [Axis] Common Stock Warrants [Member] Equity Components [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Derivative Financial Instruments, Liabilities [Member] Liability Class [Axis] Convertible Notes [Member] Hercules Term Loan [Member] Debt Instrument [Axis] Convertible Notes Payable [Member] Short-term Debt, Type [Axis] Magna Note [Member] Hercules Technology Capital, Inc. [Member] Related Party Transactions By Related Party [Axis] Loan and Security Agreement [Member] Agreement [Axis] Prime Rate [Member] Variable Rate [Axis] First Amendment to Loan and Security Agreement [Member] Minimum [Member] Range [Axis] 2012 Plan [Member] Plan Name [Axis] Cost Of Revenue [Member] Income Statement Location [Axis] Research and Development [Member] General and Administrative [Member] Selling and Marketing [Member] Capitalized Into Inventory [Member] Riverside Merchant Partners, LLC [Member] Previously Reported [Member] Scenario [Axis] Adjustment [Member] Common Stock [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Series A Warrants [Member] Securities Purchase Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Hampshire MedTech Partners II, GP [Member] Other Commitments [Axis] Riverside Note [Member] Riverside [Member] Maximum [Member] Subsequent Event [Member] Subsequent Event Type [Axis] Secondary Offering [Member] Sale of Stock [Axis] Class A Unit [Member] Class of Stock [Axis] Underwriters [Member] Class B Unit [Member] Warrants [Member] Convertible Preferred Stock [Member] Riverside Debt [Member] Hercules and Riverside Debt Assignment [Member] Exchange Agreement [Member] Warrant [Member] First, Second and Third Exchange Agreement [Member] Common Stock One [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Trade accounts receivable, net of allowance of $26 and $49, respectively Prepaid expenses and other current assets Inventories, net Total current assets Property and equipment, net Intangible assets, net Goodwill Other long-term assets Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable Accrued liabilities Current portion of lease liability Current portion of long-term debt Total current liabilities Deferred rent Long-term debt Lease liability, net of current portion Other long-term liabilities Derivative liabilities Commitments and contingencies Stockholders' equity: Common stock, $0.01 par value; 250,000,000 shares authorized; 13,306,001 and 10,886,248 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Allowance of trade accounts receivable Common stock, per value Common stock, authorized, shares Common stock, issued, shares Common stock, outstanding, shares Income Statement [Abstract] Product revenue Costs of revenue Gross profit Operating expenses: Research and development General and administrative Sales and marketing Total operating expenses Loss from operations Other income (expense): Interest expense Loss on extinguishment of debt Change in fair value of derivative liabilities Loss on extinguishment of derivative liabilities Other expense Total other income (expense) Net loss before income taxes Provision for income taxes Net comprehensive loss Other comprehensive loss, net of tax: Total comprehensive loss Net loss per share attributable to common stockholders: Basic and diluted Weighted average common shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Cash flow from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Amortization of intangible assets Amortization of lease incentive for tenant improvements Non cash interest expense Loss on extinguishment of debt Stock based compensation Change in fair value of derivative liabilities Loss on extinguishment of derivative liabilities (Gain) loss on disposal of equipment Provision for inventory reserve Bad debt recovery Changes in operating assets and liabilities: Trade accounts receivable Prepaid expenses and other current assets Inventories Accounts payable and accrued liabilities Net cash used in operating activities Cash flows from investing activities Purchase of property and equipment Proceeds from sale of property and equipment Net cash used in investing activities Cash flows from financing activities Proceeds from the exercise of warrants Payments on long-term debt Issuance costs paid for debt Payments for capital lease Purchase of treasury stock Net cash used in financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Noncash investing and financing activities Deferred financing costs included in accounts payable and accrued liabilities Debt converted to common stock Common stock issued for cashless exercise of warrant derivative liabilities Issuance of treasury stock upon conversion of RSUs to common stock Capital lease for property and equipment Supplemental cash flow information Cash paid for interest Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Earnings Per Share [Abstract] Basic and Diluted Net Loss Per Common Share Inventory Disclosure [Abstract] EX-101.PRE 10 amda-20160630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 08, 2016
Document And Entity Information
Entity Registrant Name	AMEDICA Corp
Entity Central Index Key	0001269026
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		23,582,001
Trading Symbol	AMDA
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,155	$ 11,485
Trade accounts receivable, net of allowance of $26 and $49, respectively	1,950	2,660
Prepaid expenses and other current assets	531	229
Inventories, net	8,144	9,131
Total current assets	15,780	23,505
Property and equipment, net	2,090	2,472
Intangible assets, net	3,437	3,687
Goodwill	6,163	6,163
Other long-term assets	35	35
Total assets	27,505	35,862
Current liabilities:
Accounts payable	1,960	643
Accrued liabilities	3,469	3,421
Current portion of lease liability	19
Current portion of long-term debt	10,681	16,365
Total current liabilities	16,129	20,429
Deferred rent	376	432
Long-term debt	469
Lease liability, net of current portion	38
Other long-term liabilities	166	171
Derivative liabilities	574	598
Stockholders' equity:
Common stock, $0.01 par value; 250,000,000 shares authorized; 13,306,001 and 10,886,248 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	133	109
Additional paid-in capital	214,609	210,660
Accumulated deficit	(204,989)	(196,537)
Total stockholders' equity	9,753	14,232
Total liabilities and stockholders' equity	$ 27,505	$ 35,862

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance of trade accounts receivable	$ 26	$ 49
Common stock, per value	$ 0.01	$ 0.01
Common stock, authorized, shares	250,000,000	250,000,000
Common stock, issued, shares	13,306,001	10,886,248
Common stock, outstanding, shares	13,306,001	10,886,248

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Product revenue	$ 4,023	$ 4,780	$ 8,196	$ 9,523
Costs of revenue	1,017	1,363	1,910	2,885
Gross profit	3,006	3,417	6,286	6,638
Operating expenses:
Research and development	1,553	1,553	3,161	3,396
General and administrative	1,360	1,334	2,922	3,361
Sales and marketing	2,594	3,126	5,188	6,483
Total operating expenses	5,507	6,013	11,271	13,240
Loss from operations	(2,501)	(2,596)	(4,985)	(6,602)
Other income (expense):
Interest expense	(2,353)	(1,134)	(3,253)	(2,234)
Loss on extinguishment of debt	(244)		(244)	(79)
Change in fair value of derivative liabilities	35	(923)	24	(1,100)
Loss on extinguishment of derivative liabilities		(1,245)		(1,261)
Other expense	(1)	(35)	6	(38)
Total other income (expense)	(2,563)	(3,337)	(3,467)	(4,712)
Net loss before income taxes	(5,064)	(5,933)	(8,452)	(11,314)
Provision for income taxes
Net comprehensive loss	(5,064)	(5,933)	(8,452)	(11,314)
Other comprehensive loss, net of tax:
Total comprehensive loss	$ (5,064)	$ (5,933)	$ (8,452)	$ (11,314)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.4)	$ (1.64)	$ (0.71)	$ (4.16)
Weighted average common shares outstanding:
Basic and diluted	12,761,814	3,622,491	11,981,865	2,717,688

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flow from operating activities
Net loss	$ (8,452)	$ (11,314)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	772	841
Amortization of intangible assets	250	250
Amortization of lease incentive for tenant improvements	10	10
Non cash interest expense	2,365	1,130
Loss on extinguishment of debt	244	79
Stock based compensation	145	704
Change in fair value of derivative liabilities	(24)	1,100
Loss on extinguishment of derivative liabilities		1,261
(Gain) loss on disposal of equipment	(7)	4
Provision for inventory reserve	696	625
Bad debt recovery		(7)
Changes in operating assets and liabilities:
Trade accounts receivable	711	11
Prepaid expenses and other current assets	(219)	(289)
Inventories	296	556
Accounts payable and accrued liabilities	834	(284)
Net cash used in operating activities	(2,379)	(5,323)
Cash flows from investing activities
Purchase of property and equipment	(350)	(417)
Proceeds from sale of property and equipment	23	7
Net cash used in investing activities	(327)	(410)
Cash flows from financing activities
Proceeds from the exercise of warrants	1
Payments on long-term debt	(3,424)
Issuance costs paid for debt	(198)
Payments for capital lease	(3)
Purchase of treasury stock		(120)
Net cash used in financing activities	(3,624)	(120)
Net decrease in cash and cash equivalents	(6,330)	(5,853)
Cash and cash equivalents at beginning of period	11,485	18,247
Cash and cash equivalents at end of period	5,155	12,394
Noncash investing and financing activities
Deferred financing costs included in accounts payable and accrued liabilities	69
Debt converted to common stock	2,480	202
Common stock issued for cashless exercise of warrant derivative liabilities		11,563
Issuance of treasury stock upon conversion of RSUs to common stock		120
Capital lease for property and equipment	60
Supplemental cash flow information
Cash paid for interest	$ 938	$ 1,110

XML 16 R6.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

Basis of Presentation

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments			As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592	)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592	)		16,365

Use of Estimates

Liquidity and Capital Resources

Significant Accounting Policies

There have been no significant changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

New Accounting Pronouncements

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share

6 Months Ended

Jun. 30, 2016

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Common Share

2. Basic and Diluted Net Loss per Common Share

XML 18 R8.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Inventories

3. Inventories

The components of inventory were as follows (in thousands):

	June 30, 2016		December 31, 2015
Raw materials	$	773	$	819
WIP		268		235
Finished Goods		7,103		8,077
Total inventory	$	8,144	$	9,131

Finished goods include consigned inventory in the amounts of approximately $3.6 million and $3.8 million as of June 30, 2016 and December 31, 2015, respectively.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2016			December 31, 2015
Customer relationships	$	3,990		$	3,990
Developed technology		4,685			4,685
Other patents and patent applications		562			562
Trademarks		350			350
Total intangibles		9,587			9,587
Less accumulated amortization		(6,150	)		(5,900	)
Total intangibles net of amortization	$	3,437		$	3,687

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

Level 1	-	quoted market prices for identical assets or liabilities in active markets.

Level 2	-	observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3	-	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

	Fair Value Measurements at June 30, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	574	$	574

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

	Common Stock Warrants			Convertible Notes			Total Derivative Liability
Balance at December 31, 2014	$	(11,358	)	$	(2,612	)	$	(13,970	)
Decrease in liability due to debt conversions		-			179			179
Decrease in liability due to warrants being exercised		10,302			-			10,302
Change in fair value		208			(1,308	)		(1,100	)
Balance at June 30, 2015	$	(848	)	$	(3,741	)	$	(4,589	)

Balance at December 31, 2015	$	(598	)	$	-		$	(598	)
Decrease in fair value included in earnings, as other income		24			-			24
Balance at June 30, 2016	$	(574	)	$	-		$	(574	)

Common Stock Warrants

The assumptions used in estimating the common stock warrant liability at June 30, 2016 and December 31, 2015 were as follows:

	June 30, 2016			December 31, 2015
Weighted-average risk free interest rate		0.84	%		1.71	%
Weighted-average expected life (in years)		3.5			3.7
Expected dividend yield		0	%		0	%
Weighted average expected volatility		119	%		119	%

Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2016		December 31, 2015
Commissions	$	592	$	867
Payroll and related expenses		562		683
Royalties		472		515
Interest payable		195		222
Final loan payment fees		1,091		783
Other		557		351
Total accrued liabilities	$	3,469	$	3,421

XML 22 R12.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Debt

7. Debt

Hercules Term Loan

Magna Note

Hercules and Riverside Debt Exchange

Riverside Debt

Outstanding long-term debt consisted of the following (in thousands):

	June 30, 2016									December 31, 2015
	Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount			Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
Hercules Term Loan		10,628			(706	)		9,922			17,051			(1,420	)		15,631
Convertible Note		700			(231	)		469			-			-			-
Magna Note		763			(4	)		759			763			(29	)		734
Total debt		12,091			(941	)		11,150			17,814			(1,449	)		16,365
Less: Current portion		(11,391	)		710			(10,681	)		(17,814	)		1,449			(16,365	)
Long-term debt	$	700		$	(231	)	$	469		$	-		$	-		$	-

The following summarizes by year the future principal payments as of June 30, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Riverside Note		Total
2016	$	3,111	$	763	$	-	$	3,874
2017		6,858		-		-		6,858
2018		659		-		700		1,359
Total future principal payments	$	10,628	$	763	$	700	$	12,091

XML 23 R13.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2016

Equity [Abstract]

Equity

8. Equity

1,882,718 shares of common stock were issued related to the Riverside Debt discussed in Note 7.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

Option and Equity Plans

The total number of shares available for grant under the 2012 Plan at June 30, 2016 was 921,272.

Stock Options

A summary of the Company’s stock option activity for the six months ended June 30, 2016 was as follows:

	Options			Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373		$	41.53
Granted		23,004		$	1.69
Expired		(13,702	)	$	24.17
Outstanding at June 30, 2016		121,675		$	35.95
Exercisable at June 30, 2016		81,111		$	56.73
Vested and expected to vest at June 30, 2016		119,738		$	36.37

	Six Months Ended June 30
	2016			2015
Weighted-average risk-free interest rate		1.86	%		1.63	%
Weighted-average expected life (in years)		6.3			6.3
Expected dividend yield		0	%		0	%
Weighted-average expected volatility		65	%		47	%

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Cost of revenue	$	3	$	5	$	7	$	34
Research and development		24		37		53		159
General and administrative		35		31		75		359
Selling and marketing		2		10		17		152
Capitalized into inventory		1		7		3		46
Total stock-based compensation expense	$	65	$	90	$	155	$	750

Unrecognized stock-based compensation at June 30, 2016 was as follows (in thousands):

		Unrecognized Stock- Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	370				1.5

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

XML 26 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Secondary Offering

Subsequent to the secondary offering, 5,018 shares of convertible preferred stock have been converted into 5,018,000 shares of common stock.

Magna Note

In July 2016, the Company paid Magna $888,000 to redeem in full the remaining principal balance and interest related to the Magna Note.

Riverside Debt

In July 2016, the Company paid Riverside $840,000 to redeem in full the remaining principal balance and interest related to the Riverside Debt.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Organization

Organization

Basis of Presentation

Basis of Presentation

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments			As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592	)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592	)		16,365

Use of Estimates

Use of Estimates

Liquidity and Capital Resources

Liquidity and Capital Resources

New Accounting Pronouncements

New Accounting Pronouncements

XML 28 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Accounting Policies [Abstract]

Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet

The following is a reconciliation of the effect of these reclassifications on the Company’s Condensed Consolidated Balance Sheet at December 31, 2015 (in thousands):

	December 31, 2015
	As Reported		Adjustments			As Revised
Assets:
Prepaid expenses and other current assets	$	821	$	(592	)	$	229
Liabilities:
Current portion of long-term debt		16,957		(592	)		16,365

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2016

Inventory Disclosure [Abstract]

Components of Inventory

The components of inventory were as follows (in thousands):

	June 30, 2016		December 31, 2015
Raw materials	$	773	$	819
WIP		268		235
Finished Goods		7,103		8,077
Total inventory	$	8,144	$	9,131

XML 30 R20.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2016			December 31, 2015
Customer relationships	$	3,990		$	3,990
Developed technology		4,685			4,685
Other patents and patent applications		562			562
Trademarks		350			350
Total intangibles		9,587			9,587
Less accumulated amortization		(6,150	)		(5,900	)
Total intangibles net of amortization	$	3,437		$	3,687

XML 31 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2016

Fair Value Disclosures [Abstract]

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at June 30, 2016 and December 31, 2015:

	Fair Value Measurements at June 30, 2016
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	574	$	574

	Fair Value Measurements at December 31, 2015
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	598	$	598

Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3)

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2016 and 2015:

	Common Stock Warrants			Convertible Notes			Total Derivative Liability
Balance at December 31, 2014	$	(11,358	)	$	(2,612	)	$	(13,970	)
Decrease in liability due to debt conversions		-			179			179
Decrease in liability due to warrants being exercised		10,302			-			10,302
Change in fair value		208			(1,308	)		(1,100	)
Balance at June 30, 2015	$	(848	)	$	(3,741	)	$	(4,589	)

Balance at December 31, 2015	$	(598	)	$	-		$	(598	)
Decrease in fair value included in earnings, as other income		24			-			24
Balance at June 30, 2016	$	(574	)	$	-		$	(574	)

Schedule of Assumptions used in Estimating Common Stock Warrant Liability

The assumptions used in estimating the common stock warrant liability at June 30, 2016 and December 31, 2015 were as follows:

	June 30, 2016			December 31, 2015
Weighted-average risk free interest rate		0.84	%		1.71	%
Weighted-average expected life (in years)		3.5			3.7
Expected dividend yield		0	%		0	%
Weighted average expected volatility		119	%		119	%

XML 32 R22.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2016

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2016		December 31, 2015
Commissions	$	592	$	867
Payroll and related expenses		562		683
Royalties		472		515
Interest payable		195		222
Final loan payment fees		1,091		783
Other		557		351
Total accrued liabilities	$	3,469	$	3,421

XML 33 R23.htm IDEA: XBRL DOCUMENT

Debt (Tables)

6 Months Ended

Jun. 30, 2016

Debt Disclosure [Abstract]

Schedule of Outstanding Long-Term Debt

Outstanding long-term debt consisted of the following (in thousands):

	June 30, 2016									December 31, 2015
	Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount			Outstanding Principal			Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
Hercules Term Loan		10,628			(706	)		9,922			17,051			(1,420	)		15,631
Convertible Note		700			(231	)		469			-			-			-
Magna Note		763			(4	)		759			763			(29	)		734
Total debt		12,091			(941	)		11,150			17,814			(1,449	)		16,365
Less: Current portion		(11,391	)		710			(10,681	)		(17,814	)		1,449			(16,365	)
Long-term debt	$	700		$	(231	)	$	469		$	-		$	-		$	-

Schedule of Future Principal Payments on Debt

The following summarizes by year the future principal payments as of June 30, 2016 (in thousands):

Years Ending December 31,	Hercules Term Loan		Magna Note		Riverside Note		Total
2016	$	3,111	$	763	$	-	$	3,874
2017		6,858		-		-		6,858
2018		659		-		700		1,359
Total future principal payments	$	10,628	$	763	$	700	$	12,091

XML 34 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity for the six months ended June 30, 2016 was as follows:

	Options			Weighted-Average Exercise Price
Outstanding at December 31, 2015		112,373		$	41.53
Granted		23,004		$	1.69
Expired		(13,702	)	$	24.17
Outstanding at June 30, 2016		121,675		$	35.95
Exercisable at June 30, 2016		81,111		$	56.73
Vested and expected to vest at June 30, 2016		119,738		$	36.37

Schedule of Black-Scholes-Merton Option Pricing Model

The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the six months ended June 30, 2016 and 2015:

	Six Months Ended June 30
	2016			2015
Weighted-average risk-free interest rate		1.86	%		1.63	%
Weighted-average expected life (in years)		6.3			6.3
Expected dividend yield		0	%		0	%
Weighted-average expected volatility		65	%		47	%

Schedule of Stock-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Cost of revenue	$	3	$	5	$	7	$	34
Research and development		24		37		53		159
General and administrative		35		31		75		359
Selling and marketing		2		10		17		152
Capitalized into inventory		1		7		3		46
Total stock-based compensation expense	$	65	$	90	$	155	$	750

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Unrecognized stock-based compensation at June 30, 2016 was as follows (in thousands):

		Unrecognized Stock- Based Compensation				Weighted Average Remaining Period of Recognition (in years)
Stock options		$	370				1.5

XML 35 R25.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ 5,064	$ 5,933	$ 8,452	$ 11,314
Net cash used in operating activities			2,379	5,323
Accumulated deficit	204,989		$ 204,989		$ 196,537
Debt instrument, payment terms			As discussed further in Note 7, the Company entered into a term loan with Hercules Technology Growth Capital, Inc. (“Hercules Technology”), as administrative and collateral agent for the lenders thereunder and as lender, and Hercules Technology III, LP, (“HT III” and, together with Hercules Technology, “Hercules”) as lender (the “Hercules Term Loan”). The Hercules Term Loan has a liquidity covenant that requires the Company to maintain a cash balance of not less than $4.5 million at June 30, 2016.
Cash and cash equivalents	5,155	$ 12,394	$ 5,155	$ 12,394	11,485	$ 18,247
Debt principal amount	12,091		12,091		17,814
Hercules Term Loan [Member]
Debt principal amount	10,628		10,628		$ 17,051
Hercules Term Loan [Member] \| Minimum [Member]
Cash and cash equivalents	4,500		4,500
Riverside Merchant Partners, LLC [Member]
Debt principal amount	3,000		3,000
Subordinated convertible promissory notes	3,000		3,000
Converitble promissory notes in aggregate principal amount	$ 3,000		$ 3,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets	$ 531	$ 229
Current portion of long-term debt	$ 10,681	16,365
Previously Reported [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets		821
Current portion of long-term debt		16,957
Adjustment [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid expenses and other current assets		(592)
Current portion of long-term debt		$ (592)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Common Stock [Member]
Potentially dilutive securities	1,500,000	1,000,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods include consigned inventory	$ 3,600	$ 3,800

XML 39 R29.htm IDEA: XBRL DOCUMENT

Inventories - Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 773	$ 819
WIP	268	235
Finished Goods	7,103	8,077
Total inventory	$ 8,144	$ 9,131

XML 40 R30.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) $ in Thousands	Jun. 30, 2016 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Estimated amortization expense, remainder of 2016	$ 250
Estimated amortization expense, 2017	501
Estimated amortization expense, 2018	501
Estimated amortization expense, 2019	501
Estimated amortization expense, 2020	501
Estimated amortization expense, thereafter	$ 834

XML 41 R31.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 9,587	$ 9,587
Less accumulated amortization	(6,150)	(5,900)
Total intangibles net of amortization	3,437	3,687
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	350	350
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	3,990	3,990
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	4,685	4,685
Other Patents And Patent Applications [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangibles	$ 562	$ 562

XML 42 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Financial assets measured on recurring basis

XML 43 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 574	$ 598
Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	574	598
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 574	$ 598

XML 44 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	$ (35)	$ 923	$ (24)	$ 1,100
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance			(598)	(13,970)
Decrease in liability due to debt conversions				179
Decrease in liability due to warrants being exercised				10,302
Change in fair value				(1,100)
Decrease in fair value included in earnings, as other income			24
Ending balance	(574)	(4,589)	(574)	(4,589)
Derivative Financial Instruments, Liabilities [Member] \| Common Stock Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance			(598)	(11,358)
Decrease in liability due to debt conversions
Decrease in liability due to warrants being exercised				10,302
Change in fair value				208
Decrease in fair value included in earnings, as other income			24
Ending balance	(574)	(848)	(574)	(848)
Derivative Financial Instruments, Liabilities [Member] \| Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				(2,612)
Decrease in liability due to debt conversions				179
Decrease in liability due to warrants being exercised
Change in fair value				(1,308)
Decrease in fair value included in earnings, as other income
Ending balance		$ (3,741)		$ (3,741)

XML 45 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Weighted-average risk free interest rate	0.84%	1.71%
Weighted-average expected life (in years)	3 years 6 months	3 years 8 months 12 days
Expected dividend yield	0.00%	0.00%
Weighted average expected volatility	119.00%	119.00%

XML 46 R36.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Commissions	$ 592	$ 867
Payroll and related expenses	562	683
Royalties	472	515
Interest payable	195	222
Final loan payment fees	1,091	783
Other	557	351
Total accrued liabilities	$ 3,469	$ 3,421

XML 47 R37.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						6 Months Ended
	Apr. 28, 2016	Apr. 18, 2016	Apr. 04, 2016	Sep. 08, 2015	Jun. 30, 2014	Jun. 30, 2016	May 06, 2016	Apr. 02, 2016	Dec. 31, 2015	Aug. 31, 2014
Debt principal amount						$ 12,091			$ 17,814
Number of shares issued						13,306,001			10,886,248
Exchange Agreement [Member]
Percentage of loan bear interest rate						6.00%
Debt principal balance						$ 300
Debt instrument conversion price						$ 1.34
Hercules Term Loan [Member]
Debt principal amount						$ 10,628			$ 17,051
Term loan fee amount					$ 200
Final payment fee for debt					$ 1,700
Percentage of loan bear interest rate						12.70%
Term loan, payment terms						Principal payments commenced August 1, 2015 and are currently being made in equal installments of approximately $500,000, with the remainder due at maturity.
Debt instrument, periodic payment, principal						$ 500
Hercules Term Loan [Member] \| Prime Rate [Member]
Percentage of loan bear interest rate					9.20%	12.50%
Riverside Merchant Partners, LLC [Member]
Debt principal amount						$ 3,000
Subordinated convertible promissory notes						3,000
Riverside Merchant Partners, LLC [Member] \| Hercules and Riverside Debt Assignment [Member]
Debt principal amount		$ 1,000	$ 1,000
Debt additional principal		1,000	2,000
Magna Note [Member]
Debt principal amount						763			$ 763
Magna Note [Member] \| Securities Purchase Agreement [Member]
Debt principal amount						$ 763				$ 3,500
Debt maturity date						Aug. 11, 2016
Percentage of loan bear interest rate						6.00%
Riverside Debt [Member]
Derivative Liability							$ 199
Number of shares issued							140,000
First Amendment to Loan and Security Agreement [Member] \| Hercules Term Loan [Member]
Debt principal amount				$ 1,000		$ 4,500
Debt instrument, covenant description				The Amendment modified the liquidity covenant to reduce the minimum cash balance required by $500,000 for every $1.0 million paid in principal to a minimum of $2.5 million. The minimum cash and cash equivalents balance required to maintain compliance with the minimum liquidity covenant at June 30, 2016 was $4.5 million.
Debt principal balance				$ 2,500
First Amendment to Loan and Security Agreement [Member] \| Hercules Term Loan [Member] \| Minimum [Member]
Debt principal amount				$ 500
Exchange Agreement [Member] \| First, Second and Third Exchange Agreement [Member]
Debt principal balance						$ 700
Exchange Agreement [Member] \| Hercules and Riverside Debt Assignment [Member]
Debt principal amount			2,000
Debt additional principal			$ 2,000
Warrant to purchase shares of common stock			100,000
Number of shares issued			150,000
Number of shares reduced			140,000
Exchange Agreement [Member] \| Hercules Term Loan [Member]
Financing costs	$ 267
Debt conversion original debt amount	244
Exchange Agreement [Member] \| First, Second and Third Exchange Agreement [Member]
Debt instrument converted shares						1,742,718
Exchange Agreement [Member] \| Riverside Debt [Member]
Debt principal amount			$ 1,000					$ 1,000
Debt additional principal			$ 1,000
Debt instrument conversion price			$ 1.43
Common stock closing preice per share			$ 1.63
Debt Instrument premium amount			$ 246
Fair Value of Warrants			$ 106
Exchange Agreement [Member] \| Riverside Debt [Member] \| Warrant [Member]
Warrant to purchase shares of common stock			100,000
Warrant exercise price per share			$ 1.63
Exchange Agreement [Member] \| Riverside Debt [Member] \| Hercules Term Loan [Member]
Debt principal amount	1,000	1,000
Debt additional principal	$ 1,000	$ 1,000
Warrant to purchase shares of common stock	100,000
Warrant exercise price per share	$ 1.66
Common stock closing preice per share	$ 1.66	$ 2.02
Debt Instrument premium amount	$ 268
Debt beneficial conversion feature		$ 413
Fair Value of Warrants		$ 107
Hercules Technology Capital, Inc. [Member] \| Loan and Security Agreement [Member]
Debt principal amount					$ 20,000
Debt maturity date					Jan. 01, 2018
Hercules Term Loan [Member] \| Riverside Merchant Partners, LLC [Member]
Debt principal amount						$ 3,000

XML 48 R38.htm IDEA: XBRL DOCUMENT

Debt - Schedule of Outstanding Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total debt, outstanding principal	$ 12,091	$ 17,814
Total debt, unamortized discount	(941)	(1,449)
Total debt, net carrying amount	11,150	16,365
Current portion, outstanding principal	(11,391)	(17,814)
Current portion, unamortized discount	710	1,449
Current portion, net carrying amount	(10,681)	(16,365)
Long-term debt, outstanding principal	700
Long-term debt, unamortized discount	(231)
Long-term debt	469
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Total debt, outstanding principal	10,628	17,051
Total debt, unamortized discount	(706)	(1,420)
Total debt, net carrying amount	9,922	15,631
Convertible Notes [Member]
Debt Instrument [Line Items]
Total debt, outstanding principal	700
Total debt, unamortized discount	(231)
Total debt, net carrying amount	469
Magna Note [Member]
Debt Instrument [Line Items]
Total debt, outstanding principal	763	763
Total debt, unamortized discount	(4)	(29)
Total debt, net carrying amount	$ 759	$ 734

XML 49 R39.htm IDEA: XBRL DOCUMENT

Debt - Schedule of Future Principal Payments on Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Total future principal payments	$ 11,150	$ 16,365
Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	3,874
2017	6,858
2018	1,359
Total future principal payments	12,091
Hercules Term Loan [Member]
Line of Credit Facility [Line Items]
Total future principal payments	9,922	15,631
Hercules Term Loan [Member] \| Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	3,111
2017	6,858
2018	659
Total future principal payments	10,628
Magna Note [Member]
Line of Credit Facility [Line Items]
Total future principal payments	759	$ 734
Magna Note [Member] \| Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016	763
2017
2018
Total future principal payments	763
Riverside Note [Member] \| Convertible Notes Payable [Member]
Line of Credit Facility [Line Items]
2016
2017
2018	700
Total future principal payments	$ 700

XML 50 R40.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative)	6 Months Ended
Equity (Details Narrative)	Jun. 30, 2016 shares
Series A Warrants [Member]
Common stock shares, issued	536,388
Number of shares issued upon cashless exercise warrants	1,137,365
Common Stock [Member]
Number of shares issued upon cashless exercise warrants	647
Riverside [Member]
Number of shares issued upon cashless exercise warrants	1,882,718

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - 2012 Plan [Member] - shares	1 Months Ended
	May 31, 2016	Jun. 30, 2016
Shares issuable with respect to awards granted	800,000
Number of shares available for grant		921,272
Minimum [Member]
Shares issuable with respect to awards maximum shares	342,425
Maximum [Member]
Shares issuable with respect to awards maximum shares	1,142,425

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2016 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options, Outstanding at beginning of period \| shares	112,373
Options, Granted \| shares	23,004
Options, Expired \| shares	(13,702)
Options, Outstanding at end of period \| shares	121,675
Options, Exercisable at end of period \| shares	81,111
Options, Vested and expected to vest at end of period \| shares	119,738
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares	$ 41.53
Weighted Average Exercise Price, Granted \| $ / shares	1.69
Weighted Average Exercise Price, Expired \| $ / shares	24.17
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	35.95
Weighted Average Exercise Price, Exercisable at end of period \| $ / shares	56.73
Weighted Average Exercise Price, Vested and expected to vest at end of period \| $ / shares	$ 36.37

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average risk-free interest rate	1.86%	1.63%
Weighted-average expected life (in years)	6 years 3 months 18 days	6 years 3 months 18 days
Expected dividend yield	0.00%	0.00%
Weighted-average expected volatility	65.00%	47.00%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 65	$ 90	$ 155	$ 750
Cost Of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	3	5	7	34
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	24	37	53	159
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	35	31	75	359
Selling and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	2	10	17	152
Capitalized Into Inventory [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 1	$ 7	$ 3	$ 46

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) - Employee Stock Option [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2016 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation	$ 370
Weighted average remaining period of recognition (in years)	1 year 6 months

XML 56 R46.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) $ in Thousands	Apr. 02, 2016 USD ($)
Hampshire MedTech Partners II, GP [Member]
Seeks damages amount	$ 1,000

XML 57 R47.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Common stock, issued		13,306,001	10,886,248
Subsequent Event [Member] \| Magna Note [Member]
Subsequent Event [Line Items]
Repayment of debt	$ 888
Subsequent Event [Member] \| Riverside Debt [Member]
Subsequent Event [Line Items]
Repayment of debt	$ 840
Subsequent Event [Member] \| Secondary Offering [Member]
Subsequent Event [Line Items]
Class of unit description	Each Class A Unit consisted of one share of common stock and one warrant to purchase one share of common stock. Each Class B Unit consisted of one share of preferred stock convertible into 1,000 shares of common stock and warrants to purchase 1,000 shares of common stock.
Proceeds from issuance of shares, net	$ 11,300
Subsequent Event [Member] \| Secondary Offering [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Common stock, issued	5,258,000
Conversion of stock number of shares issued	7,392,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Warrants [Member]
Subsequent Event [Line Items]
Price per unit	$ 1.00
Conversion of stock number of shares issued	12,650,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, issued	7,392,000
Number of convertible preferred stock converted into shares of common stock	5,018
Subsequent Event [Member] \| Secondary Offering [Member] \| Common Stock One [Member]
Subsequent Event [Line Items]
Conversion of stock number of shares issued	5,018,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Class A Unit [Member]
Subsequent Event [Line Items]
Number of units sold	5,258,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Class A Unit [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares in each class of units	1
Subsequent Event [Member] \| Secondary Offering [Member] \| Class A Unit [Member] \| Warrants [Member]
Subsequent Event [Line Items]
Number of shares in each class of units	1
Subsequent Event [Member] \| Secondary Offering [Member] \| Class A Unit [Member] \| Underwriters [Member]
Subsequent Event [Line Items]
Number of units sold	1,650,000
Price per unit	$ 1.00
Subsequent Event [Member] \| Secondary Offering [Member] \| Class B Unit [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares in each class of units	1,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Class B Unit [Member] \| Warrants [Member]
Subsequent Event [Line Items]
Number of shares in each class of units	1,000
Subsequent Event [Member] \| Secondary Offering [Member] \| Class B Unit [Member] \| Underwriters [Member]
Subsequent Event [Line Items]
Number of units sold	7,392
Price per unit	$ 1,000

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 137 212 1 false 55 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://amedica.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://amedica.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://amedica.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://amedica.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://amedica.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Basic and Diluted Net Loss Per Common Share Sheet http://amedica.com/role/BasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss Per Common Share Notes 7 false false R8.htm 00000008 - Disclosure - Inventories Sheet http://amedica.com/role/Inventories Inventories Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://amedica.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Fair Value Measurements Sheet http://amedica.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 00000011 - Disclosure - Accrued Liabilities Sheet http://amedica.com/role/AccruedLiabilities Accrued Liabilities Notes 11 false false R12.htm 00000012 - Disclosure - Debt Sheet http://amedica.com/role/Debt Debt Notes 12 false false R13.htm 00000013 - Disclosure - Equity Sheet http://amedica.com/role/Equity Equity Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://amedica.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://amedica.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://amedica.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Inventories (Tables) Sheet http://amedica.com/role/InventoriesTables Inventories (Tables) Tables http://amedica.com/role/Inventories 19 false false R20.htm 00000020 - Disclosure - Intangible Assets (Tables) Sheet http://amedica.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://amedica.com/role/IntangibleAssets 20 false false R21.htm 00000021 - Disclosure - Fair Value Measurements (Tables) Sheet http://amedica.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://amedica.com/role/FairValueMeasurements 21 false false R22.htm 00000022 - Disclosure - Accrued Liabilities (Tables) Sheet http://amedica.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://amedica.com/role/AccruedLiabilities 22 false false R23.htm 00000023 - Disclosure - Debt (Tables) Sheet http://amedica.com/role/DebtTables Debt (Tables) Tables http://amedica.com/role/Debt 23 false false R24.htm 00000024 - Disclosure - Stock-Based Compensation (Tables) Sheet http://amedica.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://amedica.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) Sheet http://amedica.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies-ScheduleOfReconciliationOfEffectOfReclassificationsOnCondensedConsolidatedBalanceSheetDetails Organization and Summary of Significant Accounting Policies - Schedule of Reconciliation of Effect of Reclassifications on Condensed Consolidated Balance Sheet (Details) Details 26 false false R27.htm 00000027 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) Sheet http://amedica.com/role/BasicAndDilutedNetLossPerCommonShareDetailsNarrative Basic and Diluted Net Loss Per Common Share (Details Narrative) Details http://amedica.com/role/BasicAndDilutedNetLossPerCommonShare 27 false false R28.htm 00000028 - Disclosure - Inventories (Details Narrative) Sheet http://amedica.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://amedica.com/role/InventoriesTables 28 false false R29.htm 00000029 - Disclosure - Inventories - Components of Inventory (Details) Sheet http://amedica.com/role/Inventories-ComponentsOfInventoryDetails Inventories - Components of Inventory (Details) Details 29 false false R30.htm 00000030 - Disclosure - Intangible Assets (Details Narrative) Sheet http://amedica.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://amedica.com/role/IntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://amedica.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 31 false false R32.htm 00000032 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://amedica.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://amedica.com/role/FairValueMeasurementsTables 32 false false R33.htm 00000033 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Details 33 false false R34.htm 00000034 - Disclosure - Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfReconciliationOfDerivativeLiabilityMeasuredOnRecurringBasisUsingUnobservableInputsLevel3Details Fair Value Measurements - Schedule of Reconciliation of Derivative Liability Measured on Recurring Basis Using Unobservable Inputs (Level 3) (Details) Details 34 false false R35.htm 00000035 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) Sheet http://amedica.com/role/FairValueMeasurements-ScheduleOfAssumptionsUsedInEstimatingCommonStockWarrantLiabilityDetails Fair Value Measurements - Schedule of Assumptions used in Estimating Common Stock Warrant Liability (Details) Details 35 false false R36.htm 00000036 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://amedica.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 36 false false R37.htm 00000037 - Disclosure - Debt (Details Narrative) Sheet http://amedica.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://amedica.com/role/DebtTables 37 false false R38.htm 00000038 - Disclosure - Debt - Schedule of Outstanding Long-Term Debt (Details) Sheet http://amedica.com/role/Debt-ScheduleOfOutstandingLong-termDebtDetails Debt - Schedule of Outstanding Long-Term Debt (Details) Details 38 false false R39.htm 00000039 - Disclosure - Debt - Schedule of Future Principal Payments on Debt (Details) Sheet http://amedica.com/role/Debt-ScheduleOfFuturePrincipalPaymentsOnDebtDetails Debt - Schedule of Future Principal Payments on Debt (Details) Details 39 false false R40.htm 00000040 - Disclosure - Equity (Details Narrative) Sheet http://amedica.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://amedica.com/role/Equity 40 false false R41.htm 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://amedica.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://amedica.com/role/Stock-basedCompensationTables 41 false false R42.htm 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://amedica.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfBlack-scholes-mertonOptionPricingModelDetails Stock-Based Compensation - Schedule of Black-Scholes-Merton Option Pricing Model (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails Stock-Based Compensation - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) Details 44 false false R45.htm 00000045 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) Sheet http://amedica.com/role/Stock-basedCompensation-ScheduleOfUnrecognizedCompensationCostNonvestedAwardsDetails Stock-Based Compensation - Schedule of Unrecognized Compensation Cost, Nonvested Awards (Details) Details 45 false false R46.htm 00000046 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://amedica.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://amedica.com/role/CommitmentsAndContingencies 46 false false R47.htm 00000047 - Disclosure - Subsequent Events (Details Narrative) Sheet http://amedica.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://amedica.com/role/SubsequentEvents 47 false false All Reports Book All Reports amda-20160630.xml amda-20160630.xsd amda-20160630_cal.xml amda-20160630_def.xml amda-20160630_lab.xml amda-20160630_pre.xml true true ZIP 64 0001493152-16-012289-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-012289-xbrl.zip M4$L#!!0 ( "V$#$DT0UF2\HP *+P!P 1 86UD82TR,#$V,#8S,"YX M;6SLO6MSVTB2*/K]1.Q_P/7VG'!'4#(!OMW3?8*6K5[ML2VM),_!(@ 1( ;(VO-,4"51EY:LRL[(R__I_WI:&]$)L1[?, M7]_)E]UW$C%GEJ:;S[^^^_%P,7VXNKEY)_V?W_[C?TGP?W_]?RXNI&N=&-I' MZ;,UN[@QY]8OTG=U23Y*OQ.3V*IKV;](?U,-#[^QKG6#V-*5M5P9Q"7P YOI MH]2_E/NJ='&18]R_$5.S[!_W-\&X"]==??SPX?7U]=*T7M17R_[#N9Q9^89[ ML#Q[1H*QIM\^3R6E*P^[PUY7DKO_(_V/(GV^_G[Y-H>%?%9=> 9__HORN3N& M_Y&51WGTL:=\[,O_7\X)7=7UG&#"[MNXVYUVNUV9O?[7MR?;T#_B_TI #-/Y M^.;HO[Z+K/&U=VG9SQ\4>.7#__OMZ\-L09;JA6XZKFK.R#O_+4,W_TA[3YY, M)A_HK_ZC&T_BY/XWX $?M7[E]TY8N>[#]NDWDFR,,/\*O_H.Y8?44>;5L? M>\)_P7,NGE5U%;PP5YTG^C#_ 8$9QH&!7VS+($[J._27E)=,RS2]93INH"GB*W/@O=VOQ1_ 6# K].AH[^D0(=R$[P ?*[I,Q5DD[E$.?'C@M)'76KJA?_"Y9NCO>,_XZR_OG-TU!OOI _^4$Q4 M9I;IDC=7TK5?WUW;UM('KBN[%OL\O CG#UXCIJN[Z^#;X'M=PU_F.B@J"B6) M8<_GLJN;__ON-Y1:93CI*L._?DB^'$[W(74^/ML*,&]IFU" "-DNJIO?PN7X M(X6_;;P&NC'R$JX[G%Z+O>)_'P/ _Y*C-!O/4^=V#G,,6HE;IJ#5L9^DQW&:R2IL.3 MS$+G"_LX?55M[1%VR>F;[KS[S?\Z<[U__9 Z=!2L#^EPG?9V1MDS8)+LM 4?=3-4; ^O4*ED<,9G\D(,:T6T1S);F)9A/:_O]>>%>\[)\D#10A<71!HNC#E\OR1G"XFB3Q5$GAPB+H^T6QS'T MB; XFF=QU,$'2A1Y8ZX\U_F**E5F2]Y\YAM1'<\FN&KGGLP\V];- M9_XP5T-7UG)IF33@]'?5M@'^$V&P F?UL''_X)Y5'NV6%.TQ?EJ"V)WL]B> M@$7H;+GQ[0&P__+9/JXE!%9S+-B9O_>811 M$<)8C3 J0AB%,!84QIX0QFJ$L2>$40AC'F$4@B;XN87\G'2_A=LEW"XAC V) MA0FW2[A=0A@;+(S"[1)NEQ#&8PJC$#3!SVWBYQS)X)]AX!?5U5_(M6ZJYDQ7 MC1N P?8HR;[JZI-NZ*Y.G/-C;WC2>P4B$J2Q6>8+L5T\ M?O],GEPA'PV1CR"M+HT^0CPJ%@\A /L)P#FRW2#"=@-AN#22+\_#V\5K% ACI6&\>++&2EWE)C* M&*;QXE3A81/GMV*'3?T:#IN*!1'N;"#5O7KR6WH=88._J;:.#B"B,^XI)K!\ MXHY"ID$A.%!P8"W&0%J"JG!;C^>VMB:_='+1'?G90?!YO$.'\5^O==MQIX G M#7'U:)VV8W04#9=IPQ;#_;'SDY"_"N4HA M\T6@D%NGFL\)4R-&Z:/&SF*24\7XGQ0NZ, M4[$B<278D#-"Z>S%GBK12@83QGG3C?-6L94PSIMNG#>/G3)N%XJ# MEA,_;,MUC'X>ETW+.VPO,JNXXKHM\#2(!)X&D8MP(@7@^)L8)T_A"-,@0?[I$0SG>QVL-0=( M_0U0OX#9\%*E"5]]_7IUXLRV>^DGS@K)@F,/,V*J,-Z=35YTRW.,]3U9@;%/ MM-/@A"#VXB\T$<_;L?PC1"_^:(3Y\O;S/ THB%&L#REY](P[>W\BVJ;NOGLW!'[ M8:':Y-,Z?8!D."2!-1'&+9H))ABO_8S7O.2>C/,#452X&559]]K.6U94^!C5 M-T51X787%:['+Q0ZL8E,=0XZ<=!\_A;LVS"=6 ?/Y*I0U7;.:'A-H.:4A'J M<<'A.JUM+<^6D;IPX5GF.&@1+-,0"Z,F"UK4 FO0V6]+:X$=MS21X%K!M2W0 MM843&L[4AB\CW:$(( >4[VZ(DW$$[@U/<^X\I))#,FK/GUC=.,PCOYU/T41\ M3FJ[G3@IEV]%"3L_X#&.Y*\+QA2,F2LL,ZXZ1V5K6$8PJ6#2-L:,0M[N^2UI MX#.(DQ)8J^IRY2QT&_"G88,3WWJ[N?G][C2X^-9=$!O/I'2:-(>U>_+'Y MJ5>XLPNG;]7\U$_HRI9=RDCBN=](N1U$\'P:%XN*X[F>BT6'92:D7 O&#>LT M].<)I"6D7"(.Z7/B)\Q;^B2?#H^FF8=-)?HQKN (HA]=TFN_^1D$9D7]BF2H M6M2P.'K"\,G=OLAM@ASY_D1CCM'.@.C) [+SH'>^^C2G68*@Y*HU1:9N=@&" M00W63U'&4]\$XU7$>%'4GBKC90=#11WO!M7Q;FQT-XUQ1!WO=M7Q;BQSI1P= M"*W4(*W4O+.0+8PCM%*[M%)CF6O;EB>Z"[2GNT"KMCW!8.UCL,9JL&T,)MI7 MM*!]13/9:MO&*-BJZ6S5JNU0=$5I05>4]F@IP4Y-9Z?F::?PR&84*Q3L/3GD M3P]=:<1>_&[% X$1--5>W\[G,*GY'/^9923^,/63J8$01\9F-DDJMDK.9X$I M=$T'I#^H!KF=T[2%^"60-)J4#(0O=93$FT!L4/ZXYTVC&@XZJY,:_XNE&CB!MUL+ + MR6VPY%;KV(WV<>Q&E35$J\5$/=T4\E.6@Q:9J.U,Y6^?79KF>)Y8(4LAT6V0 M: I"DRJ)MD^6/XD=6LAS;3ZFV*&/%SD2.[20:+%#MT.6Q49\-F(K=L+*I.?. M)O"]330A0&[QEO+"RU\!+Z-D^!\=H&Z(A91 MFT09A3:)Y.F!_WQS;]Y*;6GA6'E2IMZ/G '+D'$"< MF37+HA91U"*'$_(^AQ-R18<3%=]DC5R^OS7%M;OSN\^:Q@#'%L$&W)SR3)W) MWX^'SQORL"2JX]GD-]VQ^HH\^@C/^(/Y/\6GP-$RQG]8J#9Q,J?@2* /[3T' MP'>7,8^FOX @;N(6W_T.VMI672N%_0K@( ECVJB123\3TUJ"=;=CVMUX2PP+.1!Z!WLFL+CZ3'80;@4?\Y--(_K'+U1R[LDS[<-JNM_5)9$XB]Z3 M^;9 /4KTE\\W5U/IRK)7?_V0-5QTNL_6C.[)J"1S3R-W+_Z'#1]]/6W8.RIP M7Y@XYAX_ZI)ECA:=;@J_:OC$M:$^YYYFKAH.83/$!HB.?.79-GZM.S/5^ =1 M[:)KN?#M[VVC;3+ M6X0^PI^>K;L=>[)'I:J >])]V1EV=@54T*=KYKK*#/$ MAO9G#F*OCD-HWDG(>/2'U!#2AJ9Z3"Y\^N[BQXPR& TAAT?R)911GXK\H>MB MNFIO-E5&Z=MX_FER$;$W& ^5'--$U.]WRYP=J%5[\96E#KXW!#G771R"WRU+ M>]4-8^]E#^5A+S:M/V*1F7(M+_=,-^"^F<\8IN>K)^Z7MYGA:<#6!Z^WU^_% MM5B>V'0WAG6RMBN^L[ SQ+T!.H(U9H^<#+^\M_=])-6$39LQP* M43[#HS]*VFCY(8J<2AULD@WEA.&^.?A^T^=#0[=??'K+?,9]"'(M]>WN_M 428)!!!6PFF MVV 4]_!VS%,"6$E)"[(D;LR5YSI?R0LQY(2U'SSSC46;:68$.,@PR[:SOT1! MVP0BWAS]HZD;O[YS@1O?21]J6IMRPFOKU;&V! -/QDUAX%-:9#)I\92D-,_: MVBJE>=9V#"FM?9O)1,0I+3*7P7&@\J"QE'*-#IG&O!/AF@J R>?_C.0]@?G, MV^7[%G;7DP/M,G$\K=2>%)IX:AO6J MFC-R;=F?+>_)G7O&YDGBH1ZT$M=-A28M'>)\VFM2'L01&MRI]JU-$Q$U2HX[ M8M-4M-R8]3/7(N#>?+]^]UOW$I,$"\Q8$I"IR*P#2#;%U',7EJW_FVCY,)@! MF,*.^C($)SG5@5!MHJP2J##3%GCSA9@>2<;[MV1-;4\Q8:&P$)[$)'O ,(C MD"N[8#)0>B7#P*JG%V XYL:ZZ7HPN& MRCBN"R(3%)R[,.6'P]ZXI+D+4QU07N*ZBU&\UT]PW):Y[XE#5'N&&2N?,7IC MT3-9GDE7"@?TY*&<,+BW3'DP?(6YI-=+[%;5PE=OU#8'P@AJ&;S_#X-]7^@^!]@#)9<2"/XUM2]GR'059\L^R/>[5 5ICME$$B M3[A"G!7<:.5$R"(_9+G)QG+T *?A:A"WWU,19.T")4.S!B@J/E>P) M136HW,6F]:"R(!O*2G]0!BI]-OYNF5;<3"TS>G+1ZP_CWESF? ON^@8 MXF#]\_BH[!4J6_$75CPRPMA-W)*&2/RL4C]7[9/JZ#,\&=4-STUD?N6E7U;BW$7W1B]LY M??76<['^,18U.)A[,X"7YE9JYD@>#6QW&_NLK8+4<:R>D-%Z4_DLE=5XK64R2B1:;/[LD>)-T_DOI*XJY-S M^AO'\8CVV<.;<*P:):/ =_)*?\KK9?TSJ,YLXUV7S!AZ!GT'O6$O*HOY8-L, M#SZY+(R-98-Y0)MHD4+=2TSWETLZ^1@G8Z[Y9B\3ZN()M]WDE:[]@/Y.W+*/ MOC<\\=@M&1;U*NU%3D_!2=^.N09!SMG.PBLXJEIRJ 86-%S<7:4P@K* MQVI0!06H2D%=(N$ZU\3E@;M'P+H$>'W'@FA8,1E\:1H#*2>1K1\_QDN?:G^ M"B-LU.WO 1#L;+:K_YO^=COGQ\7F,][ <*C)Z!RDR1+[;K+25M[9RX2Z>*8@ MS8LK'>JO!&@#VPJPK?Y25G;E-D 3$QX,77%$E@9=LJQA.=R9+(V\=RLF&X\C3@:)2THL,)BDY>&!?COIQ[(JTO/P#E@EY\TQWTE W3=T_0099ME.G/A/WWQDQ4>L,+ M#QN5\,JYWMO;.%+: Y3J%E2<+LJXGA7Y]FIYLI!($=XZY<'P[<'P@U+AXW7^ M_1HQJ?7^R]FLY,D.N/. 4MV"]K@$7<^"-JM=E,/H(UG.*:'AS&5!NV>NY&' M9NP,[(2X@EVUIXSR[$PI\Y<+^1Z>;,+PW1]R>&5&B$:/Y5/\X&C1ZI(/$1]^U9NL8=BZ9-"+*0?NP MEXB^%0&A;/#W\"_&B1/Q0\"/' CO>WR[2_QW3;%']#29WQV=8M,"9DF(=V#H ME$_DT2!G>@$12??8^T)RV_;[-2+"'RU]EY0\CK[7K.7L(2%30YH MP7?X(G#^PY=Q;7G[\];AJ\#I2UB$_G),4N#TARUB.@?]=B M[]/B:^6U29L,=C0A2Y^O/"B3#2JN:%8> ,3+E MZCDP3%Y<.RZ%'FU5@VW6_B,?@PV.RU]^WFK[)26YDG9+2B*?^"0D)4FA=DE* M+L>CI)UOVU8?EOZ/[OI[[]5#N8!'D3YW-=#G[.S2+1MZ]G#0+ =SN0P+^^4$ MK7(*X'I7L&6_R3)0LVNR*T-U8 !^*>'6INHPN#*"$[)6A*IA8$C0O[S '\SJ M_-R'?[Z: L8&'_J93)_!FPG[1?H_W^LTP5Z+5-8)E &?+>]-B62EEP/7UCA4 M^ZP;+: IV U[F"(D[K[ M*QRP0MDL9M1()@96\1Y&P1$9@)>L_!22? M/AK]FPPW)IJ!:*CX-Z&;)L3)[.U>XMI<;8@Y68H4TB@UZ]2C8>7DV=#)F#FS M8UI_(PQ8:WE/6>X-QJ6@?.O*VXK>7=CK34;=$\;>9HRZ5N9,=G<5R,W/FJ>- MN\V0<+V,F>B&+)!;@#%/&G='KM8][I^RU%=J?%[T!^-R/-"31-XA$9*+WBAQ MI?.T4'NH#7\(:I6A7([+U$S4'KK1-\(+K]WNKF;54\?QEBNV(-WYX]HFQ$]Z MO5?=/7+"[XB--0'49[(1J.]>=KOC?@I7[P"B3.#C<8_DP=QVX.5H+0C'^)NL?*X&E,\Z7GDPM4J8,1_( M41#*!/T05JP(]$2!PK]9F%:$6JUT],N7\F3[&K;"4LEB]B9(R8N)7E?[IKK\ MO#)ZH>T.]IV9OE*-HNGJ.XYA4_:8[Y9+_"(%N1)_Y,1=Y4-74R=VREC_..$+ MMVG]G#N^J<^FB@LOCRU&B4M%+<1*D)QP*&9V&6<%UG)C[K[14;W,#\>)\X9] M5E U%LYEG67*$$XM<&2MN/B40VR-I@'2O8VM"_890"F="?9MG\E^-R1WS]1 ME-+@2=R&V@<>O%I?'H(2 "6TSPZI[&4[*0<2JA@<6S1\N7!4[<3L2;T=##-, M5N"M2-3S'DWTA^71:^/:9QF![8),^(!H MGIH:OWJQ3MP,V=7ZHYN0I6I0WYU<=,<[;#?^Z[5N.^X4!M5PX$=K^_("=?)- M-_6EM\QU];.&)1^T:]? ;?GVQ]$XT?RD!E0%>P8O0N/>J;9KPE=?OU[EBA"W MG*-S%(UOQ.93Q>KZ1Q#-W?QVR-Y6"S=N]-OR+^'=\58 \<1_;H M:A;2JY/)#G &DE9NE491J4Y"03Q%+P+GO>E;UF91ESKM7\@;F\7IK;&K['_W MO3%K..#^?NO6L,?%^FPGHE8AJO >_%%)5\M-_S)62'N[93UTY=DV.23&(O=X MC"7/-(>"5- 7*@VD[Y8Y.Q!1OHV0%72I&\"[B]X^) MRP/\*:5W#$51@X>5 LFA&_#%2"XHXHF-KPQ(<_'C17&&W!?4$O;KPCRXN7>7 M!&XI^SC/,%E_SDCYIF<:RH2F?"?.-W:$]7.?@J#[(8]9:GD67J-@'K:@K5WN M]PQ6_<;&&E_()2S@FNQSQ)1_[U>VNPDDEQ_$VCOH,][E!.=W/JF&85FF_Y7U MB6ST'2AO%?+VV%I^^+:O,WI1Z<'%6HOA+8G@^"O-Q96'KK0[48Z_TO)/&[:O>9@IIT=;_Y%+M66"^5&!5S88V9(]?1I>#>#4CH!R8-$[_E<4U<*L,^# MV#G^=GY/7HCIY78$>&X(/EDJU>8]?V.S&)K1K8 M6EE;ZJ8. D_OVQ=8W:AY/.BO[H$8!O9^,[5OJOT'P4:D!18F-X\E?>%B_A,Z MBK#96&$;J)S)#,=;5%I-Q7TU1B(_NPE+*4UER(FD[R8MK@2=D;RUU*3E':@T M!DKC5E:"UN@/F[:J')O2<95WOY I-SSN+CJ(P)L+P9/&X7?_?:1Q*REM&U&. MOD4FN6IO*C5./LJC4N_HAF8F!Y:RUS>6(!]UCP-4L*BRA"M0V-]MY[KN-A%V7QF_7'R'1MG]>%1Y.%H4%XD<@.ZHRQ_ M\Q@Z:_FRTAOU6K3\+V_$GND.WFDM@?IC68X>#Y<.7-FK_QMQL!Z;J065"2W\ MJF21D">CWK@\K.0%ND))252RXW0B=[8^R]\\^2X#7[W!Y:0:#;(-[ 9A*S7I M)0M;??ER4(W"*15;3J$3I]P8RWNNE(4]^7(X*8"\\E91H1ZO5#@'P\LR][>< M8->O]ZO5<,/+WJC.#:$6W)9<3CIPAKXL5X:U)H0V36!++IC(((^')6![WV+/ M1T'HMOA_"0@=EJ$##D+HT^X)G_),&*U)+9?'FK_=#?_1^R://R?P5 G8QT70 M?JQV? 25Q;('5"DO422[%0EDGBKB1T%GM1KN9-!91C7W\O Z+,.Q.[BV^G$1 M7"GC]LNP*P]&<+ ,8K^ B9D.R'>\8T0M5YS3>;193\ MUETDPG;[IJ#VE$1V8]I,^T)3..U#41))865"4SBG0^E5BYMB&1NRO =N EW' M^CM%6B[]CZ>:KN[2\](; 18/QD@$;D[]?QOP_UE)3GNVB"_ MOENJ]K-N?I2Z*_?=_WYV?\$?/ZSHI_^4>_Q_HB_,89:/D@S/?S 1$$-ZU)?$ MD;Z35^G>6JIFAWW1D4#Z]/DO4C##+Q*"=Z$:^C/\^2_/D?Z+&"_$ MU6[D,B"[ ,"GVW+,S64?\O^*/WGU=67 M+]?7VZ29:X]!_R^5X-:W[B]49MY+MN[\(POTL;^_M+<+P@F#++!)4G M369+09Y&DR=%:WR@D<_PJ_28;';H.J7Y]7XQ]8WCVMF":)Y!;N=8L^5DXN^1 M_#S)L,SG"Y?82TGC/:L<'4_)*"36' /Q/&R.3Z/CXRXLSX&WG9]%'%W$T8.X MK1SB5(3)3QK=K8Z"GX[ -?F@)++#;&&.)UOZ$"/>X1,'Y=/.1 TTF0DB-75ZIMK]'D9 5S M!7F.3I[CZW0AI,?G@H)*_9@Z77#+T;FED2I]#Z_AL-P9>5C-T;M?C%C"JT82 MEB,NB,G&)U:,Z\NKZ':&ROC4\%?N8(/:J/%^U!V63HM# "J:Z-%\8M:7LC3I M3!3EY/#74C4WZG0'Y2>0G1(QZE1SO%#WC%XJNJ8I.'G2&O9J$JR0C]AC) M%Y$6;Q+V.RF(L/,YR1]U2\K_$3F4:QIW;'G>N8HR:;;-AKH72?$X7>%[WL>!)6W3E1>#1H MHV5X5A026K+A%'JO-."6@%"3E0IAKZ2=\*@!2)ZS?V&0.5]Z)@]9BB/A2">/)E+M($%F9M*YA+M<*%Q*Q/%$FWQ M:D2Q)&.^*4'8K[%B-,U00,JE@IRG6=Z302I9]4\%%YH'3)&@*LA6;* M"D8YBY1=0>8&Y6 *(@LB"R*? I%3?)/R"GUNJ\R97<7SF^IZ-BT'>CM'7P/K M)IQ49<_'6+5.QUO"._J_8="G-6U8$/35FGN "2*M@M(Z*]:%T<$V6=8\T55+ ME/W\6%_9S^95#!.6/2?E[';8$1]=(S9(OR-$\M,\XZ/1 M(<4FK[;T6;];39F2H-)W?MS57*FD3H?2AT:IK=1)KR/+YU1&Z+2I6?RZEJ!E M4VE9-*0C*-E42O8ZXU'YC5M/K9H46 )5]D)L=S;YL#,>%"UJV@3LM 6_;3PD M$;AM\@BGH1?J\S.KV5'JUYGGE%@Y%/4[&DZA-NK>GBB%Y$ZO4BW7 M8H^-E=K(S$!HQM8KLH9*[I716 4D*'T6=;P$F<_"G!!D/F(!IQ2CI(J4SWQI MG-EIH \+U2:?5(=H5]9R14Q'Q3(2#RZ\=+O"C\YTYNHONKL^F<30*4\&74N\ MISNN7#77G([]X2\.3 ]KI.!8% N2RK$@S2V:.2HY^INT!.@6CD1,C6B)--%7 ME::/L@141Z2)BN[PK4C)X3(OTB*/3XJ_TV&)=C$%@5"?MR6L59 B]^6-V#/= M(=*=K<^.ERQ7DFN?/TEKT*_FB#W2,5A2W5CF.&X816_6-SY30:FQU138C1GKV0>W61,VZ(H2RS,U0R]DR_.7?(L=86IY-LB:@YVQD?C"\+!QP.A-SX6_$<8DF@<$@D;<5F>$?KB6]P-=" M ^0/:4XZHUX;TXK.1@7TAI>]FCV&*O(']CW_SY-1<,>R&*>OJJU%1_R;:GAT MFJGC>$OVW8 LB=:5(A(H]IEG4/2@ MW@2UJ2]5E]#?YJIN2R^ /8*I"Q8_JWUF45_Z]')E6&L"2] \&^??G:E H4!M MC:=0->0IQ%$FDA=:=F(^;/")^0,P^C?&Z%^BC$[7U9+3Z]/AE";G5@3&ITAQ M.3(9!FT2SL-22X;#:D[T@T0AW\:P=>>/B[E-"-@4@!;TO&R55[PZI02)?GTI M)I?C\DLL'0+07P0Q#SEC+C^]I!IBMC@.M*&5@FB0H<$+:.+57B=QAQJ-BX( M-+QLXX4C@=UZC8MJDDJ8I&KZBPZ.N2:M=6*(M+(L?)5T8:Q.>T 0IQ'$.=.G7Y)YSJUZ8QJ#X;V/\;)/B3Z8=ID9CV;^K_C M!T]7EN-^M\P7>HA,9SR=DZ'HFB5ZP?3B"?$+2PH1P(YCW*VW244/DCK/9XZJ M]UH1QHTQ-M40K&96>E2W@LN*5$U)43VR9?X&[W*MH+9O^$E'N9=Z3Y:J;N+1 M]AW\:&F2-:\; ,KJ]'P^$<2JFM_J"RKX'0LJ.K&@.L+/7RB(L#.X:EE?*+PW M*NH>-_\@H=1;S'6>2M1T![PF_V%O"W_#:4C-4)O:MFH^$W1,/JW3?97O'MZP MYYZ,,WU1=0,GNK9L>D\VYDE,G=MYZ#W\I;$;3)W+N&0%U2YX3R]!QXSA>)H43R\VB5*_7'7:[<@A!QBP' +.)B2Q@NN/Q4.F/ MJP0&,#-"WO\SV7C ?8.DQ-M=>W\SG!1-:$6$3FS2L: M V4PCE%\WR5&[T-6S &1J0X%JTQ>*!$LP%8?_OET__(V6Z!FFC[;A*JG.%OX M;4.GIA:T#L1B=U/' >LL?#['*@?=[V]RD9V)+W57<7 MDB_JTB.9+4S+L)[7TN^V]0H_7:DKW56-CG1CSBZE]^"H]$>_I#R//XQ_^;F# MD7-56X(!ZK@VV#\OA-Y.HY%BF%4U)$ #^ -^94<#;TG8#GZVB8>?Z?,P"ONE M0_], _#FYJ8C?;WK!$ ]XE<,#GP)$& ]$XJ4K$5VI/AZ^"+"V:7W"./&H@%Y MV,^8/WXIX364S9^E!>("W,4_/5W#:I8S"S9?=(;I*-FS(.BB3&)V .AAR M<^'_X=69ZBRD)Q7X948OH9B6"X Y^ H,_U/_$K[Y^O=I0UFD2VNTF M-74F.$G(I[ \33<\9%&P@'A=5]@3#4\C&LH=TL1SJ0U_._^BVA@(=>Z(3?> MZ=+R$FYMMHH]Q)22DVLL!?#:L)&BN0["QJ .; 3^R;WZ^@W5%@@"VD$/WFIE MZ(GMI8CO-1KUTAVAC(G* "R7BS:6)^4 ]G?+_N/&O+.M&>JI??&D#,?IX,2& MWQ^(7#A1$@9 02"N<0]<$.UWR](.X!BYF\$RL?'WAR(?>W1'HSV@N%9U&Q,7 M0+^KCF?3'>;OL!?_,"WP1^T7#*W=F""=#A[TF#/=T*F'1/] $ OH^[2!$%]G<5PSRNDV?;4N+QEZ-AZ6S(%6XX@7F0Z@]2 M6KTY^D=3-WY]!^.1=]*'<\%2.WEV[YAK- P%RIR=;Z=C>!#!<+Z0\FY#9IRP M8TI=1Q))R.PAZ:>FZ:G&G=__B ^6OC=T)Q?=<3(BA!X..CAQ97BMVXX[A:$T M'.[1PB?08F!&V3H19=K!;4DS+\\*REIUPDG)")/E\4R:#'^,;"P$#-1Z7.BV MMM>*1Z6O^(J[RY^),[-UUADBW=\")AWY_E9E#/L;>OG!X]+2TO2YCI4@,(J1 MXN-;X.%KWHP5DUBR$[FX1\\C )KTM)9^ H[O )I8(3 +@5?R9?=P+]?J3JM M6A&V+:.!'']<:R[]I(3A !:2B$U*HS#X 2=]40W< S8AB<8?,%,2U#;^3@,H MT76D+#@UCS(:HXB&)'92NC0]S_-G:>U6^HZS0]MOB#6A@; M3O$Y_%0SGFGF]R2@+0GV"F3?9:"+EO\L@*Z2UY)IS\4L(FK5:+<)@^44,J/C M-7-H,HHC.82&9+F4SWU[D4)DA'B1EAPQ*.W1 CD8K;1]5(%: 5RA5C- DQE4 M>_"".Y%W%CK0QIXMUIN: W65W[2!@N W;A#9UZ(Z3I"W*_<;G+B+6D6B:D6* MN$A.>E6^EE3DV,8ZS:- Q)@X&I+;F'+^E>IL66H*TLZ>%(J@1$,HT1.4.#HE M:!/O-NV:S2DU$0:$)=^F/^U;XRVKQ2)0(U!SEJ@I2:ONK,SAW[0;@SM=4\\H M=D3,;J!+K_R0N-G7P Y9[IZW\.3Z&AY>-!OY@I*"DF='R<&H:)](0UJF M& WEU=W?R7S=3J];U!)L GK:@F"Q+[68>4_,TKRB93=1<89'5K6S MY^YH9QUSU,.@2K=HT*4)PGM.%'HO@PHIB4AUAC\$E0M26>X6#6^T,:9QG-S^ M2-P_FIM0M =N1?RF7"K(<)KE/1FD$0&^/)!CCOE!^@E%R,$JO,^K+@E4$ MJ^QFE7YG,"XII-7HS7:G6]<$8_X$;N@T=P2!FN:BYE0LZO2J'0V(*-2YN]6T M==]+#KPEO M>DN;UH>ZT[8#>P9J37\)V3>Y+_4=@4F2/Y MTR$T'Z\,U7%NY_SB]*U]CVSPW<-XY.V<=S(&W%VIAD&T3^OXS\[8WE^7>J#<<_/5#"5#6M&#.>_]DU]_I[?>\JQWV1VU:*2?MO4XOK6@D M-U''8V4DCTM=JB_Q7RW'N0*00:J(.5M_5I?J,W$>+ \>9M6RTP6H=Z%,? 'J M7W25H/4W:#!GH=NP..V1S!9WJNV:L-R;F]_O\K0SE[N)?N8[ =QQ MU?5W4$B@LK8W;-\.4'\X2<"3-OS^0 PN9.6B)R>!>'/TCZ9N_/K.M3WR3OH0 M8]&O&'@*[F?#^%<'+K(WIFO<.OC>$!1KU]@;NSK1DAFH.3WSB.AVY^H&MS&Q,[-5P(V_8)#P^AV$ M&;69/^V5Y92%D,DXCI+L^0X$K01DW)-5;,ZIJ5VI*]U5#:H2;Y_ 4Z'V;SFX MB3-R_LG+!?L O-'=XC.9$]@>M&O6W]Y\1@K=F-/9S/( )* B.A$ $WP#KVL1 M[Z,4+/(M_%!8JES3H2@.M<&C31VV-;6D?ZQ@:PYN2>^)S&HF+KPGRDHW)&.N M:>-V?83?KRT;5.F*V.X:*/3E3T]?+9/6R][,%H$RQYQEP%B"7GN8+8CF&8!/ MW"UAJZ3: 'D:X*!^"3C]1.,*=XH;SC/KH#,UP,NG3X/[$3R8',7YM+XS5/,1 MA>(DZB;22E"T@O3%$RX8UA*N6")O^)E06*)'PEBW$!:MX8_XBDE/=5278%@) M_L-Z$EES"0G/%3(6,IQ%31C) )](>E7A)X9[++?H\#*.CO2>SF-Y#KSH_"S* M'U9:_O"HT=Z@9MJPR373%C8ATC>+%NK\$BO4&6:QM"G&W@JL/^AO1\3Y'J>[ MS1>R)AD%'4+*IE!P)2IX()7O':QI?Y\WB0U!T M3QRBVK,%C<-IV(O$HH'8-IFIM=Y2*IP[W@34M 6YO:*ZMPFH:0MR!T6-S2:@ MIBW(E0>G4"0*Y%7HP+:BI?AP/ABX="F,^ S*-!E=*<8I.45]WG*'?\-J^P\XNS/TS==? :)[L(EU*W8G31 MDX/R, _>DT/^] ":+QA98+5$PFHY>*E.M=>W25CWJ391B2TZMP?.%-U6] ML_5H50:_\H[<3$[X\?#Y+HL;+F-5-/99QZ(RZQ.UEZFZL,_ M?WE?WF:T,>CTV29T'XRO/JCCA04U^$\^5OETQ1 S[#4:,Z,<: ":1',0%_C&CY?%8S(>>XN.OO*TW=OA>>380Q2'9;UU*D?D^ M[9IOY:.&3SFC535<':_MTQ,>N0-:CCWOI (8]!R/0K?MK4LI:Q>.4"96+R,H M>T?'NS%Q@9PQZ'OU;[D'5#.4>=&078MJ. 9V[0TGM_I/9=$_K!O3B+^R_&IB_@Q'73E\0'+3RU]:#^H&,["XECNNA:;;7N%,KG7 M3<9/=D&]N4[=G.DKU9@NL9#F;HOZ,+XM/C6U MF.$]=1S]V=SBU'PC:+&9KE_ ]^O7JSPH4)+U>XNLIQ):S0EV1BTHQ02OGK]TM?SPU27EDUI#$;_4O>61]#72G\8X\Q=():V MI&/)HC(<'[3@H#7*5,,ZH/C2SL+@0,!>I$E"A9MOG)A;82UG8?(H7-CQ-II1 M\66S.KNA!W-E6 [H7Z Z2.X=8>?@1U6A> R0"\IREE07];(6K%QVE5H7W(QS MC$(+#I66K;_0B^%9Y<3#A6(AZ/U%:S)):,N4B;=$(>^)YLV.9)QGH;T?*=<][5N.RX+0L#2'Q>ZK>VV9+)6/NJS_D'[ M+2R[S]8_B&H7Z[*%G]/Z; 4C;>DRH]!W(U8-$.'WK+ >#E(N^X^%H?Y"^+%>& MM2;DGAA8V#ZRW1R,J6$<4SMG*@6T7!@;CGN'@<91?&^M5:,,7/5'J5R5'/\ M,'+A92 /]@'C!FOJ$L?E@GCXQA&'(GWX_8'(IS05I0 0= OCV,(.-0;:KSRQ M]YH%A?)(R!HL\# M+\]T]+/:WQ<&)WBBUT$NI2B.:$;4@[>$(=:8]_0 ;^IS?0;F!P4LQ(;DHX-> M(XC4[*YQ*0/_4R;#NGFC \;]C2BS8N0KS^#Q?)*4PA-^#RC MYC0LKB/)D\GP4O(!TQU)A87 %J:#0J*W5V$F:8XN(-$8.*9?;16$H@,/F]Y< MG;F>[9E%]76B4LE$X@)F$2X*!@ @SXC#H#N8DXD*K5.L S,7L2,4UKYPMF MQ$<.K(#XD_+J2Y?28XAAZ8D8.JR5@XPY6WPH"H(_7!P%>,D7G Z'2"O+T5FK M*-V5YNH+D.;)6$NT"H=K6QC;D$S@)K9:TV*!'(FOS(?21PX^95KFA?\%!6&N M$T-S0OH!T:P-J)&J.-(<8Q<\1]58!\0%>&+XVD!7DCPQ'%$PU-F?GHXYJ3\> MI ?$:D>Z,6>74=[V?XEP;0<('/ E$@/F6%&\T !W*"*ONKN(=MX"S%P;%L"F M=I"?'\C*I0Q-85& J6$OZL:AY+,.?W'"*>BTEJ'!-[#_VCK@A.,<<]E@-0\H M/(VL 4FUN6:UJP9VFZ,S,LQ\-\=(9]@^F::-N^5!1M0XP:FG,K=N:/(#^S M.J\@__ [*A,M51%T0%M0$ P+MSHGW&'9Q*A/ '8)EFD0%;,'+D$-LJ6#=N,K M![Y1V?7-#O[DD/15T)JS,ZZC$5[$"@OH MZ8UC5@5PB.U!SI/;\U@$_#1)QG M;20NVYS#9W^&C0?V& >M7KP&P(06-BG=QAUJ$07*W\8X91W/H*T0F3$0*F6@ M(WT1OM$MS?''!.R!_T)TD^IC)[/-8BH2G(7E@7Y^ FX&A")1X)U_>>8LV!8H M%+Q[8SB8+UV9F&7(1,^*T.V/(C4D>\JN,35-#\:Y)[ KN;CK7 -Z03E<_%]< M>0#&FJBV1&AGM\#,ZLET1QIT !X#?@A$%*0(1_I&R]@K/?K4D.U;(9ZE%!P[ M^INTM&@7.1)TD:,P]-CN-PR8T:]RBA%,/TL8#TAF@3^6,$Q"(S.>(=:9^'!(A[,RW4#)58O=G(H^O8HRG8Z/-+D)I)3 MAQL_X#4>BSD$-0)JA"Z6H,;QJ8&R\:([1Q2-/?1F@$? G8L+@\RY9JA$*=]A5%;7_!JX+ QG4<]Z MQC,FJ%OM%-0V9]!VM%];V]&Q4K1RO6@AVU1:OA],BK;%J!9E/S>;M4Z;&Q2E M: .NXW84/H[!&\FO$U9O@Q8F4'/*J*G+ZJW)TO43@#$HQX_-,&'@PB7VDIXM MG;1F.01S\K S&;2Q-T];$+R'3=@ 0_!\Z ,"T*NT]TB*JDW6L3?.[P0;)Z!9 MBC\4N/7G(&EP4D7G?9T-W!935+- M/X*_.JCO5 EV+P<6!?Q"$[HI1=ANYD8@P11#EA:+=^TOI1MZ)P<4E8[ XY-T M_XERRBL@E&\D'M6M_J@^(D##(_OP#PFU>C4MZ)WY+B]H.VU$W=<6V6PW-QTI*]WG1B C_AUXEHBEX%G0M&7M?B.M+G. MJ,460"2]1[A3D0((QFOBL0LGJ+."\1"28QM")DZ+383WN%45Z M MWJA=!1H-E+;B3W4IW8$I9_/;>F U^]:W*CE^363XDQ5%]JWO__9@%+HE^7M^ M9%/7Z+7OIX@,L(L:83:^'.?\#7T%F\(KM2)-PM*R0:,R)4S?H_=X &3K*;RR M$M23@4G9O0*BVN'%.Q<+*DE_>BH8NC:NCNX?4?+0Q>M\CE"YA>GJ*81G!BI" M&.0A;[(7D(VE+J-YS%M@4#3CS9D4'$M1_,8195JOX25,=O\2'O;OT80>R>:2 M\JU"2E\!4TG4/J'0)O XHGNL/RN%(C+S$UE;)J?KQCY<@,Q2"HEQ3T+CG?-O M""$%8@/*FWG<9G+POASNQ)E3H]<(\IF8V@FG?(+IENP6E7GAK]J-WR *G2_F MJ24)X.RF $,:*&+0,/ TXAHGC>B2X'X!4\INMAJ;\:M/,W3"]"5>PF5:0>/^ MWHI75N*&0WA)(]P @*<-S'M_7L0PNE370 #RQP9"*0A;Z,DPA->^4ZB,HZ*J M? *07E3=\$D6G1FO6?"+T 'A5BSQ'3=2V,;Y72KTQ@T#X$>]$\Y%6$7Y""#Z M/'.V#C.BEI:#USG^0-P]X<5"PZ,;*/JKZ ?S<#VU_!:6@?MF)S#A*:TRINO0 M)8//:QDOW$'&RB^V3FW:D&\R;R+[KBT:$HR#9]P)>UV <8OBQN^"Z@Y%+48L MN,%*0:'?S1:H:/!2-YHC8 SA.O$ZKK]^?IW?0.L>N L7_<1+?W0B7(\"F7;1 M+V)/7C(>Y7=8^1U.5NO0)FB;.MX35DYV<3SL_PG@/5F>F[7_11 0F+IT]WZV MD*/P$@FQ03-_MR*7%W&#IW!0#V"I:I24X+-FA$_B6AUV&"<"^UI8Q=PJ?B"$ M6\#4BO1M FXIQ^Y;Q$/DVBAPTY*J,&43@TG"27PI. M\FO!@6WZ]8H"$;%/@^=CEB6/(#E!.PFPD7F%1M #[BMR3]R\T2(S QB$WX.F M3Z4M*\L ):BXUY'!$*$ AV6#HE3YM>_ OP2+#R]&6_::7TOEMI#Z#. ^HU2% MZ&.AOR2:!0\G0UN1,CY29@D?$=J*Q_5A_PHC*Z85B_8R27!\VS5#G^^\]8OW M/'VO8]^[UL&%7@I,\R_U-C< C(-$I<.V3 NWQO#^BA"1^/UH?E6?.J7 A=>! MP9%Y,?J3!?^)!E.NIP^?HON4M]*X1TVB,O,,W@?=*2-.A]_Q,3Q-0=,2[1EV M^]K!"CUX1]H)C/G(B"@ZA!>P9)T>^?',BM7?DUQ;A6'I96@'HV!89\,_2$J, M@[6FP"UQU3=$(7PS)[J+M3I88 G-+P_/@9B^4-^H[8#&-0[ 0S"4RS"Z);T2 MK&0!1F3L*G"LAI5O7="(R=RP7N-6-3J)0"@8AKRHAL?"HS3@"S_SV"L/L=(G M&768?4QUGL7*">RL.] @O7)T8;@F3[:'(9$P H+,'>7H) ^F<;6!%9WIWK!2 M;9>%M/X%]C_6];+^A79F$!6AQ35-E3N#$=6U1=YNXO+F[V# P39.S+@>"\:8 ML[5_$H"GV]PU 8L+RZE$ZMHY:-OA#7?8Z_Y-P_!TG.CI,/TB>M;++[5SZY<= M!;#KZN'A,0[U!UG'2^)0[PG'HV$H/-Q\YHPH_0@B"%A$S,=LQS^4((R[:>T4 M7IV+NOL,;DZ9]!-ME'#?$Z77-,(3!T8K2A"V2NJVT[HVZ/_2"*FL\,,Q<-\# MUQT/KMR(KD+@N#-!H8L5_ % P8A>T?-D4'IV]+9(BE3BZ0<\ T8]QI%H9(6* M.--=VCNX0A!+ M&E)2Y[C4L)+?@)H]XRB<.@J+O@P*\B#16!T$6G,H'+;#Z$D#L3Q*RX-)\.I2 M!Z1J&\J61TV,=5+AKBP\"=-9N3AUQC4N!@E-.CO%W!_G1 @6CP2508+C-(P%\K0 M DN$!4"2^.@):+E9D,XU",.-FY8(1.M<$1MU:R :]$R,.1NH"AV'A8QP"RH= M&2 %<PB3B>HP2BJS.%DI!@+I/9-592 M0VB(#SHNE_'DND)E\$3H&B@N"0V"A 00(AWU(]9;Y#EB;5.(TN39S_RBFQ1R MHZUB34NJR5E#!1HM>UWHX+ X'O !$ 1KZ;'S-JP=1]YXL3A_+&X<4/X)YJ3; M*04C2+ECO#3##3](XF-%1C%L'Q06Y=7; I,CF(>*/0M[P6*>+61EC) 1FU4^ MQ5V0FF4\/P/ES5^2?[2)22HL&,:/=><&003XU<- [_ ,17B;82&0:5[H+"A[ MAE\:0=DSIG\2,+$E^TQ/@<"\&!.A!:%YP=_(BF6=. Z+Z-.X/-O_$KAB\7O0 MA51O.%:'64__\K1GJJIH.E^07X?[9=2,8QMY<&Z51KT #EJTRHZ\S,Z= M(G M:)I;6P66"-M[4I76:(O2TDWN*2Y49J2J*W!= 3[P(]'*LXEK6V%Z$ W' D;Y M()'B7_YY$=*!YRS!&Q>\SE3DU$ -BE_Z&9>^KMPP;G:9-/XQ@C\ LR&+>Y"1 M(N]5EFW?Z)>AVD@YQ^]F=5+UW95+"7$V8TEG>-8'=/@.GM97S+5;<57&&MA( MK"$9!?A)1+I";#(,!AF*@#46,**;O6K,6&8@.X1;@]4&5EYH&_"7GE@=T5=Z M,8%H%V#PVV )2"9M\<43+&C*'6UJ)5EAT]5$+5'FGZ")&E?L?MW-6 8PZCD0 M7^9_^?3?M1)I_U7$(* C1R#8LJC #D:=[/CSNAB3\.SU!5O,DL"Z-;X.=J:< MOM3 ><2]UZ;;*B#8SX8.I_;P.,TA4>QO)CS24RB>P) MV-C0@EO?Z/.B3M^H ]MAFE^B9]D\\9R@A<$-^I Q.$?0'%?<^WTZT6/M&8^9 M,,IN,@\_&IZIF!()X^JV7W20);&$1QSHME\$Z0":MY&MP#+N60*0SQ&;Z;+! M]H"Y&7PT%N$)RRK#2 P-=+!8DI><2/V5(^>,_NKBU(IFG4E!@FU*3FW:3I.I M_#?[Y/!<_L^!YWA2&T4/BS.S)3:UJ84?U#"6Z?N%P8T/4)$V M\5-563E01]3=%'4W$Z.VHFY<7+DF9$X4\A-U4 O)[)[E3;CZ&/2K*5ESK[Z& MC7X*(O'T*_,HW=HJ\XQ&O6:C7] R?_TTN5U5EG:63*D 1W^_N2N(H_.I_Z , MQRW$36NPVZNYM$9["I]=X\W"!=&DW_'@HW8>W&UQUC%'3?M]1^X6W?&;(*/G M1*-QISNJL@Y5B[?O1PNSPH*P3S-4A7*I((_@C2.#-,+VS -F7;PL]_NGHF\$ MH;,AGW3D7M'RS:)VV,$E87S+B:6,\.Z4[*3RF;44]%4ESUP)DU)99E7\RG_O M!&T[W]D\"_+K,TUIQO")'@GU\4@HJ$3% MEMK(@Z%CYZ\EJW7QQJ/LU-F-]H.C$(EC('$,U,)3AWA1K[@:$*= XA2HCEA/ MQ:= 5SRMEF468Z+/0E^)XZ C'B'T.I-)M]D$$-1L(C5;'%/Z3,!+L5:8[1=6 MP&M?Q*(>ENIWAN,JSS&:.\)IX+<^VZ$"Y-S2RQE8 M"O3,T^L^L;O(5W"YFS M'M8:#$OJOB $MW;LMGA[?;15C2Q5^P]QL%NIK3OUHK]C8LX_>!F/1MZJ]^&WQYOZ5%CZ.M&M0EWAGC5TE%OM]E=";=1E/Y].T.>OD64R4:I]I$/M*VV'>_UT:C2!"Z,*&' M=5MG(O$,:W2PHO^L!M ,V4&+:4V5U3U-:47CUQ:*6XM^!T%: H=62&+U%YZ( M]),RZ':ZW6ZTMR#K;Z%%^K30U/88PCCW:8(,"=._+E>I&L4Q;;=QC>0\J#;1(DZ@IGUHN M(N@YPU#K\.8BB%9'XF4=*31AK2P]0A' ^QSQ_A+BW0[P3KN<2ZOF / L2EHT:%P#-7A:9F.R, \( /3 MM58Y$K;ZX]5;B0DT6X<[+'ST0@RIZ+4!'Z-]A*JN-, :Q<%H4W5F!5 ^*=G MH<7DB[Y-:UG2:ODH"\A#?KXT?!>MMXWJA%5:9._R&H$'._L[6+4)SE;UV;&[ M*'YX0/A8:#Y<[HL>F-\TXY_>XHW))6P!JB%'4_7D=:6D3=8ST/0$ZPA1HJK08M4 M.D3B=8SQ';_-1K1%EU]ONI"2$:&WF%_K]RRB'6S2NJE0D)9!8"'FS[+;H%BA ME+:,===Q[Q5\-8*]2ZF$TF*+*X_7.]?CS=98X5(]YC-&_$Q6F?6[%>UQRX"E M51L#Z-+\Z_1JHYL-UVA=U.#>GT2Y!( DM"DYZ]^3\/.C)G &@E(! LYG* DZ MFI!T7SD-<@K#!O3"(Q9W$H,[<'*_P9?@LF*]25Y/Q'X;?3=N&^LTCP*1NOM' M0W(6ZS;Y^B8/-25/)8Z&M+,GA2(HT1!*] 0ECDX)FG74IEVS.;?"/L.G%Y7& MM8(SLH+X:UH$:GNV3,N2M 5J!&K.$C4E:=6=>?W!*2VXTS4ER5Y%&\+XC7X* M*MW3+_4@UU?JH>BIM"C:(2AY_,%.FY*#4='*IX*69T_+%*.ATC,O<3#0EO!% M6P\&6ETX3QP.G$/T31P.-(P4XG"@*900AP/'IX0X'!"' R+,*U C4',ZJ"E) MJXK# 1&\$B%E05*TV:J@Y=G3,L5H$!=B8A=B-%VC5QX7*GA\ M^(5?08'=A,$R7JGW9(+2"7XH$'_GL:B@K53J[9;(C8](>1I'?Y/ "'(7CD1, M+.&!Z?$4A-A%ELR[*]+*)@Z+H--Z%>8, &5UILG[4K9>QX,^GGG&J6-]8G;+>(0JQ5A-NZW/*#?LB7:]F1+'V+4.WSFOW,G M21Q -($+3"J$N*L&B_INN;P M2#.T2/AVZ2D N$,0\CUSOLU%J\^[ ML'04VLJ.:+M68LB^"9AI"V[ET41@MZ78K<^Y:(*Z](_!I2>"X5/R1NR9[A"M MA>Q;$_-U.[VN:%@I]J4VXK9RYCTQ2_-JH9K/5'&&1U:UL^EV/ M!D04ZMS=ZFH#7OB&027[5IPV@M0B+']>Q,&7GZA 4HCHQ]:(9EW&Y1&.6V-- M;6:&QWI12T2U38 $7E,=WJX(?K:6XFRATK.%HBFU/L/XD%.8Q?&"V&;.F#Z5 M"]&I>"&;;8>.KM=%#&Z;)U.XD.J)>3*"925IX] M6Z #["Q4&Z:VYM(L4GFK@Y[Z;$&;@M,>OR#I,!KVZ[UPK0O>MS=:.@(+-N#3 M-KD(JDC /!'G&NPMHLZP1_#*LEV_D,0*5FA1AUN=S4"C4-.,]A+&OSV3=B)^ M]G3ZPZ6@=DAMU0G;*GL.#UK (TO5Y44V*"RSE()JD13S?"UR6;-=8"M6:<01 M93E$68Y6W/EO1F-900\CJ(?0XGK^A]4G&/2KN5+Z=SH:T2Y4@%I]ABU8=_Z0 MYC;!>#:@!?NPVZI;-&[=^(IQ2GTUVKJ7X_)+/1P"T%\$,??&G7PY*IKR=RQB MEJ2C]DWI*E4KD;<5F<$7@,$YD=Z#L;HFJNW4G_K8EGM@OZRC)(5,G!NEGQMQ2/K#7QQ:-MS&3$AZ=A/4/Y^ISH*>$- /Y$]/A]\1LQW_ MN(:^2G1: #SRY4I=T]@\/2::S6R/Q"NHJZN5;;WAV07!DPO=CIP<.;#E8;4; M"H/)?W86ENU>N,1>2J;J>C9AE=#C<..QEHG5=\/YPWF<9%UVE7T3"YK%7J 0 M\+.OV%-.Y&#JKQ\\Y^)955J MD;_Z#T\YINX8H%.&HZ\ABJ:F1CD[\E4X[I5GVT"&8'0\M$.*WY/YK^^N;6N) MX>^+K@S_7(M]'E[TNN]^B_%7P"Y^\M>QY)C&@X>7$L>"%%DS$^$G(<(AQJ8I M\D0/;1TTQUC%?PI)V"8 PR_NPO( :#XD&D_(+28L.6\>AY7A8--1?7H>MMH3SP.VPP?"A_IE- M#!4M1XSHF0X1U9DSE<10U!BM#KO#<:]"[-9G,%2 FGMKK1KHY[60_>IAGOY( MB&:%BJ_2>ATMWD9O_*@@CS>VD =K.F*9B.26"B\ *RVH'WV7^*"I@CPG$#=="U)I6BDYUHL7&994GI)^4KK34#4/'?$.D$08,6(9A"NU86B F(3H2 MO/#?JNFI]EIB.1'CK-?":I-TOFZGV^U*J! P06M.B%^#XU7%]$6=EM,(1F%Y MD,'C&M[OY3F:^'T(;F1 .E*0( F?5=:(50,]A*J.(D_WNPRJ2ZS2\6]6QB/( M=N1G@I(%]B&;"6_S16>E8&2L6#4:)\M>!X^ O&_ZD M,!"=)B._UW^FOZYLD +V_,KP'&ERJ?RE0]'^7H='9.5RP/]&4L&?H[]L%.BX ME((@,UNM(\UAH]A@!Q\$?U&,NI'X-,N(QIHMV&9R"2*\,-:7TIT-!-)7(88= M6AF&F#- X]1[!A&5_*H@?M&7&=OMC#4GPU+5:&E5\J>G&EQ&';#7#38>X"J2 M5@MO_31@[-]A\D>12I8JZB2;0@=(H (&4LV(DY*R;#V!$E%9/92HJ"" #JH$ MSA=/:^"\N6XC%FS=HIK"\55&@"" WO&> &C3U0%P>,8X!%.>&2?C M@O$UPR SUT.\V=8*O*?U5GV!&STLT DJ],R '4V5)5"S\W=8!()BZS.V*,L, M20*_^2_ZJDN=S\$,H8G-2)=YD ?%-R!3W]ZNDU5HB-JZ80;S0-9N2R1;^=FF@)6-:J1X(%M>]%['-IGW-$OP7O^5^-??H[O5XR/PO&7 MEJ;/=0X/TU] 5@UG\9F(\8[FS6@V/:A/4U]Z2Y:U_\3K7W)FT*2G4 "EN65+ M!/3B&O5NN ?2_0=X;14H!XH%/JZ_\_P$^BNNJF,3I]T;V(0&!D;)YS*Q7 %+ M!R6AHFO97#33^LEZ1JA)?^I' 9OBU@.2Y1FNK[9!_BW8A UGP.G .R0N: <+LX8IO4*&L_0 6.P+8#2<#B/2"M0Q"ZU'G8L)X5V$?EWLRP' M_AN#6P(U:[-=!X$<\3TX?>8GLL97W 5@"O>)^(I>+<_0))/XZH=I$<9%>)-" M OZPGNB8F(.-2P1FP!V0WX'>]G E4#M8&H?C:I M2D'A[47DG8M%*.Z^F/(?4G@2:'VO@^; 6G'2-X+EY6#@.R"Y"5]VI*]?KZ3W MH=H+GHVHO$PXQ MP_;*LQV/VPS,XXR.[%@&W0K8LR IGLF-Z:0 <-^9F;<[A2#8CY/V4(0%0LW MK G+<]$@IUM-VK X4/@Z[OP4EI]&PQXU;C9=J?-0U%G01.U!GW;F >:^4[!D$17C5F38,; MM7-I4NYE87"(PA"ZDP%3R6.?JT*!)&_PG.Y06+4 1"T)8P[T)\TMYI6$P4 8 MWO(A44;;((D'A'@4AN.Q()04B%V0)M 7>N+-44M&8RMV)W2[T.F'Z_3 HU&S M]+2_@^;1TFG*->90X1!:U)-B9E0ND<^KEC8<+AIZ4C/=+2ZW<8N3>URI)F84 MV@2R6, N0%G"UF267E J.ZJG918EH["D%T[W$1/@TJ7!YC=ZG8JI,P1WYA]M M#'O2BMBL"OL.,'GQ^RBD[WV%MLD(,>-Y:AA1)/&DF9 ^,51@[?B8HTNY,&.Y M_ B$8.P;,!T]@_HOV*9A?&HBKR473SXBV& 3T"A%%!_]+?BX"E^YPU%=YAE@T#]I80\&%MNFLNQLB2@M5&: MA'9;J([SVVW,#-QI;: .C V:-_RT31=Z*X0:P6-'U1Q$RF*QR;;HO"P%D)!1 M[FYL45I,5+]$=Y;0^Z 'Q)&#>5 8.D/6BV5X2W+QFBP[%RB/" &CIX*)]@>. M! C'B+/J!Q%]::>04+V2%A&G[30X(N,XDP=%\/,(FO?BQTIZH$]'=7G4_>A0 M8,+C_S 6:JSYN0[5%7)_V]Q"620-KM#?R11W=FP?]3QT.X?H[^$.;1-[9F&4 M(/K;S*"DK*;%W)@&C>ZK4F)/#7%*-U50,DKN3;4O]W;O@4QS)O9!:1K@REAW M(G[D;@I+>U$WICEW4+A*?1Z3]>P?(^-VX3;;=YA:..Q MW2#-.AH=8FYMY5AEG#0#A_G-P.%X!UR,73=A\RL2TJ-EQW582QT8D"V4)OT0 MFVQ-66+8\LPP-TLC'STX2HMG>&6K()_U-1^N?M^/F5.3"LUW_G9$ M2I(PTW4#[C&$SC4I)IYXNK/PSQDI0(DC;OJ=/RQ;9(J/QF0Z36M)_J%A&N=3 M3- ^5C1#!]0 W40YW@ "/'W63;_\7XI/3;VBRU"$Q+[*]M6[;6'1F(5',=B1 M0"9Y+D'EYAQS$5'HOZEK:<@LJLV=@;=)2YAT6\VJ^$EW/,L05^;K,,J/<7,O MT-V3"9T@+2L1!V3:1-AO?H'#6/AB,\2$;>6BD8=$. /9!##]Q!(=@VV@Q])S M-\\?69ZA]%E-F$-?L'M=^A3QQ% _$4D-CP3_0K<\/"A<1I(< ^)33X=Y&BPZ MXR?XZJ:.^8>9ID8"#LVSH[W?6):CK+#L3C])]ME3<;^ET7[W3(/S MH7D2*141VGP/10KL&2[L,3QU:'JD'D],95OAMBB37Y45,Y0P,>."GQ)P$^/O+(]))5AJ3!CK\.,E(P@5*\?-5"F=(K8P7$GFIV411JV@T7. MX-(TXD\];F;Y"F-S ^L$NUM88QK#,9U;4F=(XJ&(;U>ZBBJVH8KNS:JH< MXE04J3UI=+>Z!NWI"%R3RQ1'=I@MS/%D2Q]BQ#M\XN NU9FH@28SP8](U.PS M-S3#U6'@+O@C[?IRQ9QRPYTL<%L<=Z/)@>"7^OGE.XFPQY5JVVLT.:^@ M,*ZO1WFW,U3&IX:_<@<;U$:-]Z/NL'1:' )0T:;IS2=F?=U )IU)X>K(S<=? M2]7B:JNCD06?8JTFX2C)BCU%G^BJ2@QD4 M'FA78=*:*I5WB^J&)N"F+=A]KQ26U0;HV_.A3SM+%K<%NQ<"MP*W K='"@Q6 M@)A$(:^<&D2,AE5VCQ$4*L&NZY^C57=.%!X-VF@9GA6%A)9L.(7>*R7) MD%"3327QJ%?23GC4 "3/V;\PR)POO1)DL>Y6FI^RTB[%55-X6Q&=*:O5R9.^ MB$@VF#ZRW)$'(B1?Z>GT6*YRTVKN"/4=./?/TO!K"X7D8:TEVVW&" MG%^)XWR4>*L_B3;9L8HF/0HGHIC&D#N]LJR^=JF,IJ.MX1W M]']C0>.UM":J'582]F@)_+#TZ4I=+PDKU;I1'E<4YJRS,&?SZJS\@U;#_L)* MND;K,U)2/ 7RF%_2S[%:3= V,U@1+:RR!8<5U#"BO2&:0K8S9@9ZGZ9>T@>7 M=P3ECTGYL'ZX(/\9DI]F A^-#BE6<[7%R?K=:@J)!+6X\^.NYEHB=;I\/C1* M;<5(>AU9/J="/Z=-S>(7J@0MFTK+HD$708YI3X.186- MAE.HC;KWG.AS0JF1)THAN=.K5,NUV&-CQ3 R,Q":L?6*O)Z2NUDT5@$)2I]% MI2U!YK,P)P29CUAB*<4H229EIB<,!OE_*S=8)LOQ^^L'S[EX5M751VSXACWA M#,L!P^$1,/;)L&9__/8?_PN!_JO_V -VMU]8!N#<^?*GI[MKS'Q(>1&[D2/> M[\G\UW?7MK7$,^6+K@S_7(M]'E[TNN]^RPEIC6F>. %-'QA?2FR-R6221G2D M]Z%,,,M1H*00??9L3&'$KO.._B8M88J%(Q& 7 LR7BDD2/Z.-.@-.[WQ6'(6 MJDUH6NS,6L)+ "+RSRL!^U5W' _>]E:62<>=J<["( Z,^D;LF>X0?$WNR+T1 MWO:DL,)04^E5M6T5\VWY +H)OZU*QT1O)6NE)0.&9M8J@N_->U*(7#!"[:5U@#S>(Y#B,AJAII M=)FFOG+KI:1""Q^YG5]9RQ4Q'14+T]PSL&@SR@=XA(*RH(_]X$LIYJKB5UM;*M%^!%58(/*\L!,$ _Z.;,)L"C= S3HWGR\':& MHE%?5-V@MQ902:.VH>UE/< .O:F!\"C2E^7*L-:$=*3/NDUFKL7V!Z3JE64Z MGN&"QO<)?&-B6B!H*$IJZ3V.PG';'_U"Q\,?_*_&O_R,5T/&W6ZGV^UR.#O2 M'-2$U.LKG;XRP&7!_L7^$)M(Y**-2^-8&U0.J,HNV@!EGW%/3I*5TD=U$S=M M7E5'FBAR1QDI#<*UKU 22#^*"HE#1+<%B2DZH=@V$37EE\#67(E)7('Y"F#X MB\.4$07'XAO&##0(:A-DWJW&)5/P#HR"!51G3&J$% M*6Y%U$^*O]-AB78Q!8%0G[==5*G@:LP7WU6_L_79\2[)I$3/JKV<,>A7DUI[ MZ[D.&*7TNBA8.-$;H[AA%*UYU?@,9:7&)K"RTNF-1+9^I3G>-=*S#VJW)FJ6 MI%Z:4LWM=W2JB%;A:4:[4SR5'KCT)U3MODX]4),NOZRTH%5]YD1-$O_E;:7; M1Y#XR_W.J.N4@Z.#P&D,3T<3D_O*/W+2J],U65H5.^YQ,));0"WPM-$#^D.:D,^JU\3K!V:B MWO"R5[/'((JYTAP3/]\(-(J^5%T8$<_CYZIN2R^JX;$<$VLN$76VX%E%_!"? MYZ.RW!,-7I4\QT]^_81&_L7#;&$9Q+GX!CH6GL;Q6$K=TM*(T4&-"H/:Y$]/ MQ[P6A^#9G!$!13=GAH>^$D]("G[RDPU"./UO:!*,L49 8JE0\.'_;^]J>]LV MEO7W"]S_0 2Y0 O(JN17N>TIH+SU&"=IC#C!^5BLR)7$AB+57=*.^NOOO.R2 M2XFR+<>229E STDBBHUTD$=$68D("9!B/* :2\ M-D_P=2&,3B3@&Z8AC*CPS' ?A-<+;RXE)N,DV9S2=<)9& F%= "+0ZF77DN= M0O"%,)2?<0IHAL/]4^00S^91. [ABYE,ITG0)2IP%!7JKP=C)24P"0;" T$A M8TH3P#&^=*_@O9@TEJF%MPAE%'A^IJ[Q04^.QT +'B7X4^ M\9$997,SRO0Z MC& YX$D5F, WYJ8U9YW0.IN9FW#*)\Y,+BMG,_/442K@8,O7=W5Q$S/$Q(3E MB0IXPB2O:2^X1^XUIY/@<8K7A#M()'DT1=!FESQ%2L-IC5,:KD#(/["0OW6% MG.;5D/2"_9&4.B>_Y-Y!FX/TQ,MPTJ3-^7VY/Z>GVTFYR#.YK'VQQA+:D+_U MSV YWET.4'?P^-BWWT/0_[6+^3U) (^?_[.=Q6QPH&Y%*^5>$_AODOJ;8'L4 M79M;Y]I%Z4Z[342":+F[6^-B.UD_O%.#\#H$QSS@($D#A7$WHO1(2!Z[M ?: MQ:G%XNSE^5[$@%NA7 O'66>I?.ZK<_Q(%V\[TQGMS1V]@,N3B^+;=0 61!$: M.;&6;0'SZB4H%=G3)>$!7YSY+OJ'9,81+7P=Z5Q>)3@9?B2FH"+=X>D4_N!> MEW1O!0<&7UWAO1,.KN04'D,,A2C1FJN;HRCQZ>FBSKGMBKG+BZDG5?B-N'#Z M/,4@:]65T\/[=+9"%Z(5KB2US+.:GXI_#T3;4"WN7HSOUW)>U.X=_@JSW8E-PW] MM2M9UY4\:AMYWL6B3U)+H?PIQ>$", BB9(YANB:9J3N]&3C<(W27VC%WJ_5. M]1UA1Q9*FTNTQ8S")O0=>YI,*(8!;&H4[Q]N=Z4\_S^4C3T1[A M<=2/N7L$?% [YNX3DDSMF-LVMUS#F"L9180>!4?,3*BO,L7ZZ.8)XHYQIU]CF-NZA]OT8+:I%QKMP;P6\S %VOZA-#?J.'0MX4^U^_3FYP2+ MVD0[_3FM3Q.U\7-:GR;&^Y[3^AQO$YZNP=[R=7?H#!E2S"&5PZ4MMZ08?N? M.'VX.WR\H[--S< F)\%O/M@.EP)T^FZ6XA[&>;45F1N%\S2?+AM^O_Z4Z8.) M$/.?WX3:CQ*=*?EQ[)['GR1!O&-%FKZ:"B7IR+X4"X**^ PJ62&MO-!KP__ MI0G__?3@J/?BMWM.:X>^07Z\]'M=SYDU9;J4YETLVN@IJ*VK<_4Q]H9S%48> M=\$^!?_BHN/]?NG]8.@^/ONE>.#W2_OI MX))T 1.0W\!A.^SUTBGX M^_0E'[ ?C'9:;\*6P2C[8+H:F\ MYIX.?'J&6F?<$&=EHEYIDN_73/*].TFB",;^([GF;N*GQ,9C[P><6_&X(=!Y MLNNY?$,L%SFA1AK@Q*+7"C/4691RCPB=C;3\.Y/882&,1>S;I@66F2.%O39L MAP/X EX6'@1AE)'!-5<),)D:<'#'"\NPT0([)D2&D6'L8\\'[J009S0A[$G! MG 0B_L+&#_!#=PB!'1JBB/QL'HJ)2& &0>9+TP_"-+.?8S/[)2J66*&E_*J] M0,S$A-IYP,.^U+22+_N=7J^'_^,.$H4LI1)<>FIS%$X2,-MTM" R CE&=,8P MU3(:L\R%FH2RVZH 5@&H\;F-!ZXL_-DI[]-\Y>VZ)O U-MD /R+3GA^)<,8* M%T08* )A\Z7$2 5\"?N".FS,1)KBSF+Y5B@*1@& HP8BK1;PVTQID@U8+6^$ MC6%PV86?AM?@-V KE \B!J&@^BND922C4%Y+?/D"SG(QXK8J](Z96'BP?Z@S M2+2PNVE,<\56*!+<0-X<+(SP9DOC30CB'">I-Q77L)/P_Z#*\D]FUR)U$DQ/4L2!/P!PF#B1<>;[04V^,T:INE9VPV<&^ M;!9 AY;V.!&BPH?D+GF)?A5_S<'/1?9LR8TJ$Y6A1M MJFY4B$K*$(.?AW!(@UXZ0#@X4@TF0M#APS; 3DTO^UUX%R@<>E^'M/59Y^C\ MT)#XRI+H/D+TV6>ZWEOLYN7.B&A -1=2PT'$K8LE6POXCU(K+7PA?GM36&IS M:ZFM?:KT3B;16WX?$9$_/5=PWBME+PKPUQ3@P9 Z92;RI'1N&ZX0:0C4)0IO M>XHL$:9"^IFBDXH1^\*\M1DO,C6R"F'5H9;M8F@I6@Q4 MI^(W&538AH6TTM-E6T])7X;7\)RQ,VAL,8=_?;.'_4LX$HZ\&1SCN V(C%B2 M*9UO(5L-P;:,W=5 (SC:FUB&>Z83G7/4**%<_7F%ZCOI]/J#E=4M1&A9O,B. M&DD9VU_9/&$:Z+:]58.5L(?HTI+L]O LD_)!3&(!/J=I6-.>XWB.5QSC"XMR49+:]*I6NYUCFT7N3P MPYOASQ_51,3A/Q2<((U6Z0 MU'Q=1#G9&E5.(+0B6(*Q8DS4 7DVPQ9HV02+C5;!&Y#G&S+R8_B[S\'6?J_C M]<_/3[N>)2S43KQ&FRZZ"V^<^-A UD9L#(X/V3+ B&PL_)0;P>(>TJ985H<@ MWO!KL-T5[AQ?*C$+_3R&532EY9=''G;>%?;V 3X7%"23W.D7%C/#,+:(3&#R M&JQ=#:2G:"]I6.A./@VT@= HIIHJO4*)90[,0-J7FKK>LJV2BV MBKM&RIL84^>9+3(%Q?H*?%KA5W+ MRU/B$2>.^=1..O"^7'E7R-4.>%U^UY5M^XTCM> $%7*)B\'!3^!+BJ)7;)&; M,)VZF.[ F7=1 K2)#LKSE9RG)-!$RR$GKY4CW&Y@,7\%O98"!PH\'Q5&^:4* M>LJ44X0=L4O:_BXEOAPR?"7 V_XX'OH^7M" ?/#O]U#UTTQQHU[R;FS/@+4- MX#5&-$06D)!5-S0PN]M&O9WV!H4S"&IO+A2K4 $"I@*R8VBWD+&319)UJ9(3 MT_!;V[NCDH@#^7GH!7__]IL_%?%$F@O#V2S4>NFLNGK[NG0;=Y5A6_G*-V)@ M[8;O*NQ Z*>"E@1;#(@?(VM)6O#)<9*D,3@#7I 'Y+7'W#=W4FY+B$H6W<88 MD>]$:P(BR1/&$ (- -^C.@DJ54$'] 61$"5XV.GBC#6WYJ!1\.(#IAE)@9%* M#C]1XW:P.WGFL_P6IF-N3BIG07A&OM'22"]RA>Y%D&^L=_'>,$#IXD=^,-$] M_#6\R,BLPL7EX[GX[8]P]."U($8F,/S$FY;ZOT<+"9O[+8SP^&_,JV M-)C=76LYR\S$Z)6D Y"86BQ[Q;DQC.,,QODDX5Q*\=QY!^P%Y7#P'YQY3@8F MYGF2N@;DAM819P><=,RE?KY%81?A2!$(O'PB&/I?'(5?/8J>*S#;]XLH0X% M,N]00#3DR=M6&.TZ\_F&1SF9&48/V->D:#<4';;L>^QL4'J6IW.Z[HCET!9H MOG ,;\,[;F?3X@9/7YGBFX 984P1 *]O/:Z[10-U1WK;LK .79I(U;*T M5]F%JUUUD(B ;T109@I+AD@"O8C13=CM7^:X5B5WYNJ+ZZ,@IP]Z1YUU^RL MSYK"\O1RBB0[AQTH,;S& (EBKWPD'?UBU"$/;)7+:U>"7ADG_VHJ9:HY0R0 MD]5/. M^KT:5SVL2/)28L;]TW:_EWT5^;O/1T;J7!@SU,;XD<&3"4>[&OEJ%"Y6NQI/ MOQJX-ZY#_81;XP%ZLS[(9$.T<_7/&[*L#J7Y]Z^>:1A:7\N:?6;-(VF+.V&5 M;*7E.7@$QKDXB.38:(:M*.5+C,J&@<57TD[^&,8G)=5"H+K94-OL?V5F?W?E M@(/#35$1:U],^6S7\H>3\TTA5[?+LA_K+5K[+0V'AYN"NS]MMZJG,7C?FZ!O M*%NKMTX3:UFSSZS9E=6[(TOWM3%G,2AGKLTP8> @E6I&=TM[K5F^AW/]T\[Y M21-QGYO"X ?8A#4P!)_/^L &.-HJKFV%JGT\&);[93LNYTA^T?+C^*WF6G.] M#[F07[@.OY@3D=.F02[E#'">GLT0J,SR,0E_*!28)HC9&-^?QE?*2^Y>=;W? MA\,2](J2E,^LG50]SE](X).OTI/YPE*2GM;9C$'%3&X[ISAP>A7?S'EBAO1R ML25%N1CQH7 WN$-NGO-H:@(9GR"/C%'2W_)S_*; 9/J74_>6LM[6D:3DM8PS MKH')XW,!)[07*7U=;^BGF4D]MXEC/B7H!2%6-]H,FD0[/.IZ5\DL)VV68-Z7 MDQM6$)K;CRW_TG'6P=8VLGS, \B*F<_[$ 0G@-<@N@1W=?DD=9(I7^H]S/G.I\MX43QA+Y]Q MJ_96P6)NR]_,@7?S?$J7GIR[Q!0BQJ>? 7-:X,IMVB8J$E.#:!$-GDFX2O:D#A$.# MU2;FFZ(:L_7QG$9J4P/S!,42#,"R NF4ZKDIG1!_,A+QU_Q?'<;>@G-+PZ1 M7B@AG%:$S['4H013%#FM5D2H4B^HJ@=1JI!XJE2J?3(:&S9>.4"TIDR%/L _&UC'?L!*I(O:"T=\Z)0(_ MX\=+A8UF#TPDL6_=Y#O>ZCQ=6RVG:!DSSAD+&/P>&%PJ6$&=E8^'Y.0_ ^V M*:Q1?K@A"E=,J"NXQW+CT%U3L@Q#*B* 1VD?V;IB*L1(:9]S"O'+XSO4'14U ME@Z$M3JM]":":R\C>9QT#^VKNMXE&''*U/LA/H^QNT4%2(6UN_/*Z_S,=P[U M0&I?A2-G#W"A1Y'-WR]+_HJ^@D/AANS'6'):-VA45L*,H8># ,G)J"AY"0*J M10&!'6=Q1+CF81FNY'?@D(B8H7*B_$R M!%\64V[UVE>COXA@>>57Z^*5(WC=C*NPX@,[Z[1<@52X7>RC+2^ OGL%F&F@ MB!',L4 K<'1)7I_ 2CE=K\9\4SKEH_OEXB8%QM.;BP6C)Z6F1,W!\S-*%60Z MPKSY21FG"]$!$6=RA:%$PBWK:=$W.U6KC*.BJAP!2=)=J+S3A4M(.%[[M@X;4;-$8SG(5^3=" L3 M$?GPFCU5](!-N)\LOVD2X;G9R4UX6JLUK^O0E,';3:)KXQHC^@1BM>+XN=RL MK67.(1L3*\&^<<)NIF#9/4=%@63B:(V ,X3PQ ME&?G;P !(K3N0;I$[ M>-B;!L@;)5FZ[OQS&)";NG1Z3Q+&H\)W@&;^(W&*'_& )SK( YB)@)82?-8U M@9.R5B<$U(+V16L56_ K*8T%3%:DM0F,I5RJUS2.F]UN()4P&F/O@8]XY'B( M1ANMPK68+RH.,1BTP&OY(!%7#0:VX,1@F[Y_340X]FG^^Y)E:6)'#GJPF"A) M4@%Z(+U!Z2F;-RX<#9 A31TU_:IJ6NL,4(F*>^$,A@P%.ACLU92-.WAA5%B= MJ(4I:S6VD)@ N1/<507[..BWS.95C(,-(EG+\7R0(><&0"5Q@KN%]M+>HA_@ M(,6DO?*LVS!81:&IJ7DFZQQD]5VN>==6F+Y*X _7JWPWO'KE;MAL'AC70KH7 M!!,09%(9CO5E<1N+@#*>L:C8N8Q5(]@)%IOJW*IQ1L3=*.$'R4(:Z$T3H9YS M9P$/7&P8EJI*2[BE2Y3A. C;@]C1XANR$#X9RS!%T /VL/$#H05P*!SQ'XR%GFWA1/)+&<2_(Z /WNLM4!QLS@&.B7/=;W)_A M4%_EHHPM0F8DCD?^.-[O3(P@>E]R5PKQF"QG.S8Z*UFZ"83" !V1WV.:C_'* M5%_JC0F3G$URRGPPF\ '7A&3?XB6+5_2E[U8UC*P MAJ0-)@"D.EB#"X4.5P1$B\O=Q#TT1:RDG4I9'7Z+6F 75 M4H,T7*15N1 $&"05ZM9\:]#E $.QH"K4FGUG/((>G1FP"\H[V[S8;D^#5U.] ML4\[!=*GLZ7IGH.>0-1T#"CG6S=DA;*T@\V>7 ]641E+0'[0N&:/+\^K4 8C M27,@7DKR!HL%:+>TZT+<8C08&*S,I6Z(D(3!"( MD5K8--?XG9SS];O6'-JD "6??TN\XD FZ$+2&SKIL/7T5Q9,2%511E.>8H3G MI6O&\4&>!_"K5B^G@]!_E/,P!^#SI5]:TWMKJ]P2X;.G4FF=W:*TPMAXBE/! M1JJ8@^N*C0%"LO*43%52Y$E07 K;0O @#HJ2#9SC.ICD#7CBP #V..%3D:,( MVJ0SJRM7C)N[3!H;3[4#L VYN0=99&=M&GU::?*#?<"R"%.\E$K4ZT0A2A0Z M*\,XH!M4[@#K #WL0R2KQ7!J,9R:BT'28CBU&$Z-QZEI,9SJLAHMAE.=5J/% MZ3:QES3ZSYI&T18OAU"*]/(C"%L-I?]:RQ7!JI:'%<&HQG)Z> MK#J,T+*FOJS9E=7;8CC5'\*FQ7"JF4U8 T/P^:Q/LS&_U=^H5%=#%Z M]3.2NR_WYIBED\0VORL'K_%NI)*V]I[OUG5[B=U>8C?Q$J:$1L 0 .VM6)M4 ML-M8@5$?)\?;B?]\$C=%[_,VS+5$S6%O9V&NL[.C>K._7_??BLG6FUH6\3P<-Y$UCN'NT8S^U.;<([Q J#=Q7[W[B M'3LZ[SO]WJ8G?AWVZ'-:HT&G=[;-H&Z#C^_/"59WYV&?>JB*P^XAR@A"*$6R M%K;G?\O-._VC37*@:!N)O#YXO!]W1<$GE>P1%'\;! M14S%E?:3BQPAG=."ASX7,PXUXF-]'+\RV JOD]DH9'B0O0G57ZR@PU-UJZ;: M1P.<;RO@B*(V5M_&ZAL8&BY#R4=MJ+X-U>];J/ZUP3!@& >\G)Z&\S9F_X1Q MWJ/.^7FOW@O0KF8=5[/!CO\;>2VC9(ZP*D7?A>:YE;L1J>/.Z6";P>;ZCK ? M_-V=[; %YGRD$C5L/&$[H?'?&2O'@)8T4#AW(UHGIX^4;]INW)USM\''ZV[.OO1TX&;:5. M<_G;X,/]/;7;;[-\[+33?ZP#Y7OHV'T!V;-:Y9/.>:_6 MJ[S_=@=U:$9TW-JIMC9IY+;8]_%1$XVB=J$W7NC375MGCY<=M-TLG_6%O$/? M5YD,'(R5O]9SA B2@J<[#9#J,T0:F!&2ILA5*_U:#.$'C]#*)EA M3]0'W.NUB22/>;FU!?C"-BGH:=9R<+JIM?S\4H(NQ4(E460:H'-DTX+E-M"G MW(<;\/J.L!ONG@ZV65NY.X-A"ZSYE"Q$A'Y> \5O1UEE9^W6W*+BZS<@8^\I MCE'J3BUUB@W5*6+6/!G<$=;@>9M3NTV\[0:DYCT9/(:(O"@1,>Y1:@LYENU! MNGZC=GKGVRQ%KN\(.\(0:8*5^Q1'*:6^[USPGE.JQ4DCT:Z?TPH=G>P8!:(Y MYS@GK8C5J\]ZJ(PV?^'61)733<$5:ZMYVH6^=:$W;NE5FT25^Z>.+">=O)&C M]'42@P;%:[R/P%_T.?#3X0S[N_?7Y)H<'QR>V5P3^/O@3Y_0 OY\^\V?BG@B MAQ,EJ2'\![ITM5__6RH?Z-2?I9J]![^&OWWA97'(;_AR]>:%%T@_G(E(_^O% MP=&+WPZ/CWN]7C'9.TE>GN,E^T[ZX_@=-[B/)Z\3S= T3SRUT[/2U-916K5J M%[%.588_-T_AB]?-:3DUZ ZB?[M4(;Q]#J>6<3QQX!G\Q8<#;)A-X&G/MHS' M:QBAI&U.&"V\D<2\G9D(I!?&GOP[HY1-#8=@-+,(_F(^5\FW$+&@X8F7)[U> M!UC1\6["=$HP04K.!&;B*"_()#:KAY]F*DP7W;(H5//A=HZQ^*28O/5*QG(< M^J&("IEZ)_%5/^TY M .)X:QAPY@C3V<%1_T_S_)]7V4C#:L, ;Z]7YO]!3&+Q1Y+*^\QN,!B49K=, MV4XIWWAM!JBP-J#>6:U+)<<2]E%PE8*VOIK"QM(76H-*_S)/XF(%2Q,5G6!#+\ M^6VMATK__K3_=[605IP%4E M(DP,_?8?N;AW6B8(1__P]+QW>%IZ=WDT>-VO/WT;J2C\&?\?_OG_4$L#!!0 M ( "V$#$EX')C@&PX *J# 1 86UD82TR,#$V,#8S,"YX M*W\DOU''QQ;WBCM,DG-W-G>8QZ C&.F8'.YU#BEI-BO0_8T)VY4/=[V8[M3S MYL>MUN/CXYYP%_31E5_4GN56(S=T?6FQF%;WYJ)+]MN=H_;109MTVK^27_?) MQ=7MWM,8!+F@'L!@]W_V+]H?X+_._GWGA^.#_>/#SA\5!_2HYZMXP/;3AW:[ MVVZW.]70;[BR8N2/1S=S]>SI]'PRU%K^,?ZBP8\D194S:C!&POU&DCH<['@SU7 M3EK[P%WK]YOKH89K!(#'3PX77XK .Q\_?FSIW@@T!_DTDDY$^J"%W2.J6$P9 M>KD!G@OE46&EX&TO1D@"OV\%G2E07@AZ%(#R"-1F&3C%K+V)NVA!!\!W#IOM M3O.@$X'[JCFA=!ZCC*D::=)A!Z() M PW_.$$/.T:-W@/?!!\@@!22QKX63#H?>>P*^U)XW%OB#)0S/4"#G]W#*F*<"?:>;S K>!ZUB ME&6AAL]=83,!#.*3/0CJVQQZOJN]S@=4@EA3Y@&(4V" M=+_9&@SR'5?YDL$?R4'TA J'02LF!B*KD4@T5!W->485M\ 8%]SQP:5OF8G^?U7N"5)C;)XC54?E#?Z385Q^DN5RL=@FY5K.:"/)V\BYYV%9BJ9KJGD*2\Q,XA ;.5R]:3E\LUF>Q0DK#&!FNLWG?BGE5S89]3T?BYKS94&:JWOPD) 4NDF M +/F@[%ZAJMR:>A;1]A_7'=\QRA06+@Z;0'U^.Q\SR=+M#E=(DL$?U1?QB/OE> M/GFR)K3("QSJ&S-F=L_7?'6-$2L4!:'3PF!+($[8EQ:( $25T\OWG?ISZF_B!LL5P3&NJ'V9BNZ5 MH4399GH(R&.:A2/MG-FR)S)+8P)38H-E % M/+/)22FN:7O2VRX+9 MG7(5JC)W2L> F.54C3!BFE O20=VK#'G>H>KR&A)-//D47.?A(X%V(45D]-D M\]P+)OE"3_/((LO('%G'>5#P]"#L1V[\W+ES 7NJYDG2>Y)P#YY%[CUP7<[[S4Y#FP<_-E8-R> MN%0>QV__Q"3,IK%N^QE7+N'%-EG+-U\VA-GSP';'XG#H#N@R^G!3/6; 2HMF,N<);@1F# M84@\#HD&PIW4SIK!$?GBL%?29[3)8:[F%E#9A3[CB8-B U0%-ELD5U(K/X6P MLY'!1LW5VU\$Z.NM<]<"-663@9<0,-LR5V\KM64S]9Y7;^*# 4DT8KT#7ZF- MX@7JS*$ H:PI@*OFC$G/%8$*83&Q8%MPX]K,J6;X#8F:G2%7+3,Y0V))#'@8 MACS<:!XBYPBY()J-G8>8C7DYFSONDK$ADPN.IS2H9'F$KN.X5EB2PFK/1/"_ MF#U@DKL IS)O5/[V4Q2N7)519=*,I*&0U:^)S$S M)."FWBYC^."P>+.Y#H+9P+EBE/&+Q=VNL_@KQI*4X#DHLVER9:G<5X[_W^; M_S#8W;$QT==C'N,MBJ<-Q?$^U$;8-I5L?-J@,YLVHVL._P31]IYF3@2"I W7 M8VJ+9K41#AR1H-+*4]Q!]D!B&X#@0VENO(;)# M1^N*#"C,^8:R7B/]5Q42O&]=(3,.^XU$/5^-\JH"P]195^#T;/M&\E[$@R3% M#2\2;:UN$@W_SMXV>@*"N](C(G=KJ>GRVN#:W>MP_VE P;^:$5X3FYJ=_>9! M9^])V2M.UV%BI8;UF(CP-F"B^%;>BL-'"#CN^[5&++NTMV3@0AQ\:*Z0JXYO MO '8-'XA8HLYGHI:FBM2FW"3O[UW!HCH)!_1.3M' M+V1F,T:>XR*\ #EX(7MST?WS$X7)C2?;F7+%Y1-N3WVNI@CD)@Z2]" "2#^\ MBPIE.&ULA,D=!\]IG#:@#0,AWK9]/-?Y[KV.X[8?7-\9]8V";R9.&Y:$?2/, MVB#32Y['ILA.F@+MG405WTD\4FZ_CP"Y0!BTL- N@N.%\)?N3(^ MJGS'\& )BR1^!F9SV6PV^H:BXE16NP/>Z,_SBY=R7>+=M)-WS8,\*&*P3 MWM]MNS+.(3&VJLF8@GRK8I[CAT;]<7@DI2_O^&3J0=P9,=D?#_%LE#[, /LG MA]EGRS1I)Z4%@&4Z^@A6L&>X#X. X8+N/&AOZW:EC8 3+@T0Z/ M<^+)* 5N&GZ8I@9TB6QWA5UT85WDV"\A\6:C]31'@Q+S"!('99XS_]7G\]G"2^O!OIF)8WC31 5 MQ"6UIF%@>H!<*';K"G!;#D>)0XSGCHL'4@>2<8L-F QO^PT-]CSR#*-G3UAE MVC9 ;ET>] .\4B5(M9?=B60:(BW+LU!;E^.*2^5UH=^D)SXU+ MK1GFGX/:NAQ#AC=A=(L7Z++.K7-]QW6IQ :'D-84>!M0Z0EHNKX^3XM0"7+K M\JQJF@,?V52L)#15 =RZ-#_3V5Q-N02=V[C.12KO]3X-,JMA%NLOY=T;YUS7>/KZA)?)N@7=&R=VP=A M,_D(H0,<(,UN8<_6^=5*/"O3[MD;TV[Q\OF&UTU\R5@2&U)=6^OOR+U:#TIJEMJ,H>;#Y/$9I&_JB*K6,4B]B&AH)Q].CA^=W2 "/.X3]GSIX/'A\GTX?/5U0$2$68^#C@CGPX8/_C; M?_[[OR'X[Y<_32;HDI+ _XC.N3>Y8G/^5W2+E^0C^I4P$N*(AW]%_\1!+'_" M+VE 0O29+U/]5=[O(HI6'P\/7U]? MWS'^@E]Y^%6\\[A9=P\\#CV2]S6].9^BDZ/C'X]^/#U"QT?_0/\X0>>7M^_> MYL#(.8Z@C?SU?YR<'_T,_SL^^7+\T\?3DX_OC__'<, (1['(!SQZ^_GH:'IT M='2# INOI^]X^'QX E2'_W5S_> MR!)/ M*)-J\LA!1B5[::([_O#APZ'Z;=:TUO+M*0RR,4X/,SAYS_!;JFE?0"+H1Z'@ M77,/1VJ6=0Z#6EO(?TVR9A/YH\GQR>3T^-V;\ \RX2L)ACP@]V2.Y)\P6?)1 M00<^]3#,C^6A_-TAZ"=>$A9-F7_!(AJMI;+"I<(*^%5GBY#,/QW@I8\GV=R0 M(_[9A#9:KV#1""KG_ $ZW [D&0ZD/!\6A$2B"U5CX^%AW.$06%^0")H$O3 U M4@X"4"XN(C4B9O/92MH?T(0 ]4B;$Y(%88*^D&LN.H78OZ?!&?B,Q>(RX*^] ML-:(!H$U"Y\QH_]20@ 9/,3+)0[7L_D#?69T#DUA#7@>CV$1L.<['E"/DD[8 M.W4ZT'P6U(.ASVD01\2_)9%4Z!T)0&DBX MH>E $,"\/].G@$R%,+!(;>T' 7.)::B0#0)-&@8:J1FG_(FR;[#K-I@B!J3#2"]^$N2/&,:Y>#%93FWM[3F?49W0 M*,YH*R1?,!C5<9@L=SVTZS(#WDHPBALSQ:2C&L^EF:$S(!W)O9GAZZ(;S-69 MP:FW'-/[F&$R(K9G)^(.\M M$NL[\7;I[ >G0$"?2V'"6I!&RGZ\-YV???D;QW_V%;$8_"MC"XFS! MT1>^>8_C;5+ZJJ!7)^/!+HCNDC*P=!0'A2U*VM2?1CGUC('IC,,0S*VT,^)L M?4U>2/ ;C1:4Y:W^3DF(0V]ANHR< +<7,5<=TCD)Z8O2=L;:.F.LRLVC@+\] M,@XA9_@B-T57;!5'0K%X.I"@]P1O+Z(&$Q O5\J[/X);OV(7(J+RD((]IYY0 M;CA_DZN-13E[ PERD,%'BEB*,&N_-.1_MUX'BW;ZVET=S6"@"I*8P0J09\B@ M]FO.GB<1"9<%#"9P^_JHQP^:^2'MV,R;TR292DPUFRA)./1C>W,0.T/6X+.8S^2S T$)X"V@N)DL2 M1N [%2Z8W1ZLUAONDV!7MG<;;D^BN(#^^9J0!]@$4!DX0[!9)Y@&05H6D6PY M()C_%_$A1*4K\835!&5?PK;%Q0T@4J]3$6\N9ZH!+4$\"75Y' W_,<("HF 5':$TJZ0M\] M,AS[%'[S?59\E:$',U)"K,P*#\LJ3P&K$J\Y%D^JSBL6DV>,5X=R*AR2(!+9 M3]3DF!P=I^5>?TY__'N2X?@,$1A@SP8(\!,)U+"_I^TJS0XM DX2M0(,+*$J M0KPE43=^+565G<+LF88>XJ%/PD\'QUGW$/:7YDR]TBYM<2CD)D.91M#S,J.? MAWRIDVXJ2=Z#@Z+P8? #]$KH\R)2H"TJZRXD*TS]BS?I @L_EFT(*'AG#,B M-E/=B575]9""L(&6"_>O""6.J-7]F O .>UU:ZBO%L9V+BU:<%[2A8WB+6=>UXZYI;F9#GZPHP,M MB\XII' 8U1F_-+5U('"^PVL9/1J'S-7VMC\_21TMZMIU3E#PT_9*>F78;@:;&MK()X*45*_',RIQ[5F%436MLNT%ACYH)P M3H=3WZ=2$K+PAOI7[#->T0@'A3FHV;T8T-KVE,8Z-!>$>^F MM&TU37FK[GN^G=VHP:769O?62F3;;FZI,^/;O0XI#\P[@>GEWP/JS_ GC4S2 M/'HJVR9S2_69B,(Y_17C(Q/-M;5W*$[I92:U[#NGK?HU!.#7;,%U$-K.L&Z] MYHP$8J;(9IY_=(UG3<,]9S1 T'V2&L7F9K+_R1G9Z[EQU%RHDXF>ED)'8Z:T MGYU1F@%+)IK[Y;#*[37\>Q_5FLTOI95*-T]W+=U$WY5&^7Z\0M0MWE0KL?K> MC-7-,(C/T68@57A;&@K)L1PI8_TUE)?30S[7)8U*C6QF4'% Q#UY(2PFVK*4 M6D/;X72#F*ONM9DWYXR[O(@@;VDHH+I N=3,=FC<+?]&OAJD/['L6Q.[PI[3 MHEA-KJ*AJ=6DM2#RVK=\&4/>2>:JUBJ%ILM7:\ELK^M6==0RU0;<.[?6D\>4 M P ]]9>441$E5V ZM=9):-L>F.K-4 +.:>Z!!-#G,^"^P>%74N!4XS0U-+9S M8Z;ZZN;;.57EK%TQV+*6]J$:FUYL[(P1K'-0#8E:U6CF:*V9B4[.FC88KLTT M"$!YF:%.FZ AL>F7,&5"*H.(&;MXD^!B*A;2IWEU*FFZM0S ME89S$W*31I4\2!;DZQ/9S[01G@&I;>/15X_&TA@_WUJ84KPRI7CA4:(K!ONA MN/2(=243NTU'MO<:QGK;ED%'5^,5BTA(1!:5J/1E^P)L;FW[/*[OFM/Q[&#P M+^$9!/[E9K;/V/KJI)%+]Y2QV1)> L=)V40,+&XROV=DSD.2M/N"WXBXH8R' MZ@V'9-9!F%+N)3E/N"'1@OM7ZK&/-N.:S]\]@K"],;(@\;;XI2$>V.&L=[P] MB'V1=:]^U_P@[+1,0O%*,]N+HQ%US=OM?S:XIMVSV!UG].JG0B^\,V)[*R3Z0Z=>3H53Y# YCN0OY"04IGZ^2ETMS' MI(_J:>M1^_3Q_R:U_P+KJ:"J[VMKNNNNBL9UAVU9Z98!S7IZKK _L #HJ^Z(Q\!YGUG,NP MVFP1B^/*3)_(E\^+"W6/XIR*Y!:]J5YU/5A/X0RKXFYA.:=M%XZ)S]H^O=A0)M'2WG9I^#7G VQPMS]-W'I% M?KO'B1\UF(LIBY]F\] )?_OR>WI&:T!OF#8X<5'E/3O>V@A4K M AB_Y&'^ JPL:@U?FJJ')(V>Q%!'+B9WNIESU&,609_S^"F:QT'VUE?[JM-3 M&>K1X4R0B52<4R7$QZ&,D\])\N<5JS]SKCW2,* V5*W#::(^4G+/7=;1I^^A M9S?^&]]%[Z-UL_X,YX'#":;=)/DMS(S"AU#[3( 2F:&>'?VD]MKC-N9=WY_A!' X#;6;))WS\BWR2,HL=CLA;NS#YMXT_?S@%S[U(+Z1 M'R9L>9Y=LU/MT8>C9\L:U5:WK;T%YI[A \@>(;ZJ(VH(= VUWJ<31\^M>ZB] MO\B^%;.6GPKM8-8:^W!DAE\)$H^=*H4#./VP7CW-2] MA[ A_4[NO/B(5[LFVRD*>'HLS3\)67[A2[\:JZI'94T"?DX)FLX79U8>C)3;;+54S@;FG]&RF7O(0 MV(E#;R&1SXV>3#:A=;3(IO]2[A:0>\IM_DY=\@GH:E3?KN9^O=C>1&W#<[W" MN&_&Q,E[2N.)0A=:[2"*\3SZ>*+061)W7B*I#RGTCS8# MH,T(8[U/>(8%]5019!!'Q ?ER:-_4'AJN&595C-_/U7Y4UTIQM+.$/26/#<( M_:&D0Y3V.!8_33GW$NR?J[ ;CR&&A]52)5["]J&.+2-#U0.QH1%>8AJJ+X_< MP-J&TA49;"T1*NDRJN M:%]\#X$9WKD-=70>\YDL;?/P>0$L/KH-9\[.28 ^X M6MRM#JJQT]T#_*W,X[G\-%L@;N6!CBQ0;V:SYJ=W,I3IF"@?U#6A3!Z\!?%C M>6I[3SP.FX^ IE?B+N9SXJD'J+T "Z&Z4/G8&2<1M-H%WB<#W.V$+SMJ,-5V4 M;@WZ1-H^SI*#C+SP7KL M-L6%1FD'U6N2AL35L8;.:K%K/6^2IO&MOYMNMIRSS#/+UX\X+8A^VOG(BO- AT MR\Z$VN[3OB6 ZK7Z'1ALH[?OI(G/,4TFI&Y!J,AE_EI/!5].(S M+.W:WJ8O^[Y_:\UO+SJ7GD]LS#::^:9:^JXU[[A/#]7(4,%-I=4,."@D&=.F M_C3*J6?LGLC/+L(\D+&Y.%M?RP\P_4:C!65YJ[]3$H(>%]I0\K260&P35-GE MY4A+^= ,*\)1L1_.4 Y891,$>EHCA1F]*M#%UCGN?:1-NC12S6G5OY*[SIBN M:N51P-\>&7^2-^AE0O.*K>)(*+9/M3JI94K-=%+/76W0YFI:;Y34H!:%&15! MHP0U^BY1U^GW+F@%+%F\7*D<7%(&="$BNE35887*P+3R/N=<*_-:VM9,Y@4D M*)990)C+&S!Y;DS"02F>@BKV(,KZJ4=1CK5?:F54R[LVG8E4Y--T:N+ YKC. M>?OGEU,:#8G-)_L25.I3FZHB0,AW'TR9:2.SO>GM5$_U+3X3*3BWP;U8K@*^ M)N2>J.U8G\EH0&I[^]I7A\;2<$Z/*:?W?(V#/J:D3F [J;7ENFOCW#E-94_^ MIU?G.Q75UM[VY9F^>M+S/?['MU*\,FH(KCEFZ;6.2Z);+)+2A-#V)1=C99@R MY.CB2=Z1Z;]QZJ*S_5)LW\5D)@>'TONR)L@L;5([^T_*B?:9(Y$C%D*4&02? M$68RYR7OXTZB]$*N-E"IG?,K-LJ12:%CI'J65WW+_-H,4(J7CSM76&-CJ^_8 M/D6;YSL?&4X2C21_%+N3(_,>;(!CHQXL-)2U[,%\=1+%_)H;0 M24-I9B&MFL8BD!L, E9[A^)=]ES>]V2)*CKI5H[\S>4:G'\5^Z3_Y$R$G_PO M4$L#!!0 ( "V$#$F!L.>,(R4 .QK @ 5 86UD82TR,#$V,#8S,%]D M968N>&UL[5U9<^,XDG[?B/T/W)K8B)F(<=NRZYZIG9"O:D?X&A_=._NB@$E8 MXA0%>$#2MN;7+T!1%"D2!RE22+K4#]UN&T=F?D!F(C,)_/5OK]/ ><8L]"GY M]F[PR]X[!Q.7>CX9?WMW?[LSO#TZ.WOGA!$B'@HHP=_>$?KN;__SG__A\'_^ M^E\[.\ZICP/OJW-,W9TS\DC_XERB*?[J?,<$,Q11]A?G-Q3$XC?TU \P9_F$_\U7G_R^ ]:#7=+8^;B;*SAQ?'0V=\;?-S[>+#G#/;^[OQ]WSD^O?SE]9$S[']]/_@_PPDC%,5A-N'>Z^>]O>'>WMY@WOVO M@4]^?!7_>D A=C@\)/SZ&OK?WN78?#GXA;+Q[C[OM?N_%^>W[@1/T8Y/!$PN M?K?H)4:IZC?X\N7+;O+71=-2R]<'%BSF.-A=D).-S/_J15F'?.,/N_,_YIOZ MBJ%S1(?^US#AY)RZ*$H6I)8B1]I"_-_.HMF.^-7.8'_G8/#+:^B]6^"4")O1 M -_@1T?\EZ^K;%8.E^>[B"^EZ:[XVRZ',IYB$@V)=T(B/YH)7-DTH973GPPV M8?CQVSLT]=#.8AF)&?]@TC>:/?']%?IB>[QS=IL1>8@"(<_;"<91J*.JLG'[ M9%PCQEF?X(@W"6K15-FS%0+%/L0"D?#J\>I)J"J.1,CA$>J)X0DFH?^,SVFH M%6+]D5IGX B%D]. OM2BM=2I%;*NV!@1_]^)$+@,;N/I%+'9U>.M/R;^(V_* M]X#KTIAO C*^IH'O^EA+]EJ#MK2>0]_E4Q_[01QA[Q)' M!KS#C(4TIN)WRA MZE>V^1BM$'U&GCG4E!E(N*)I2R1P]3[V'P(\#$,#C21KWPHQI\AGB=V]P"B, MV7PCZ"A2=FJ%++YT68R]K.I)E19]"U(_-F1I^N7VNFSHR<M M@]SJ)/;8WA$!&2\.\-7C#78IM[F!GXQP]7CR^(C=*/E]@,(P&2(Y+EX1;J(] M#J! DH1\)(^?U+S\83AEM!,A;H;DC9W$ZBZ\=<9LV]S5I=V@:]LD[@AE0\D\ MC+#X_"?";)JCP83<^J-UP :S>:)%]*G,5V\+0W;*8K>3# /$6H3OAS<.=*681MYT)77QUNWRW7E /!^NR MO=YT&Q+%"1^?SC"^Y4Z +P[._+!9[C ,@K0L8NYR\,/\O[''CZ@^Y>U"XZ. M+7HV),Q[PC)B\DT$29>4'S%#?KX?OB#FM2>PYG-VG22JJPX;#-5)$JFV&C?L MKR*6GV\6]%8USA,@*3I:U#Z):J,/"5T3/@1SXP>\X_E340GR*])=+GW!BA.9N*:??J 64URBUV[IQ4%03T* MDP[=TT5H-*Q+VJ+/1ME(ON19KYKWWB"[U]SO^W0#=^C3#QL+>@ M7 RX7ID@_[488F_^S\#9<1:]\C_R$]0[/G\+W_:#/'598,%3@[6Y<3Y8V&6[CAK4%]8X/2] M&:?+:1SZZ"PG2E9A82I'S+414-7EB@4N/S3A4HSI)(-NA)WURA@+['X4>L(/ MW8"*4!K_G_S8"63IZ(+-W/C.<@)G.4-G>[)&P6.!O4^K["5#)7RE@SE\M/E" MO)Y_4\ '=-(1.V*GJD:R0/7G5:H+/3JC2E(Q62#M2YFT13=GT:\C M4%E'DJ M!WNK5(J^\T\EG&+OCFA5%%86"!VL$IIV= H]NW(P\J67!;+V5\F:-^V(CI5: MS (E!ZN4+!IW9BG4U9@%XMZO$C?O?8CFYB+?O2-R3:HS"R1_6"4Y-T)JH0MC M="5F6?5F@=B2<5IV[.(C"Q6^2 M@/K.WB#]1/8/Z:]'V8&92Q^?\1\SH /T@(-D[E':N*KM+@#2DY5E0';:;I7D MY0H5'.0% MS EYYU#F8?;MW6!O20M?J]C[]B[BVLTJ2D)UG9&0TY$$35]]Q0*K:MLJ6I7Y M%ATZ1:%3+<52= #A("XK.$ZS-V9HY'NTBDDYG20!1"%K%2AE5LO0[.^]$6Q& M@PI.VH)GD5AIJ.[6QB]A3@;A05,(*RKY+HZ'HU^%HN .RQUFTW.*R$6:/RPA M(EI7-QZ];QV,8B[32- 5ZY\:42Z3]/NFBDPBZ1L_N:'&XX@B'^!L91_$8$ GV3A CG.9PZ+KQ- Y$ M _+@.$ E+'8( /_N"647$LKU)P*^&MGF5^BY6EXU06J(2@/]'5$H\HR"I M#>#*C+$9YS7)G,D7A%%W\%";X"'2DFX-!1A M=XN)3W%8)/+F7$5PDGPR-RD/"H 4GOLVJ:%&KD'(@6A=Y$+^9KYX1.\.E'#45F%NFR;CK^AB)\FC%OCJ MYM7P"R[]TR9"D%-#K: (.6FT(/J:X6>?QF$PN\%/E'%?39='TO4<63J :/=2 M-6HJ-F!JR1L<+E;GT/MG'":?PVA3LO).'>S#3A#3L2!%RRY15% MWY@?)*^B"6;S3QB.8L:P*E)FT-E6*K=CQ]:4NJ8%N:+Q&P55 MQJE!4FN#@9^U[D4N1&;6^:![^T7$]HN(VEG#'G\1L:;J.9Q5#Z"."70Z*>RR MS@W(&YI5KJ;8Y,,"?4\[T89-@&BR;'KP-4EWX$,.9,!;()"C(KD;MW4'ZE)3 M2W$/X_VXFH:M(+]/6MMX">N*45H9?E2U<"&EW=OC4K9(]JR@2DN39P8X?9BS %-I07>23WY*0#BDQ]-F0N\[ZI.SZ,4#DPN>UCH]@T?CFF MP%;I/I R6\5Z"SG;-L_^IT*J^)R+W%MEWR :8-8;1(V#@E3C^@7]&&#B"G5P ME=8=F,JL'U$(!3>'LPOT3\J.1-&3.JI0:Q ]0?&$-+F;,+T+14L+!DP.2/6 M'LA.O* )9,:@JR0&+AQ@"WG(P8*-KP[0L8 XC.@4LQL%&./F'O#KL30@,ZGMWXXTFD15'3T5;!1#M0FC#7>BF% MY(Z3)*=_C:+T1MCY3\.GIV!14JZ\Z,2P]ZC*TL"'JRZ'4CMK=Q.>D534ZSK5 MM0?JKV/=4&;0/@K6L%'/S6HTF!TGNRE\M19!KYQMVRL!LM-M;;5 =K[O&/+P M%+$?6E]MM:6M3,PZVY7J.9+B9-NZ%]G\SFB89I5\,OY.J??B!X%J+YOT'PW@ M>=RZ &D=SF >GQ3,Y^XF&4XIB])O31L%221C]1'SIEQ"==^*+%SB:(V=7=6[ MCQB;\R55V582Y95O&9@E9TNO TA?-=A@BK:2GYW"T0L1UT=![@F#M*DWC++> M5^1&5$,PCIZHS>;NUKF(C_SN1Q.?9*U^]3'C$$Z4.?F#TOL$,CD5<[X9I877 M%A:T.BC*CT.)DQ&<5).'SL/,26AV7A*B\ZTSNF&DD1?B3%4B\2JPR0'"&UQ2 M\U.8],"M\"))F_=XA1PTMI=K+-54]\V-#U)CR_8/IR5E6.B MA329<,J63=& @1W)*@RNA564I,I51Y/:0D,-<1%+BPG0VX M(8?J-K'80'32 \L)PB[PC" _AY\9PMR3%_RI('8]V9L1LM[_PS^- Z MT4&+J58M^(SP)GY4J;-U9UD+B=XMDDBD%_YQFVCVQ!=N'_%>N+]YFY7I,F,C MK.@-R"&6[42#HTT%4S!U[J[IK3=!Q]L>Q[=)BR,V'=(&)GNV9#\<) F<-9 MA>P28=V'_*=[0A]"S)Z%M<]'3Y15#N^;53F47Q)84IL5/LR690\5A0X)S4Z> M:&=.M?/'>0'$P9]@U3FHU_ _EO'J745$IL5,K@A0=[-_>FP;3&D(5RXUL(FS]66SRK9QL+"[J:T' MCA4+H3.%H\8!W$'Y+:] R =XD*L4+OIEFTH'K*'L0W%;T/Q?0O%V]5GN0=MQ;,F M^GNC*YK;*J$TPD5+N-2E@%=K);[K*T>]BQ8WO%E)*Z3NF.8Q^DZFL_6MR@^GJ-N57PNY9&,;8)-#8YG3;9;F&W&":L9;Y_<[1%,]:G9'Y#?-G9'&E M_,:6JIR$[?)M69;0BR06Y%^1Y>\NL5&9A*3K3["$S&0@@_[]V]9FR"*.IL]\.)=.._ /UR;I)UBJ=F4KVP(?0!8-#;DG,GU*/.C[,-'D8>1/N3C( MN'SZSD2B+ GZT*PD*$>)$W-2')\X2V*RQS %.4Y*3ZY2J/NG3(:NRV*ZXA@J1FRBTPUG^+^HL5ITQ8+\I6E\:T*(S>3IUR8^JMG;R M4@WD+@<.>(9J/80@YZ8Z0'&C6:I?A3()<+A\6. (/?F1J$EPE>DJ?4=+>2O% MMJ!UR6];WVE!8--SBHBAX/.-1P-+UT'4%7>9:'DJJFET52+FX9CA9%M+3+MH MM-(&J.FNH+3M"+5.AE(U7J#-DHF5RZ=*@)T9SS9E"-((-I'S1LV;T#5#XJ6O MY\XR4I0:5MUITV9-M51I':(WI"%.?19&0SZUEZ@OV@B">H-L/%IJB$D#+F0@ M?6H9I9-7=X+(&)O!(6D]&GR&*7@EO5)_X[/MI\\>HF4EL#K\4-46J*^BH!AJ M"C)/J=D(+"EFK0.G!HT3M80/2GVH+/TLAA.:G5TN'5^WZUQ]A.[FN M4"+I&_\9L]#W\ 6GA1NX2)RZ"?_5^?F14NKZCM:>]:@#@2D;4@O?]EN8%VA, MT"6-L%+Z*ZU& TO/7=41=27-4KD>M.R=9D KJ[,+2R)?W[QIKW2=I;Q*M]P[ MM5MK^!MBOG#O;KBOI_9-RRUA>Z8RSJ#51^7IU'D]56WM^*)2Z]I>TARVZE?R6$;DHU5 ;D@HU+%D=38O0=9A+)OZ?[S%E!0LB2%X4O+6R$I4[H5'UEZG(^[B<^\>LB8 M#S ZV.LM6'6YE#L*=H-Q;^S>/J.36\-;]S[U_EZW[:U[D-&!?(X"?NM>.R"F MGZCKCL>%9J-]2S:LSLUO%13+]U'3R*'LY!H_A,D3=-'"/JH/K)+FHWU+YU3C MFP_5E$OE?6 W4CM\0(F!2^=C.;'6^B&EZZ 7Z!.A_]7TJ071]; MRVVC\>6-GOHM%1=WJA,:A@:4&%N^?K=8P7J*7#R?-^ 8; M->4RA*S7LA'7?T+!G-2K. HC1#R?C*^(B.*&B_S(OY=71U46NAF/ A_'^MQ( M*Z"A+W53]B(_4(Z-I;N,'3I)/A*T6;,FA4W2"CYB6 M>.F!W6XT)GGK\^HQ3;5>L1M_/(DN8R&4J\=EI>H1]Z.Q=SA;/(Z6-E1X+VL. MW /$VV!0NBKLQG$J>3MYY:ZV'V*NB%R<_3%C:%!S+>B&Z^D*,&-+BCNDR%!. MI\U_%(FIA"\%UL9#P,>W)BM23%LN3 ZW E!=UN&"@]8''3GKYN+UXH"E7.KJP'?/#4E$L! MLAO=R9Z:&GK_C,-(,+#TM.0H*;O!A\J ?"E>MD,ZB]?[)TF\/3RWZ;QMFD\N-ALTWAM'=*V:;QVM5B[3X+#EVP5R9O* MOV4/QV@%6]&R#WDX&=E 7ARW]%=)2YKWQBE2L@LMC5,B5G^[KZ2# MI940OX07XQ(E>,(G1U>(UF0G/4J+\I=[/D5^EVC[0* MIYH#F.HP'QA,+QGUQ1>PJ4$P<[G:?.GEM(6%&1#2U 9?]@I>5.J%ZDH\>B8[_F(S6Z1R" GG^-K MXB_R+K"?]=+R"LV?R)$I GY7C[FG9;5G?8.^ED(R6AAH;4Z@1F@Z!1!TW*9U MD"&'<;:/(!L_@FS7/=\^@@Q976X?039$<*.I_EO,^)E\N+C?3/WZ;E5;2P%I M\X=W943#] IS]V;I\P0K36UEK^L\-EU-M%1E=54<8%88L'B'$;!89?1*]8?= MY7V#@^0U(<2B68'V56]"H,[O*C2RI-=*@JP0=)$/>#JK MIJQ!ZR-S/"#K&E'8<_68>_-)25H^9N<&9.? MV].1:@]D1Z^IP:'KL014#]K"&+(^[7 =0-:_$BT3Z>=O1P;D^0I!5: (X9N*9QN3Y^/DK$Y?X)?F3LCK%I+^M\N4:U9G& M;,B ;#FAWNR]8L5#S\FKG&L-"A?%EGB309O+=6ZP4#U9DSL/*,2>2-YR?8:2 M5(-1Y?I@M7)]/MJA&,W)#[>M9=_6LM?7EOVM9;\.$!'%HVJ_OM@*MCM?Q1&T M3.V1_O#8V&RV#O'NA=Q,:(^+=O>#@&0M2 ME#5B\@Z6"B(E"YN:D@Q3__QDU0]VZ^>WU0]P90U9M;^1ZH<++LMI/-6!4FAF MZS:VJB5.-61*-;Q=K7.!7HW$GF]FJ]+=0.PE,J4*R*[8AR^(>?I$R4HSV!:V MDB=H]=5);/)P-3J4KV(XG"W;I+=P)YPMV2.>Z0&AF]GLV/UJ>%=#^=U)%YP3 MT?^E!-FML;7<(/M(VV^AC;^%MEO)OOT6&K+BWGX+;8@@:%VHT_TRU3_/3L^S MUF=DGK%>P^S6F09N*K@S;F6KIZ>+)\N,)_P.XVA"F7ANJH,%))OJ[2XB)<
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end